Vascular calcification and mineral bone disorder in chronic kidney disease by Kinsella, Sinéad
Title Vascular calcification and mineral bone disorder in chronic kidney
disease
Author(s) Kinsella, Sinéad
Publication date 2013
Original citation Kinsella, S. 2013. Vascular calcification and mineral bone disorder in
chronic kidney disease. PhD Thesis, University College Cork.
Type of publication Doctoral thesis
Rights © 2013, Sinéad Kinsella
http://creativecommons.org/licenses/by-nc-nd/3.0/
Item downloaded
from
http://hdl.handle.net/10468/1299
Downloaded on 2017-02-12T08:31:02Z
 Vascular Calcification and Mineral 
Bone Disorder in Chronic Kidney 
Disease 
 
 
Sinéad Kinsella 
 
January 2013 
 
 
This thesis is submitted for a PhD degree in Medicine 
from the National University of Ireland, University College Cork, 
School of Medicine and Health. 
 
Supervisor: Professor Joseph A. Eustace 
Head of Department: Professor Fergus Shanahan 
I 
 
Table of Contents 
List of Tables .................................................................................................................. IV 
List of Figures ................................................................................................................. VI 
List of Appendices ........................................................................................................ VIII 
Declaration ..................................................................................................................... IX 
Acknowledgements ....................................................................................................... XII 
Dedication .................................................................................................................... XIV 
Abstract ......................................................................................................................... XV 
Chapter 1   Background .................................................................................................. 1 
Introduction ................................................................................................................ 2 
Measurement of Renal Function ................................................................................ 4 
Definition and Classification of CKD ............................................................................ 5 
Prevalence of CKD ....................................................................................................... 6 
Bone Mineral Density, Osteoporosis and Fracture Risk in the General Population ... 8 
Hyponatremia and Bone Health ................................................................................. 9 
Bone Health and Fracture in CKD ............................................................................. 11 
Renal Osteodystrophy and Limitations of DXA ......................................................... 11 
Chronic Kidney Disease - Mineral Bone Disorder ..................................................... 15 
Pathophysiology of CKD-MBD ................................................................................... 16 
Parathyroid Hormone – Normal Physiology ......................................................... 17 
PTH and Calcium homeostasis .............................................................................. 17 
PTH and Phosphate homeostasis .......................................................................... 18 
PTH response to Vitamin D ................................................................................... 19 
Metabolism of Phosphate in CKD ......................................................................... 19 
Phosphate and Fibroblast Growth Factor 23 ........................................................ 19 
Phosphate and PTH ............................................................................................... 20 
Phosphate Homeostasis and the Renal-Gastrointestinal Axis .............................. 21 
Vitamin D metabolism in CKD ............................................................................... 22 
Non-invasive assessment of Bone Health in CKD. .................................................... 25 
Calcium .................................................................................................................. 25 
Phosphate ............................................................................................................. 26 
II 
 
Vitamin D............................................................................................................... 27 
1, 25-OH Vitamin D ............................................................................................... 28 
Parathyroid Hormone ........................................................................................... 29 
Biochemical Markers of Bone Turnover ............................................................... 31 
Cardiovascular Disease in CKD .................................................................................. 36 
Vascular Calcification in CKD ..................................................................................... 39 
Pathogenesis of Vascular Calcification ..................................................................... 40 
Assessment of Vascular Calcification ........................................................................ 46 
Plain Radiography ................................................................................................. 46 
Aortic Pulse Wave Velocity ................................................................................... 47 
Computed Tomography ........................................................................................ 48 
Relationship between Bone Abnormalities and Vascular Calcification .................... 49 
Post Transplant Bone Disease and Vascular Calcification. ....................................... 51 
Hyperparathyroidism and Health Related Quality of Life ......................................... 55 
Primary Hyperparathyroidism .............................................................................. 55 
Post Renal Transplant Hyperparathyroidism and Quality of Life. ........................ 56 
Study Aims and Hypotheses...................................................................................... 59 
Chapter 2   Moderate CKD in Women is Associated with Fracture Occurrence 
Independently of Osteoporosis ................................................................................... 61 
Introduction .............................................................................................................. 62 
Methods .................................................................................................................... 63 
Results ....................................................................................................................... 67 
Discussion.................................................................................................................. 79 
Chapter 3   Hyponatremia Independently of Osteoporosis is Associated with 
Fracture Occurrence ..................................................................................................... 84 
Introduction .............................................................................................................. 85 
Methods .................................................................................................................... 87 
Results ....................................................................................................................... 91 
Discussion.................................................................................................................. 97 
Chapter 4   The Burden of Chronic Kidney Disease – Mineral Bone Disorder in 
Successful Renal Allograft Recipients: The ABC-HEART Study ................................. 105 
Introduction ............................................................................................................ 106 
III 
 
Methods .................................................................................................................. 108 
Results ..................................................................................................................... 113 
Discussion................................................................................................................ 136 
Chapter 5   The Association of Hyperparathyroidism and Bone Mineral Density with 
Vascular Calcification after Renal Transplantation ................................................... 142 
Introduction ............................................................................................................ 143 
Methods .................................................................................................................. 146 
Results ..................................................................................................................... 149 
Discussion................................................................................................................ 158 
Chapter 6   Association of Hyperparathyroidism and Health Related Quality of Life 
Post Renal Transplantation ........................................................................................ 165 
Introduction ............................................................................................................ 166 
Methods .................................................................................................................. 168 
Results ..................................................................................................................... 174 
Discussion................................................................................................................ 196 
Chapter 7   Conclusions .............................................................................................. 204 
References .................................................................................................................. 211 
Appendices .................................................................................................................. 238 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV 
 
List of Tables 
 
Table 1.1: Classification and Stratification of Chronic Kidney Disease 
Table 1.2: 2005 TMV Classification System for Renal Osteodystrophy. 
Table 2.1: Patient Characteristics of women undergoing routine DXA scan, with 
or without an available serum creatinine measurement within 1 year of the 
scan. 
Table 2.2:  Patient Characteristics of women who met study entry criteria by 
eGFR Category. 
Table 2.3:  Patient Characteristics by Self-Reported Fracture Status. 
 
Table 2.4: Bone Mineral Density and prior history of fracture occurrence 
among 1702 women undergoing routine outpatient DXA measurement, by 
MDRD eGFR category  
Table 2.5: Crude and age adjusted OR (95% CI) for Association of osteoporosis 
with eGFR (ml/min/1.73m2) 
Table 2.6: Crude and adjusted OR (95% CI) for Association of Fractures with 
eGFR Category 
Table 3.1: Subject Characteristics by Serum Sodium Level 
Table 3.2: Crude and Adjusted Odds Ratio for Association of Hyponatremia 
with Fracture Occurrence. 
Table 4.1: Patient Characteristics of 89 enrolled Renal transplant recipients by 
CKD-T Stage 
Table 4.2: Bone Turnover Parameters of Study Population by CKD-T Stage 
Table 4.3: Bone and Vascular Health Parameters by CKD-T Stage 
V 
 
Table 4.4: Logistic Regression Crude and Adjusted Association of Osteoporosis 
with iPTH (per 10ng/ml increment), Odds Ratio (OR), (95% Confidence Interval) 
Table 5.1: Characteristics of Study Population by Aortic Calcification Index 
Calcification Status 
Table 5.2: Linear Regression Univariate Associations of Measures of Vascular 
Calcification with demographic, clinical and laboratory variables. 
Table 5.3: Linear Regression Crude and Adjusted Association of Osteoporosis 
with measures of Vascular Calcification, ß (95% Confidence Interval) 
Table 6.1: Patient Characteristics by iPTH level 
Table 6.2: Distribution demographic, clinical and laboratory variables for 
subjects with SF 12 Physical Component Score below Vs above the sample 
median value of 53.6 
Table 6.3: Distribution of demographic, clinical and laboratory variables for 
subjects with SF 12 Mental Component Score below Vs above the sample 
median value of 55.6 
Table 6.4: Univariate Linear Regression of the Associations of SF-12 Physical 
Domains with demographic, clinical and laboratory variables, ß (95% 
Confidence Interval) 
Table 6.6: Crude and adjusted Odds Ratio (95% Confidence Interval) for 
Association of iPTH (per 10ng/ml) with Physical Domains of SF 12  
Table 6.7: Crude and adjusted Odds Ratio (95% Confidence Interval) for 
Association of iPTH (per 10ng/ml) with Mental/Emotional Domains of SF 12  
Table 6.8: Crude and adjusted OR (95% CI) for Association of Scantibodies™ 
Whole 1- 84 PTH (per 10pg/ml) with SF 12 Domain Scores 
Table 6.9: Crude and adjusted OR (95% CI) for Association of Intact PTH 
(Scantibodies Assay) (per 10pg/ml) with SF 12 Domain Scores 
VI 
 
List of Figures 
 
Figure 1.1: Pathogenesis of Secondary Hyperparathyroidism in CKD 
Figure 1.2: Cardiovascular mortality in the General Population compared to 
ESKD treated with dialysis. 
Figure 1.3: Pathogenesis of Vascular Calcification in Chronic Kidney Disease. 
Figure 2.1: Study Population, 1702 subjects with available DXA and creatinine 
measurement. 
Figure 2.2: Box plot of lowest measured bone mineral density by MDRD eGFR 
category. 
Figure 3.1: Study Population, 1408 subjects with available DXA and sodium 
level 
Figure 3.2: Distribution of Serum Sodium Values in 1408 women undergoing 
DXA scanning.  
Figure 3.3: Odds Ratio (95% Confidence Interval) of fracture occurrence by 
sodium category, 
Figure 4.1: Boxplot of iPTH level by National Kidney Foundation stage of 
Chronic Kidney Disease 
Figure 4.2: Boxplot of 25-OH Vitamin D level by National Kidney Foundation 
stage of Chronic Kidney Disease 
Figure 4.3: Restricted Cubic Splines plot of iPTH with 25-OH vitamin D in 
successful renal allograft recipients with (panel A) or without (panel B) 
hypercalcemia. 
Figure 4.4: Boxplot of areal Bone Mineral Density by site studied 
VII 
 
Figure 4.5: Scatterplots of 3 biomarkers of bone turnover with areal Bone 
Mineral Density 
Figure 4.6: Venn diagram of the prevalence of elements of CKD-MBD in 89 
prevalent renal allograft recipients with an eGFR > 30 ml/min/1.73m2 
Figure 5.1: Scatter-plot of Correlation of Aortic Calcification Index with Lateral 
Lumbar Radiograph Calcification Score 
Figure 6.1: Scatter-plot of Correlation of iPTH (ng/ml) with Whole (1-84) PTH 
(pg/ml) 
Figure 6.2: SF 12 domain and composite scores for Study Population (n= 90) 
Figure 6.3: SF 12 Domain and Composite Scores for Study Population (n =90) 
stratified by Gender 
Figure 6.4: Univariate Linear Regression association of SF 12 Domains (all 
domains) with intact PTH (per 10ng/ml increment)  
Figure 6.5: Multivariate associations of SF 12 Domains (all domains) with intact 
PTH (per 10ng/ml increment)  
Figure 6.6: Responses to Parathyroid Assessment of Symptoms Questionnaire 
(n=90) 
Figure 6.7: Comparison of individual disease specific symptom scores between 
patients with iPTH value above or below 100ng/ml. 
 
 
 
 
 
 
VIII 
 
List of Appendices 
Appendix 1:  Patient Information Sheet and Consent Form Version 4. 
Appendix 2: ABC-HEART Study Data Collection Form, Version 1.  
Appendix 3: Parathyroid Assessment of Symptoms Questionnaire, Version 1. 
Appendix 4: DXA scan request form and questionnaire. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
IX 
 
Declaration 
 
This thesis is submitted to University College Cork in accordance with the 
requirements for the degree of Doctor of Philosophy (PhD) in the Faculty of 
Medicine. 
 
I declare that this thesis is a record of my own work and has not been 
submitted for any other academic award.  All information sources have been 
fully acknowledged and referenced. 
 
Parts of this work have appeared in the following peer reviewed publications 
and presentations: 
1. Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA. 
Moderate Chronic Kidney Disease in Women Is Associated with 
Fracture Occurrence Independently of Osteoporosis. 
Nephron Clin Pract. 2010 Jul 2; 116(3):c256-c262.  PMID: 20606487 
2. Kinsella S, Moran S, O Sullivan M, Molloy MG, Eustace JA.  
Hyponatraemia independently of Osteoporosis is associated with 
fracture occurrence. Clin J Am Soc Nephrol 2010 5: 275-280. PMID: 
20056759  
3. S. M. Kinsella, S. Chavrimootoo, M. G. Molloy, J. A. Eustace 
The Association of MDRD Estimated Glomerular Filtration Rates (eGFR) 
with Bone Mineral Density, Osteoporosis and Fracture Occurrence. 
JASN. 2007: 18; 830A. 
4. S. Kinsella, A. Harrington, S. McDermott, P. O Shea, J.A Eustace. 
X 
 
The Effect of Residual Secondary Hyperparathyroidism on Health 
Related Quality of Life in Renal Transplant Recipients. Oral Presentation 
at the Irish Nephrology Society Annual Scientific Meeting, Dublin, May 
2012. 
5. Sinéad Kinsella, Joseph A. Eustace. The Burden of Chronic Kidney 
Disease-Mineral Bone Disorder (CKD-MBD) in successful Renal 
Transplant Recipients: The ABC-Heart Study. Presented at the American 
Society of Nephrology, Renal Week, Philadelphia, November 2011 
6. S. Kinsella, J. Coyle, A. Harrington, MGM Molloy, C. Bogue, JA Eustace. 
Bone Health, Vascular Calcification and Hyperparathyroidism after 
Renal Transplantation.  Presented at the American Society of 
Nephrology, Renal Week, Denver, November 2010.  
7. S. Kinsella, J. Coyle, A. Harrington, J. Brady, B. Murray, MGM Molloy, C. 
Bogue, JA Eustace. Hyperparathyroidism, bone health, and aortic 
calcification in renal transplant recipients.  Presented at the 
International Society of Nephrology Nexus Symposium, Kyoto, Japan, 
April 17th 2010. 
8. Sinéad Kinsella. Bone Health and Chronic Kidney Disease.  Presented at 
the Royal College of Physicians William Stokes Award 23rd October 
2009 
9. Sinéad Kinsella. Bone Health and Chronic Kidney Disease. Presented at 
the UCC Medical Alumni Annual Scientific Conference 18th September 
2009. 
10. Kinsella S, Moran S, Molloy M.G, Eustace J.A. Hyponatraemia, 
independently of Chronic Kidney Disease (CKD), is   associated with 
fracture occurrence among female DXA attendees. Presented at the 
American Society of Nephrology, Renal Week, Philadelphia, 
November 2008.  
XI 
 
11. Kinsella S, Moran S, Molloy M.G, Eustace J.A. Hyponatraemia 
independently of Chronic Kidney Disease is associated with fracture 
occurrence among female DXA attendees. Oral Presentation at the 
2nd Annual UCC/Cork University Teaching Hospitals Research Day 
June 2008.  
12. Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA.  The Association of 
MDRD estimated glomerular filtration rates (eGFR) with Bone Mineral 
Density (BMD) osteoporosis and fracture occurrence. Presented at the 
American Society of Nephrology, Renal Week, San Francisco November 
2007. 
 
 
 
 
 
 
 
                                        ___________________________ 
Sinéad Kinsella 
January 2013 
 
 
 
 
 
 
 
 
 
XII 
 
Acknowledgements 
 
Firstly, I would like to thank my supervisor, Professor Joseph A. Eustace, for 
introducing and mentoring me through this voyage in “patient-centered 
clinical research”.  Thank you for your constant positivity, encouragement, 
good humour and calm instruction. 
 
I am indebted to the renal transplant recipients who graciously and generously 
shared their time and experiences during the conduct of this study. 
 
The support, friendship and Wednesday morning coffee provided by Abina 
Harrington, Phil O Driscoll and Fiona Byrne were the source of the most 
enjoyable days of this project. 
 
The early and continued encouragement shown to me by Dr. Liam Plant, 
Professor Michael Molloy and Dr. Michael Clarkson is greatly appreciated, as is 
the support given by Mary Daly, Department of Rheumatology, CUH and Rita 
Lynch, Department of Medicine, UCC. 
 
My fellow sufferers Miriam O Sullivan and Éanna Falvey have been constant 
companions both throughout this endeavour and my academic career to date, 
I am extremely fortunate to call them my good friends. 
 
Donal Sexton deserves endless gratitude for welcome visits to the “Hot Desk” 
and for making the journey West to provide continued moral support. 
 
I am grateful to my Mam, Myra, my sisters Elisabeth, Catherine, my twin 
Siobhán, my brother John and my Dad, Seán (especially for knowing when “not 
to talk about it”). My sister Maureen (Buiochás le Dia!) always had faith in me 
XIII 
 
even when I didn’t and has been the source of constant support and 
encouragement. 
 
My nephews and nieces, Andrew, Sarah, (for executive assistance), Fiona, 
Emma, James, Isabel, Susan and Darragh who seem to have almost grown-up 
during this project, and have provided much needed distraction and 
entertainment.  
 
Finally, this study would not have been possible without the financial support 
of the UCC Medical Alumni Professor Denis O’Sullivan Clinical research 
Fellowship and the Irish Nephrology Society Research Bursary. 
 
I am indebted for the support and kindness shown to me by all of the above 
and the many others not acknowledged here. 
 
 
 
 
 
 
 
 
 
 
 
XIV 
 
Dedication 
 
 
 
 
 
 
 
This thesis is dedicated to my Dad, Seán Kinsella, 
A Legend and Contender, 
for his unwavering support and belief in me. 
Master of bizarre words of wisdom regarding the eating of 
elephants and the lighting of candles. 
 
 
 
 
 
 
 
 
 
 
 
 
XV 
 
Abstract 
Chronic Kidney Disease (CKD), osteoporosis and mild hyponatremia are all 
prevalent chronic conditions that may coexist and are often under-recognized. 
Mineral-Bone Disorder begins early in the natural history of CKD and results in 
complex abnormalities of bone which ultimately confers a well-established 
increased risk of fragility fractures in End Stage Kidney Disease. Hyponatremia 
is a novel, usually renal mediated metabolic perturbation, that most 
commonly occurs independently of the stage of renal dysfunction but which 
may also predispose to increased fracture risk. The extent -if any- to which 
either early stages of renal dysfunction or the presence of hyponatremia 
contribute to fracture occurrence in the general population, independently of 
osteoporosis, is unclear. Renal transplantation is the treatment of choice for 
ESKD and although it restores endogenous renal function it typically fails to 
normalize either the long term cardiovascular or fracture risk. One potential 
mechanism contributing to these elevated long-term risks and to diminished 
Health Related Quality of Life is persistent, post-transplant 
hyperparathyroidism.   
 
In this study we retrospectively examine the association of renal function and 
serum sodium with Bone Mineral Density and fracture occurrence in a 
retrospective cohort of 1930 female members of the general population who 
underwent routine DXA scan.  We then prospectively recruited a cohort of 90 
renal transplant recipients in order to examine the association of post 
transplant parathyroid hormone (PTH) level with measures of CKD Mineral 
Bone Disorder, including, DXA Bone Mineral Density, Vascular Calcification 
(assessed using both abdominal radiography and CT techniques, as well as 
indirectly by carotid-femoral Pulse Wave Velocity) and Quality of Life (using 
the Short Form-12 and a PTH specific symptom score).  
XVI 
 
In the retrospective DXA cohort, moderate CKD (eGFR 30-59ml/min/1.73m2) 
and hyponatremia (<135mmol/L) were associated with fracture occurrence, 
independently of BMD, with an adjusted Odds Ratio (95% Confidence Interval), 
of 1.37 (1.0, 1.89) and 2.25 (1.24, 4.09) respectively. In the renal transplant 
study, PTH was independently associated with the presence of osteoporosis, 
adjusted Odds Ratio (95% Confidence Interval), 1.15 (per 10ng/ml increment), 
(1.04, 1.26). The presence of osteoporosis but not PTH was independently 
associated with measures of vascular calcification, adjusted ß (95% Confidence 
Interval), 12.45, (1.16, 23.75). Of the eight quality-of-life domains examined, 
post-transplant PTH (per 10ng/ml increment),  was only significantly and 
independently associated with reduced Physical Functioning,  (95% Confidence 
Interval), 1.12 (1.01, 1.23). 
 
CKD and hyponatremia are both common health problems that may 
contribute to fracture occurrence in the general population, a major on-going 
public health concern.  PTH and decreased Bone Mineral Density may signal 
sub-optimal long-term outcomes post renal transplantation, influencing bone 
and vascular health and to a limited extent long term Health Related Quality of 
Life.  
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Chapter 1  
 
 
 
 
 
Background 
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Introduction 
Chronic Kidney Disease (CKD) is a common condition that remains under-
recognized and under-treated.  It is associated with increased morbidity and 
mortality and its outcome is related not only to progression to End Stage 
Kidney Disease (ESKD), but predominantly to complications of decreased renal 
function, including increased cardiovascular risk. Disturbances in bone mineral 
metabolism are almost ubiquitous in progressive CKD and are central to the 
development of both the bone and vascular complications which are over-
represented in this population.  Bone Mineral Disorders begin early in CKD and 
result in complex abnormalities in bone which ultimately confers a markedly 
increased risk of fragility fractures, with their associated morbidity and 
mortality. Nevertheless, the extent to which these abnormalities result in an 
increased fracture risk in subjects with early, as distinct to those with 
advanced CKD –for whom this relationship is well established- is unclear.  
Increased bone fragility is associated with vascular calcification, an association 
that has been observed in the general population but which is particularly 
notable in some subjects with advanced CKD, where it is potentially 
augmented by pathophysiological mechanisms that are markedly upregulated 
in advanced CKD, such as severe hyperparathyroidism. Renal transplantation 
restores endogenous renal function in subjects with ESKD and is the treatment 
of choice for suitable patients with renal failure. However, cardiovascular 
mortality and the risk of fracture remain chronically elevated despite renal 
3 
 
transplantation, in keeping with the prior history of ESKD and despite the 
restoration of renal function.  The mechanisms underlying this apparently 
persistent ‘metabolic memory’ are unknown but one such potential candidate 
is a state of persistent, relatively autonomous hyperparathyroidism, which is 
evident in a poorly defined proportion of transplant recipients. In keeping with 
its described complications in subjects with primary hyperparathyroidism, 
such persistently elevated parathyroid hormone (PTH) levels may potentially 
influence not only bone health and vascular risk but also Health Related 
Quality of Life, although data examining these putative relationships in the 
transplant setting are sparse.  
In this thesis I will seek to quantify some of the above associations, in 
particular examining the relationship of renal dysfunction with fracture 
occurrence in women in the general population with early CKD and secondly, 
the association of persistent post-transplant hyperparathyroidism with 
abnormalities of bone mineral metabolism, decreased Bone Mineral Density, 
vascular mineralization and Health Related Quality of Life in renal transplant 
recipients.    In this introductory chapter I outline the relevant background 
against which these investigations are developed and the current state of 
knowledge to which the studies described in the subsequent chapters 
contribute.  
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Measurement of Renal Function 
The National Kidney Foundation (NKF) Clinical Practice Guidelines1 state that 
estimates of Glomerular Filtration Rate (GFR) are the best overall indices of 
the level of renal function.  They also advocate the use of prediction equations 
using serum creatinine and demographic variables to calculate estimated GFR 
(eGFR).  Recommended prediction equations are the Cockcroft-Gault and the 
Modification of Diet in Renal Disease (MDRD) formulae, (Level A 
Recommendation).  A number of other predication equations such as the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 2 have 
been developed since the publication of these guidelines, and while they are 
currently undergoing validation they are not yet in widespread clinical use. 
The 4-variable MDRD prediction equation reports an eGFR indexed to body 
surface area (ml/min/1.73m2) and is readily calculable with a calculator or 
computer if age, race, gender and serum creatinine are known.  The MDRD 
prediction equation was developed using a database of 1070 patients with 
renal disease and validated in an additional cohort of 558 patients.3 The MDRD 
equation is more accurate than Cockcroft-Gault in patients with GFR <90 
ml/min. While the MDRD equation has been validated in patients with renal 
transplants4,5, and in older individuals6 it has not been validated in people with 
normal or near normal renal function7,8 or in individuals at extremes of body 
weight.9,10 A recent retrospective study of diabetic patients found that the 
Cockcroft-Gault prediction equation was a better predictor of renal function 
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than the MDRD or CKD-EPI prediction equations in the overweight and obese 
diabetic population with well preserved renal function.11  
Definition and Classification of CKD 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(K/DOQI) Clinical Practice Guidelines on Chronic Kidney Disease in 2002 
provided the first definition of CKD independent of cause and introduced a 
classification system of severity based on the GFR level.  CKD was defined as:  
“kidney damage persisting for greater than 3 months (as defined by structural 
or functional abnormalities of the kidney) with or without decreased GFR, that 
can lead to decreased GFR, manifest by either pathological abnormalities or 
markers of kidney damage including abnormalities in the composition of the 
blood or urine, or abnormalities in imaging tests. CKD may also be defined as 
GFR<60ml/min/1.73m2 for greater than 3 months, with or without kidney 
damage”.1  
The Kidney Disease: Improving Global Outcomes (KDIGO) Group reviewed and 
modified  this definition and classification system in 2005 to include reference 
to treatment modality (if any), namely the addition of the suffix “T” to denote 
renal transplant, in addition to the CKD stage and the suffix “D” to denote 
dialysis treatment.12 (Table 1.1) 
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Table 1.1: Classification and Stratification of Chronic Kidney Disease12 
Stage Description eGFR 
ml/min/1.73m2 
Classification by 
Treatment 
1 Kidney damage with 
normal  or increased 
GFR 
≥ 90   
 
T if Kidney 
transplant 
recipient 
2 Kidney damage with 
mild reduction in GFR 
60-89 
3 Moderate reduction in 
GFR 
30-59 
4 Severe reduction in GFR 15-29 
5 Kidney Failure <15 (or 
dialysis) 
D if Dialysis 
(Haemodialysis or 
Peritoneal Dialysis) 
 
Prevalence of CKD 
The National Health and Nutrition Examination Survey (NHANES) is a health-
examination survey of the civilian, non-institutionalized population of the 
United States conducted by the National Center of Health Statistics. It collects 
data in order to provide estimates of prevalence of chronic conditions in the 
United States. Data has been collected for several different time periods since 
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the early 1960’s.  These surveys have found that the overall prevalence of CKD 
in the US population has increased from 11% in the period 1988-199413 to 13% 
in 1999-20042, (based on the MDRD prediction equation). The prevalence of 
CKD, eGFR< 60ml/min/1.73m2, has increased from 4.7% to 8.2% over the same 
period. The reported prevalence of CKD Stage 3 in those over 70 years has 
increased from 25% to 37% between 1988-1994 and 1999-2004.2, 13 
 
The vast majority of patients with CKD die before progressing to ESKD. In one 
study of 28,000 patients, Keith et al followed patients with an eGFR of 
<90ml/min/1.73m2 for over 5 years. This study found that even among 
patients with advanced Stage 4 CKD, death prior to renal replacement therapy 
was more than twice as likely as progression to ESKD.14 Higher CKD stage is 
also associated with a graded increase in complications of CKD such as 
hypertension, anemia, malnutrition and disordered mineral metabolism.1 Go 
et al demonstrated an independent graded association between reduced eGFR 
and the risk  of death, cardiovascular events and hospitalization15, confirming 
that CKD is an undisputed risk factor for all-cause and cardiovascular mortality 
which increases with declining GFR.   
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Bone Mineral Density, Osteoporosis and Fracture Risk in the General 
Population 
Osteoporosis is defined as “a skeletal disorder characterized by compromised 
bone strength predisposing a person to an increased risk of fracture: bone 
strength reflects the integration of two main features: bone density and 
quality”.16 There is no readily available clinical measure of bone strength.  
Bone Mineral Density is used as a surrogate measure and accounts for 
approximately 70% of bone strength.17  Therefore the most commonly used 
non-invasive tool for the diagnosis of osteoporosis (and prediction of fracture 
risk) is based on measurement of areal (mass per area) Bone Mineral Density 
by DXA (Dual energy x-ray absorptiometry), which is determined by the 
mineral content of bone.  Bone Mineral Density measurements have been 
shown to correlate with the risk of fracture at several skeletal sites. The World 
Health Organization (WHO) diagnosis of osteoporosis is based on Bone 
Mineral Density measurement, where osteoporosis is defined as a T-score of 
at least minus 2.5 standard deviations (SD) below the average Bone Mineral 
Density.  A T-score is defined as the number of SDs above or below the 
average BMD for young, healthy white females.  This is in distinction to a Z-
score, which is the number of SDs above or below the average Bone Mineral 
Density for age and gender matched controls.18 Recognized risk factors for 
decreased Bone Mineral Density include advancing age, female gender, 
oestrogen deficiency, low body mass index, immobility, family history of 
osteoporosis, low calcium intake, smoking, alcohol consumption, co-morbid 
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conditions such as thyroid disease and medications (including corticosteroids, 
anti-convulsants and calineurin inhibitors).16  
In the post menopausal population, decreased Bone Mineral Density is 
strongly associated with fracture risk.  Age related changes in bone quality are 
also associated with increased fracture risk.  For each additional decade over 
the age of 50 years, fracture risk doubles, independently of Bone Mineral 
Density.  Thus, while Bone Mineral Density is a good predictor of bone 
strength, it remains a surrogate determinant as it does not evaluate aspects of 
bone quality, which contribute to overall bone strength.  In addition, bone 
quality (and therefore strength) is adversely affected by the normal aging 
process and consequently measures of Bone Mineral Density do not fully 
predict fracture risk even in the healthy population. 
 
Hyponatremia and Bone Health 
Recent attention has focused on serum sodium level as a novel marker of bone 
disease and fracture risk.  Evidence suggests that mild chronic hyponatremia 
(serum sodium levels of 130- 134mmol/L) is associated with subtle central 
nervous system impairment including gait and attention deficits that may lead 
to an increased risk of falls.19 Several case control studies have  reported the 
association of mild asymptomatic hyponatremia with bone fracture in the 
ambulatory elderly,20,21  although neither study was able to control for the 
presence of osteoporosis, a major potential confounder of this relationship, as 
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the prevalence of both osteoporosis and hyponatremia increase with older 
age.  Evidence also suggests that hyponatremia itself contributes to bone loss. 
In 1954, Bergstrom et al. demonstrated that acute hyponatremia in 
experimental animals resulted in release of sodium from bone22, 23, analogous 
to bone resorption and calcium efflux from bone in settings of hypocalcaemia. 
More recent studies by Verbalis et al. confirmed that chronic hyponatremia 
(>3 months) significantly reduced Bone Mineral Density compared with 
normonatremic rats.  Using the NHANES III dataset, Verbalis et al. also 
reported a significant association between mild hyponatremia (<135mmol/L) 
and increased odds ratio of osteoporosis at the hip (OR 2.85, 95% CI 1.03-7.86, 
p<0.01).24  Mild hyponatremia therefore may be a readily identifiable and 
potentially modifiable risk factor for fracture both in the CKD and general 
population. 
The major clinical consequence of osteoporosis and decreased Bone Mineral 
Density is increased incidence of fracture. As Bone Mineral Density decreases 
and fracture risk increases with advancing age, rates of fragility fractures, most 
notably of the hip, increases.  The lifetime risk of a hip fracture above the age 
of 50 years has been estimated to be between 17 and 19.5% for females and 6 
and 8% for males.25, 26  Fragility fractures therefore are a major public health 
concern and are associated with prolonged hospitalization, disability and in 
the case of hip fracture, with an increased mortality at one year, which is more 
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pronounced in males. (RR 3.3 for females and 4.2 for males under the age of 
75 years relative to controls without hip fracture).27 
 
Bone Health and Fracture in CKD 
The prevalence of bone fracture is even higher in patients with CKD than in the 
general population and is not limited to patients with End Stage Kidney 
Disease. A 2.3 fold increase in risk of hip fracture has been reported in patients 
with eGFR <60mls/min/1.73m2 compared to those without CKD.28  Fracture 
risk increases further with declining renal function and patients with Stage 5 
CKD on dialysis have a reported 4.5 fold increased risk of hip fracture relative 
to the general population.29 The occurrence of hip fracture in patients with 
End Stage Kidney Disease is associated with an increase in mortality ranging 
from 50 to 64% at one year30, 31, compared to a one year mortality of 20% in 
the general population.31 
Renal Osteodystrophy and Limitations of DXA  
The utility of Bone Mineral Density measurement by DXA in predicting fracture 
risk in patients with CKD remains controversial.  Disorders of mineral 
metabolism and bone turnover begin early in the course of CKD and become 
more severe with progressive loss of renal function.  These abnormalities lead 
to a wide range of disorders of bone quality and turnover, leading to an 
increase in fracture risk independent of Bone Mineral Density.  The bone 
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abnormalities seen in CKD are collectively termed renal osteodystrophy.  A 
histological classification system for renal osteodystrophy was introduced by 
Sherrard et al in 1993, describing the spectrum of bone disorders in CKD as 
mild,  osteitis fibrosa (high turnover), mixed uremic osteodystrophy, 
osteomalacia, and adynamic (low turnover) bone disease.  These bone lesions 
were found to associate with PTH levels.32 
In 2005, KDIGO introduced a new classification system for renal 
osteodystrophy and recommended that the term “renal osteodystrophy” be 
used exclusively to describe the histological abnormalities of bone seen in 
CKD.  This classification system is based on evaluation of bone turnover, 
mineralization and volume (TMV Classification System) and was felt to provide 
additional information based on indicators other than just bone turnover.33 
(Table 1.2) 
 
Table 1.2: 2005 TMV Classification System for Renal Osteodystrophy.33 
Turnover Mineralization Volume 
Low Normal Low 
Normal  Normal 
High Abnormal High 
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The gold standard for the diagnosis of renal bone disease remains quantitative 
bone histomorphometry and correlations of Bone Mineral Density with bone 
histology are poor. Bone Mineral Density gives no information on the rate of 
bone turnover and cannot distinguish between abnormalities in cortical and 
trabecular bone. Therefore Bone Mineral Density measurement in the setting 
of CKD can be misleading, depending on the site of measurement, as high 
turnover bone disease may lead to thickened sclerotic trabecular bone, while 
simultaneously causing bone loss at cortical bone sites, such as the distal 
radius.34 Falsely elevated or false normal results may also be seen, depending 
on the site of measurement, as all mineralization along the path of the X-Ray 
beam will contribute to the Bone Mineral Density result, for example, DXA 
performed at the lumbar-sacral spine will also detect mineralization of the 
abdominal aorta, unless assessed laterally,  which is common among patients 
with CKD.35  Similarly, low Bone Mineral Density by DXA does not reliably 
distinguish the type of renal bone disease which may be present, for example, 
low Bone Mineral Density measured by DXA may be present in both high and 
low turnover bone disease states. Therefore while fracture risk is increased in 
patients with CKD, fracture risk does not correlate well with Bone Mineral 
Density as measured by DXA, as numerous other factors influencing bone 
strength are equally, if not more important and exert more influence on 
fracture risk as renal function declines. In addition, CKD is associated with 
increased levels of frailty, Vitamin D deficiency, deterioration in muscle 
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function and general deconditioning which predispose to an increased risk of 
falls with subsequent fragility fracture.36-38  Given these limitations of DXA the 
KDIGO practice guidelines recommended in 2009 that patients with CKD Stage 
3-5D, with evidence of abnormal mineral metabolism, should not undergo 
routine measurements of Bone Mineral Density.39 However, this 
recommendation has been called into question following a recent study by 
Yenchek et al. accompanied by an editorial commentary by Nickolas.40  
Yenchek et al. in a longitudinal study, analyzed the effect of CKD on fracture 
risk prediction by DXA in a cohort of 2754 community dwelling older adults, 
followed for a median of 11.3 years.  This study demonstrated that low Bone 
Mineral Density by DXA predicted fracture occurrence in patients with and 
without CKD, even following adjustment for mineral and bone abnormalities 
(elevated PTH and low Vitamin D levels). The majority of patients with CKD in 
this cohort had CKD Stage 3, eGFR 45-59.9mls/min.41 Additionally, Jamal et al 
have suggested that in early CKD (Stage 1-3), in the absence of abnormal 
mineral metabolism, Bone Mineral Density measurements by DXA may be 
useful in determining fracture risk, but that this cannot be recommended in 
more advanced CKD.42   
Quantitative Computed Tomography (QCT) may have more utility in the 
prediction of fractures and assessment of bone health in patients with CKD.  Its 
main advantages are that it can distinguish between cortical and trabecular 
Bone Mineral Density, a distinction that is particularly important in renal bone 
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disease.  Secondly it provides an assessment of bone volume, (reported as 
mg/cm3), rather than the areal Bone Mineral Density (g/cm2) measured by 
DXA.  The WHO definition of osteoporosis (T-score less than 2.5) does not 
apply to QCT; instead osteoporosis is defined as a QCT Bone Mineral Density 
score less than 80mg/cm3. 43 
Chronic Kidney Disease - Mineral Bone Disorder 
The term renal osteodystrophy was previously used to describe the spectrum 
of mineral abnormalities and bone disease that occur in CKD.  These disorders 
included abnormalities in serum calcium, phosphate, parathyroid hormone 
(PTH) and Vitamin D metabolism.  As mentioned previously, KDIGO 
recommended in 2005 that the term renal osteodystrophy be reserved for the 
description of the range of morphological changes seen on bone biopsy in 
CKD.  It was observed that these biochemical and bone abnormalities 
contributed to the excessive cardiovascular risk and significantly increased 
morbidity and mortality seen in patients with renal disease.  It was recognized 
that abnormalities in mineral metabolism, bone health and cardiovascular 
outcomes were closely inter-related.  The term Chronic Kidney Disease- 
Mineral Bone Disorder (CKD-MBD) was introduced by KDIGO in 2005 to 
describe the clinical syndrome linking the clinical, biochemical and imaging 
abnormalities seen in CKD.33 
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CKD-MBD is defined as a systemic disorder of mineral and bone metabolism 
manifested by either one, or a combination of the following; 
- Abnormalities of calcium, phosphate, PTH or Vitamin D metabolism 
- Abnormalities in bone turnover, mineralization, volume, growth or 
strength 
- Calcification of the vasculature or soft tissues.33 
 
Pathophysiology of CKD-MBD 
The development of secondary hyperparathyroidism is central to the 
pathophysiology of CKD-MBD. The aetiology of secondary 
hyperparathyroidism is complex and multifactorial. The main parameters 
responsible for continued PTH secretion in CKD are hypocalcaemia, decreased 
1, 25 OH Vitamin D and hyperphosphatemia.  Calcium and phosphate levels 
are preserved within the normal range until late stage CKD, 44 while elevations 
in PTH levels and Vitamin D deficiency develop early in the course of the 
disease.44-46 These mechanisms are initially compensatory, serving to maintain 
a normal serum calcium and phosphate.  However as CKD progresses, these 
mechanisms become overwhelmed and pathophysiological. 
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Parathyroid Hormone – Normal Physiology 
PTH is one of 3 major hormones modulating calcium and phosphate 
homeostasis, (the others being Vitamin D and FGF 23).  PTH synthesis and 
secretion are regulated through an exquisitely sensitive calcium sensing 
receptor (CaSR) 47 expressed widely, including in parathyroid tissue.  The CaSR 
senses minute changes in serum calcium concentrations and PTH is 
responsible for calcium homeostasis on a minute to minute basis, maintaining 
serum calcium concentration within a very narrow range.48  The PTH receptor 
is heavily expressed in bone and kidney and is also found in the skin, heart and 
blood vessels. 
PTH and Calcium homeostasis 
In response to decreases in serum calcium, there is immediate exocytosis of 
stored PTH from secretory vesicles into the extracellular fluid which occurs 
over seconds to minutes.48 PTH acts acutely by increasing renal tubular 
reabsorption and releasing calcium from skeletal stores. Sustained 
hypocalcaemia results in a reduction in intracellular degradation of PTH which 
occurs within minutes to hours. In response to chronic hypocalcaemia, PTH 
stimulates increased renal hydroxylation of 25-OH Vitamin D to active 1, 25-
OH Vitamin D (calcitriol), causing increased intestinal calcium absorption and 
osteoclastic resorption of bone and further calcium release. Prolonged 
hypocalcaemia increases PTH gene expression (over hours to days) and 
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increases the number of parathyroid cells resulting in gland hyperplasia (over 
days to weeks).48 
PTH and Phosphate homeostasis 
Factors influencing calcium homeostasis also influence phosphate 
homeostasis. PTH has a number of effects on phosphate metabolism.  Both 
calcium and phosphate are released from skeletal stores and absorbed from 
the intestine in response to PTH secretion.  In the renal proximal tubule, Type 
II sodium-phosphate transporters are heavily expressed and are responsible 
for the reabsorption of 80% of filtered phosphate. PTH, Fibroblast Growth 
Factor 23 (FGF23) and dietary phosphate are the major regulators of these 
transporters and their expression is rapidly reduced in response to PTH and 
dietary phosphate loading. Intestinal phosphate transport is less well 
elucidated, but Type II sodium phosphate transporters have been identified in 
the small intestine. These intestinal sodium phosphate transporters are 
regulated by 1, 25-OH Vitamin D and dietary phosphate load.  Unlike the 
regulation of renal proximal tubular sodium phosphate transporters, current 
evidence suggests that PTH does not regulate sodium phosphate transporter 
expression directly, but that it affects intestinal transport of phosphate 
indirectly via its stimulatory effect on 1, 25-OH Vitamin D.49 In health, the net 
effect of these mechanisms is a correction of serum calcium concentration to 
normal with little or no effect on serum phosphate concentration.  
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PTH response to Vitamin D 
Parathyroid cells express Vitamin D receptors (VDR) and the PTH gene has a 
Vitamin D response element. Calcitriol (1, 25-OH Vitamin D) binds to the VDR 
and inhibits PTH gene expression and PTH synthesis.50  Calcitriol also inhibits 
parathyroid cell proliferation.51 
Metabolism of Phosphate in CKD 
With progressive CKD, single nephron phosphate excretion increases but due 
to the reduced number of functioning nephrons, the kidney becomes 
increasingly unable to excrete phosphate and maintain a neutral phosphate 
balance, resulting eventually in hyperphosphatemia.  This positive phosphate 
balance initiates a cascade of responses in an attempt to maintain a normal 
serum phosphate level. 
Phosphate and Fibroblast Growth Factor 23   
Fibroblast Growth Factor 23 (FGF23) is a potent phosphaturic peptide, 
secreted by osteocytes. It was originally identified in diseases associated with 
phosphate wasting such as tumour induced osteomalacia52  and autosomal 
dominant hypophosphatemic rickets.53  Further studies established FGF23 as 
an important regulator of phosphate and Vitamin D metabolism, both in 
health and CKD.54-56 
FGF23 binds to FGF Receptor (FGFR) with the highest affinity in the presence 
of its co-receptor Klotho57 and down regulates expression of the sodium-
phosphate co-transporter in the renal proximal tubule, thereby inhibiting 
20 
 
phosphate reabsorption.58  FGF23 is secreted by osteocytes in response to 
dietary phosphate loading and increases in serum phosphate via unclear 
signalling pathways. It exerts a potent phosphaturic effect serving to maintain 
normal serum phosphate in the presence of adequate renal excretory 
capacity.57 
FGF23 also directly inhibits renal 1-alpha hydroxylase expression, preventing 
hydroxylation of 25-OH Vitamin D to its active metabolite 1, 25-OH Vitamin D.  
In addition, FGF23 increases the activity of the catabolic enzyme 24-
hydroxylase (CYP24A), which degrades existing 1, 25-OH Vitamin D.59 FGF23 
has also been shown to suppress PTH secretion, which in turn leads to a 
reduction in 1, 25-OH Vitamin D thereby reducing intestinal absorption of 
phosphate.60 FGF23 affects intestinal phosphate indirectly, mediated through 
its effects on circulating 1, 25-OH Vitamin D levels. The combination of these 
effects may explain why elevations in PTH levels and Vitamin D deficiency 
develop early in the course of CKD while calcium and phosphate levels remain 
relatively normal until late CKD.  FGF23 levels begin to rise early in the course 
of CKD and have been shown to be an important predictor of 1, 25-OH vitamin 
D levels, independently of eGFR and serum phosphate level.56 
Phosphate and PTH  
PTH is an extremely important modulator of phosphate metabolism. PTH is a 
phosphaturic hormone and acts on the proximal tubules to suppress sodium-
phosphate co-transporter activity, inhibiting phosphate reabsorption.58 PTH 
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also stimulates osteoclastic bone resorption and phosphate release and 
promotes the activity of 1-alpha hydroxylase (resulting in production of 1, 25-
OH Vitamin D and increased intestinal absorption of phosphate).61  On a 
cellular level, hyperphosphatemia inhibits the release of calcium ions from 
intracellular structures resulting in decreased intracellular calcium, stimulating 
further PTH secretion.62 Prolonged hyperphosphatemia, such as occurs in the 
setting of reduced renal function results in increased PTH synthesis, secretion 
and parathyroid cell proliferation and gland hyperplasia.62 In CKD this response 
becomes a pathophysiological vicious cycle as the kidney cannot mount a 
phosphaturic response to PTH.  
 
Phosphate Homeostasis and the Renal-Gastrointestinal Axis 
It has generally been accepted that phosphate homeostasis is regulated via 
control of phosphate reabsorption in the renal proximal tubule.  How dietary 
phosphate intake and increases in serum phosphate signals a phosphaturic 
response is less well understood.  It has been proposed by Berndt et al. that 
the small intestine mucosa senses an increase in phosphate concentrations 
and secretes a circulating substance that exerts a rapid phosphaturic effect in 
the kidney.  This group demonstrated in animals that infusion of sodium 
phosphate, but not sodium chloride increased renal phosphate excretion 
within twenty minutes.  This response was not attributable to alterations in 
serum phosphate, PTH, FGF23 or an increase in GFR. In addition, renal 
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denervation did not alter the phosphaturic response.63  Marks et al. have 
suggested that the circulating substance proposed by Berndt et al. may be 
matrix extracellular phosphoglycoprotein, (MEPE), which is a phosphatonin 
with an inhibitory effect on intestinal phosphate absorption independently of 
1, 25-OH Vitamin D.  It is expressed in duodenum and jejunum and also in the 
renal proximal tubule.49 Further elucidation of these pathways is ongoing and 
will provide important insights and possibly novel therapeutic targets in 
disorders of phosphate homeostasis. 
 
Vitamin D metabolism in CKD 
CKD has a number of adverse effects on Vitamin D metabolism.  As mentioned 
previously, FGF23 inhibits 1-alpha hydroxylase and stimulates 24-hydroxylase 
resulting in decreased levels of 1, 25-OH Vitamin D.  This has both direct and 
indirect effects which contribute to the development of secondary 
hyperparathyroidism.    Firstly, decreased VDR binding of 1, 25-OH Vitamin D 
directly results in increased PTH gene expression, PTH synthesis, parathyroid 
cell proliferation and gland hyperplasia, independent of the effect of 
hypocalcaemia.51 Parathyroid hyperplasia is associated with important 
abnormalities of parathyroid cell function, most notably the development of 
nodular parathyroid tissue with reduced expression of both the VDR and CaSR.  
The net result of these changes are a hyperplastic nodular gland, 
autonomously secreting PTH and no longer responsive to circulating calcium or 
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Vitamin D levels.64  In addition, decreased 1, 25-OH Vitamin D leads to 
decreased intestinal calcium absorption resulting in hypocalcaemia and 
increased PTH secretion. 
In summary, secondary hyperparathyroidism develops as an initial 
compensatory response via complex mechanisms but it ultimately becomes 
maladaptive and contributes to the pathophysiology of CKD. (Figure 1.1)  
Abnormalities in these parameters, both individually and collectively are 
associated with the increased fracture rate, cardiovascular and all-cause 
mortality seen in the clinical syndrome of CKD-MBD. 
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Figure 1.1: Pathogenesis of Secondary Hyperparathyroidism in CKD 
Reduced kidney 
function
Adapted from Wetmore J and Quarles D. Nat Clin Pract Nephrol. 2009;5(1):24-33.
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Figure 1.1: In normal conditions, the system provides an adaptive mechanism 
that normalises serum phosphorus in early kidney disease mediated by 
fibroblast growth factor (FGF-23). FGF-23 is a bone-derived hormone that 
inhibits phosphorus reabsorption, thereby increasing phosphorus excretion in 
the kidney. An increase in serum phosphorus levels also leads to a decrease in 
the conversion of vitamin D to active vitamin [1, 25(OH)2D3] by the kidneys via 
FGF-23, causing a decrease in serum 1,25(OH)2D3 levels. An increase in serum 
phosphate stimulates the secretion of FGF-23 by bone osteocytes. The kidney 
is the major target organ for FGF-23. FGF-23 inhibits phosphate reabsorption 
in the proximal tubule, leading to phosphaturia. Inhibition of 1α-hydroxylase 
by FGF-23 leads to decreased levels of 1, 25(OH)2D3. The phosphaturic effects 
of FGF-23 along with suppression of 1, 25(OH)2D3 formation provide a means 
to lower serum phosphate levels. In CKD, the reduction in kidney function 
leads to diminished response to FGF-23 such that serum Phosphate remains 
high. Reduced kidney function also leads to low serum calcium and calcitriol 
(activated vitamin D), both of which increase PTH secretion from the 
parathyroid gland. CKD-derived hyperphosphataemia thus drives SHPT 
development through FGF-23 and hypocalcaemia. Adapted with permission 
from “Calcimimetics or Vitamin D analogs for suppressing parathyroid 
hormone in end-stage renal disease: time for a paradigm shift?” James B 
Wetmore & L Darryl Quarles. Nature Reviews Nephrology 5, 24-3361. 
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Non-invasive assessment of Bone Health in CKD. 
Quantitative bone histomorphometry is the gold standard for diagnosis of 
bone disorders in CKD39.  However, bone biopsy is not widely utilized or 
available in clinical practice.  It is an invasive and specialized procedure and 
importantly, there is a paucity of pathologists able to analyze the specimens.  
As such, non-invasive methods, mainly biochemical parameters are used as -
albeit imperfect- surrogate measures of bone health, frequently in 
combination with radiological investigations. 
 
Calcium 
In health, the adult human body contains approximately 1kg (25,000 mmol) of 
calcium, 99% of which comprises the mineral compartment of bone. Only 1% 
(20mmol) of total body calcium is measurable in the extracellular 
compartment.  Homeostatic mechanisms regulate concentration of calcium in 
the ECF rather than total body calcium content.65 Serum calcium 
concentrations are tightly regulated within a narrow range, predominantly by 
PTH and do not reflect total calcium balance.65 Total serum calcium is the 
usual measure of calcium status. Ionized calcium, which represents 40-50% of 
total calcium, is physiologically active. The remainder is bound to albumin or 
to anions such as phosphate, citrate and bicarbonate and is physiologically not 
active.  Total calcium levels are affected by protein binding. In the presence of 
hypoalbuminaemia, there is an increase in ionized calcium, relative to total 
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calcium and total calcium measurement in this situation will underestimate 
the physiologically active ionized calcium.  In clinical practice the serum 
calcium is typically corrected for the serum albumin level using the following 
formula: the addition of 0.02mmol/L to the measured calcium for each 1g/L 
decrease in serum albumin below 40g/L.66 Using the albumin corrected serum 
calcium value has not been shown to be as accurate as ionized calcium and 
may not offer any additional benefit over using the total serum calcium value 
in patients with CKD67. Measurement of ionized calcium is not routinely 
available, but may be preferable if serum albumin or plasma pH are 
abnormal.68 
 
Phosphate 
Phosphate represents approximately 1% of total body weight.  Mineralized 
bone contains 85% of total body phosphate; of the remainder the intracellular 
compartment contains 14% and extracellular fluid less than 1%.  Phosphate 
circulates mainly in its free form (85%) with the remainder being protein 
bound.  The majority of circulating phosphate therefore is freely filtered by the 
glomerulus. 69  This filterable fraction becomes important as with progressive 
CKD (and decreased filtration rate), the overall phosphate balance becomes 
positive in patients with CKD stages 4-5D.70   Serum phosphate levels may be 
influenced by diurnal variation, post-prandial state and changes in pH, 
(increased with acidosis, decreased with alkalosis). However, in health the day-
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to-day variation is approximately 5-10%.  Due to the high intracellular 
phosphate concentration, levels may also be affected by haemolysis. 
Both high serum calcium levels and phosphate levels are associated with 
increased mortality in patients with CKD and on dialysis.71, 72  It is 
recommended therefore that serum calcium and phosphate levels be 
measured regularly in patients with eGFR <60ml/min/1.73m2 and more 
frequently as CKD progresses.39 
 
Vitamin D 
25-hydroxy Vitamin D (25-OH Vitamin D) is the parent compound of Vitamin 
D3 (cholecalciferol) and Vitamin D2 (ergocalciferol). It is metabolized in the 
liver to 25-OH Vitamin D3 (calcidiol) or 25-OH Vitamin D2 (25-
hyrdroxyergocalciferol or ercalcitriol).  These compounds undergo further 1-
alpha hydroxylation in the kidney to become the active metabolite, 1, 25 
Vitamin D.  Quantification of 25-OH Vitamin D is the best measure of Vitamin 
D status as it includes measurement of nutritional sources and skin synthesis 
of Vitamin D. It is also a stable compound with a half life of approximately 2-3 
weeks. 25-OH Vitamin D can be measured by radioimmunoassay, 
chemiluminescence assay or liquid-chromatography-tandem mass 
spectrometry. The latter has the advantage of being able to distinguish 
between 25-OH Vitamin D2 and 25-OH Vitamin D3.  However, this technique is 
28 
 
expensive and requires specialized training and is therefore not widely used.39  
25-OH Vitamin D levels show seasonal variation due to increased 
cholecalciferol production during summer months following sun exposure.  
Optimal values of 25-OH Vitamin D have not been well validated in CKD but 
are taken to be above 50nmol/L (20ng/ml) in the general population.73   
 
1, 25-OH Vitamin D 
This is the active metabolite of Vitamin D and this term describes both 
hydroxylated Vitamin D2 (25-hydroxyergocalciferol/ercalcitriol) and Vitamin 
D3 (calcitriol).  1, 25-OH Vitamin D has a very short half-life of 4-6 hours and 
levels are approximately one-thousandth of the 25-OH Vitamin D level.  The 
measured level of 1, 25-OH Vitamin D is affected by prevailing 25-OH Vitamin 
D stores, 1-alpha hydroxylase and 24-hydroxylase enzyme levels.  Due to its 
short half-life and the multiple factors affecting interpretation of the result, 
routine measurement of 1, 25-OH Vitamin D in clinical practice is not 
recommended.39 
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Parathyroid Hormone 
Secondary hyperparathyroidism is an almost ubiquitous complication of CKD 
and the measurement of PTH is a widely used non-invasive surrogate marker 
for the assessment of bone turnover and bone health.  PTH is an 84-amino 
acid single-chain polypeptide, synthesized and secreted from the chief cells of 
the parathyroid gland in response to reductions in extra-cellular calcium 
concentrations.  The majority of secreted PTH is as its intact or biologically 
active form, 1-84 PTH.  The remainder is compromised of PTH fragments 
namely C-terminal truncated and N-terminal truncated PTH fragments, of 
which the N-terminal 7-84 PTH fragment is the most abundant.  This molecule 
usually represents approximately 15% of circulating PTH fragments.74  It has 
however been shown to be over-represented in patients with severe primary75 
and secondary76 hyperparathyroidism.  Once released into the circulation 1-84 
PTH is degraded peripherally to C-terminal fragments.  These fragments have a 
longer half life than 1-84 PTH and represent the majority of total circulating 
PTH in health.  CKD and ESKD can result in accumulation of these PTH 
fragments.74  
The first generation of PTH radioimmunoassay consisted of a single antibody 
directed against the entire PTH molecule and measured fragments of PTH 
along with the intact 1-84 PTH molecule.  Second generation PTH assays, 
which are the most widely used in clinical practice, use two separate 
antibodies.  One is directed against the C-terminal fragment of the PTH 
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molecule and the second is directed against the N-terminal fragment.  These 
assays were initially thought to quantify only the full-length biologically active 
1-84 PTH molecule.  It is now known that they also measure other large PTH 
fragments, predominantly 7-84 PTH.  While the activity of these PTH 
fragments remains uncertain, they have been suggested to have, as yet, 
unconfirmed direct biological actions in skin and bone.74   Third generation 
PTH assays also use a two-antibody technique but in these assays one 
antibody is radio-labelled and directed only against the first six N-terminal 
amino acids of 1-84 PTH, while the second antibody binds to the C-terminal 
region of 1-84 PTH. These assays are more sensitive and specific for the 
measurement of biologically active 1-84 PTH.  Typically mean PTH levels are 
30-60% lower using the third generation PTH assays compared to second 
generation assays77.  Wide variations between the different methods of PTH 
measurement have been demonstrated.78 This had led to concerns that 
patients may be incorrectly diagnosed with either low turnover or high 
turnover bone disease, based on PTH cutoffs, depending on the PTH assay 
used and demonstrates that results from different centres are not 
interchangeable.  Some investigators suggest that the ratio of intact PTH to N-
terminal PTH fragments may be useful in distinguishing between these 
disorders.  It has been proposed that a ratio of less than one indicates low-
turnover bone disease, although this remains controversial.79 
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Biochemical Markers of Bone Turnover 
 
Bone Formation 
Bone Specific Alkaline Phosphatase 
Alkaline Phosphatase is a ubiquitous enzyme that is present in high 
concentrations in the intestine, kidney tubules, bone, liver and placenta.  
Although similar, distinct isoenzymes exist in each of these tissue sites.  The 
vast majority of circulating alkaline phosphatase originates from either the 
liver or bone. The bone isoenzyme of alkaline phosphatase (Bone specific 
Alkaline Phosphatase (BAP)), is produced by osteoblasts and is a marker of 
bone mineralization and maturation.  BAP levels are elevated in the circulation 
during active periods of bone formation and bone growth, particularly during 
infancy and puberty.  BAP is not filtered by the kidneys and is not dialyzed, 
therefore plasma concentrations are not affected by variations in GFR and 
levels depend solely on the rate of release from osteoblasts and on its rate of 
degradation.  Total circulating alkaline phosphatase has been used for many 
years as a marker of bone metabolism, but in the presence of liver disease 
levels may be unhelpful.  Radioimmunoassays have been developed using 
monoclonal antibodies that can reliably detect the bone specific form of 
alkaline phosphatase and have been shown to be more sensitive than total 
alkaline phosphatase in the evaluation of bone turnover in CKD.80  High levels 
of BAP in CKD correlate with PTH levels and histological evidence of high bone 
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turnover.81  However, low levels of BAP alone do not reliably exclude high 
turnover bone disease.  When evaluated in combination with PTH levels, the 
sensitivity and specificity of predicting the type of bone turnover is 
improved.82 
 
Osteocalcin 
Osteocalcin, which is also known as Bone Gla protein, is the most important 
non-collagen protein in the bone matrix.  It is a 49 amino acid peptide 
synthesized by mature osteoblasts.  Osteocalcin is produced during bone 
formation and is dependent on Vitamin K and is stimulated by Vitamin D.  Both 
intact osteocalcin and the large N-terminal mid-molecule fragment circulate in 
the blood.  Intact osteocalcin is much less stable than the N-terminal fragment.  
Electrochemiluminescence immunoassay ELICA assays have been developed 
using monoclonal antibodies directed against the N-terminal mid-molecule 
fragment and the N-terminal of the intact molecule. The assay therefore 
detects both intact osteocalcin along with the cleaved fragments. Serum 
osteocalcin is primarily cleared by the kidney and the molecule can 
accumulate in uraemia. This occurs when eGFR falls below 20-
30mls/min/1.73m2.83  Osteocalcin has been shown to correlate positively with 
PTH in pre-dialysis CKD, independent of eGFR.84 
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Procollagen Type 1 N-Terminal extension Peptide 
More than 90% of bone matrix consists of Type 1 collagen.  Type 1 collagen is 
derived from Type 1 Procollagen which is synthesized in osteoblasts.  Type 1 
Procollagen has N (amino) and C (carboxy) terminal extensions.  These 
extensions are cleaved off during the conversion of procollagen to collagen.  
The Procollagen Type 1 N-terminal extension peptide (PINP) can be measured 
in the serum and is a marker of Type 1 collagen deposition in the bone matrix 
and therefore a marker of bone formation.  PINP is measured using an ELISA 
assay, using an antibody directed against the alpha-chain of Type 1 
Procollagen.85  PINP correlate positively with PTH and BAP and negatively with 
forearm BMD in haemodialysis patients.86 
 
Bone Resorption 
Tartrate Resistant Acid Phosphatase (TRAP) 
TRAP is an enzyme released by osteoclasts during bone resorption. It has a 
number of different isoforms and specific antibodies have been developed 
that can distinguish the different sub-types, using enzyme-linked 
immunoabsorbant assay (ELISA). The isoform TRACP5b is exclusively 
associated with bone resorption rate and has been shown to be elevated in 
patients with osteoporosis and is negatively correlated with Bone Mineral 
Density in post-menopausal women.87 TRACP5b has been evaluated in 
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patients with CKD and is unaffected by GFR or by haemodialysis.88 Higher 
levels of TRACP5b have also been shown to be associated with rapid rates of 
cortical bone loss in patients receiving haemodialysis.89 This enzyme is 
relatively unstable, and samples must be separated rapidly and frozen within 2 
hours before analyzing, which limits the utility of TRACP5b as a useful non-
invasive marker of bone resorption in clinical practice. 
 
Type 1 Collagen N-Terminal Cross-Link Telopeptide  
When osteoclasts resorb bone, minerals and collagen fragments are released 
into the circulation. The N-Terminal cross-link telopeptide (NTX) is 
preferentially released from Type 1 collagen by osteoclastic activity.90   Serum 
and urine concentrations of NTX can be measured by ELISA using a monoclonal 
antibody against the N-Telopeptide of mature collagen chains in Type 1 
collagen.  Urine assays are corrected for urine concentration by indexing to 
urine creatinine levels and are performed on second void urine samples. 
Serum NTX levels have been shown to correlate negatively with forearm Bone 
Mineral Density and positively with PTH in haemodialysis patients.91 
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C-Terminal Cross-Link Telopeptide 
Similar to NTX, C-Terminal Cross-Link Telopeptides (CTX) are degradation 
products of Type 1 collagen and are generated by bone resorption.  In C-
terminal telopeptides, α-aspartic acid is isomerised to the ß-aspartic form as 
the bone ages.  The ß isomerised telopeptides are specific for the degradation 
of type 1 collagen in bone.  CTX assays are based on the Crosslaps antibodies 
which recognize the ß isomerised aspartate residue. CTX can be measured 
using an automated analyser.  CTX has been shown to be correlated with 
forearm bone loss in post-menopausal women and serum levels decrease 
significantly following treatment with anti-resorptive therapy.92  Serum CTX 
was also shown to correlate with cortical boss loss and with BAP and 
osteocalcin in haemodialysis patients.93 
 
 Sclerostin 
Sclerostin, a product of the SOST gene, is a protein expressed by osteocytes.  
The main action of sclerostin is to decrease bone formation by inhibiting 
osteoblast proliferation and promoting osteoblastic apoptosis.94 Whether 
sclerostin also has a role in bone resorption is unclear. Sclerostin levels are 
higher in patients with CKD Stage 5 on dialysis than in healthy controls and 
post-menopausal women.95, 96  In a bone biopsy study of 60 haemodialysis 
patients, Cejka et al. found sclerostin to be a strong predictor of bone turnover 
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and osteoblast number and in this study low serum sclerostin levels were a 
better predictor than PTH for high bone turnover and osteoblast number.96  
Administration of anti-sclerostin anti-bodies has been show to increase Bone 
Mineral Density in humans.97 
 In summary, bone biopsy is the gold standard for the assessment of bone 
turnover and bone health in CKD. As bone biopsy is not widely available in 
clinical practice, PTH levels have been used as a surrogate to diagnose high 
and low turnover bone disease. Recent evidence suggests that PTH used alone 
is not a reliable marker of bone turnover in patients with CKD. The use of 
biochemical markers of bone formation and resorption, in combination with 
PTH may potentially improve the diagnosis and monitoring of CKD-MBD. 
 
Cardiovascular Disease in CKD 
Cardiovascular Disease is a common complication of CKD and ESKD and is an 
undisputed risk factor for mortality, the incidence of which is greatly 
increased, even in young patients with CKD.  Go et al have shown a graded 
increase in all-cause and cardiovascular mortality in CKD patients as renal 
function decreased.  This study showed age standardized cardiovascular 
mortality rates of 2.1 per 100 person years for patients with GFR 45-59 
ml/min/1.73m2 which increased to 36.6 per 100 person years at GFR less than 
15ml/min/1.73m2.15  Similarly, Foley et al. showed that mortality rates from 
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cardiovascular disease for patients on dialysis are approximately 10 – 20 times 
higher in patients with ESKD than in the general population, regardless of age. 
In particular, even in young patients on dialysis, mortality from cardiovascular 
disease was similar to that of octogenarians without kidney disease. (Figure 
1.2) In this study cardiovascular mortality was defined as death due to 
arrhythmia, cardiomyopathy, cardiac arrest, myocardial infarction, 
atherosclerotic heart disease or pulmonary oedema.98 After successful renal 
transplantation this risk of cardiovascular death, while attenuated remains 
markedly elevated.99 
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Figure 1.2: Cardiovascular mortality in the General Population compared to 
ESKD treated with dialysis. 98 Reproduced with permission from “Clinical 
epidemiology of cardiovascular disease in chronic renal disease.” Foley RN, 
Parfrey PS, Sarnak MJ. Am J Kidney Dis 1998; 32: S112-119. 
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Vascular Calcification in CKD 
Calcification of the blood vessel wall occurs at two sites, the intima and the 
media.  Intimal calcifications are associated with atherosclerosis and are due 
to calcification of atherosclerotic plaques.  Intimal calcification occurs 
preferentially in the aorta, coronary, carotid and femoral arteries and lesions 
tend to be discontinuous.  In contrast, calcification of the arterial media, also 
known as Monckeberg sclerosis occurs as diffuse sheet-like calcification of the 
tunica media without intimal involvement.  Medial calcification occurs in the 
elastic lamina of large and medium sized blood vessels and is common in 
patients with CKD.  It is also associated with advancing age and diabetes. 
Medial and intimal calcifications may be present simultaneously in the patient 
with CKD, but their clinical consequences are different. Intimal lesions are 
associated with plaque rupture and distal occlusion of the vessel lumen, while 
medial calcification is associated with increased arterial stiffness, increased 
pulse pressure,100 increased cardiac afterload, left ventricular hypertrophy and 
predisposition to heart failure and sudden cardiac death.101 Medial vascular 
calcification was originally thought to represent passive mineral deposition; 
however, it is now recognized as being a highly ordered maladaptive process, 
influenced by several systemic and local inhibitors and promoters of 
calcification. 
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Pathogenesis of Vascular Calcification 
Vascular smooth muscle cells (VSMCs) are central to the development of both 
intimal and medial arterial calcification. VSMC’s retain their ability to 
differentiate and proliferate in order to repair the vessel wall after injury. 
However, they also have the ability to undergo phenotypic change and can 
differentiate into other cell types such as osteoblasts, chrondrocytes and 
adipocytes.102 This phenotypic change is induced by injury to the VSMC which 
in atherosclerosis is due to lipid-induced inflammation.  In CKD, the injury to 
the VSMC is due to abnormal mineral homeostasis, (where elevations in 
calcium and phosphate have a synergistic effect), 103 chronic volume overload 
and hypertension.  Once the VSMC is injured, apoptosis of the cell and vesicle 
formation ensues.104 This induces phenotypic change of the VSMCs into 
osteoblast-like cells. The apoptotic bodies also act as a nidus for calcification in 
the vessel wall. Calcification is accelerated in the presence of high levels of 
PTH, Vitamin D, calcium, and mostly significantly, phosphate.105 
While vascular calcification is common in CKD and ESKD, not all patients 
calcify, despite persistent abnormalities in mineral homeostasis.  This has led 
to the identification of a number of local and systemic inhibitors of vascular 
calcification which protect against calcification in health and in a certain 
patients with CKD. 
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Fetuin A 
Fetuin A is an extracellular protein which is a potent inhibitor of calcium-
phosphate precipitation.  It is produced in the liver and is a negative acute 
phase protein, with reduced circulating levels during inflammation. Fetuin A 
acts both systemically and locally to prevent vascular calcification. Systemically 
it binds calcium and phosphate and prevents VSMCs from exposure to high 
levels of these minerals. Locally, Fetuin A inhibits VSMC apoptosis and 
promotes phagocytosis of vesicles by VSMCs, thereby removing the potential 
nidus for calcification.  In addition, VSMCs can secrete Fetuin A and protect the 
cell from calcium and phosphate mediated injury. Fetuin A levels are lower in 
patients with ESKD compared to the general population, 106  and lower levels 
are associated with increased cardiovascular mortality.107 
 
Matrix Gla Protein 
Matrix Gla protein is derived from bone and vascular smooth muscle cells and 
is a potent local inhibitor of vascular calcification.  It is dependent on 
carboxylation by Vitamin K in order to become fully biologically active.  Matrix 
Gla protein inhibits vascular calcification directly by preventing precipitation of 
calcium and phosphate.  It also acts to prevent differentiation of VSMCs into 
osteoblast-like cells.  Decreased levels of uncarboxylated matrix Gla protein 
are associated with declining renal function and increased vascular 
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calcification.  Vitamin K antagonists, such as warfarin prevent the 
carboxylation of matrix Gla protein to its active form.108  Nutritional Vitamin K 
intake has been shown to be inversely associated with vascular calcification 
and mortality.109  The use of Vitamin K antagonists such as warfarin has been 
associated with increased coronary artery and valvular calcification, 110 
although other studies have not confirmed these findings.111 
Osteoprotegerin 
Osteoprotegerin is a glycoprotein member of the tumour necrosis factor (TNF) 
receptor family. It acts as a soluble inhibitor that prevents activation of nuclear 
factor κB (RANK) ligand (RANKL) with its receptor RANK. Osteoprotegerin is an 
important modulator of bone remodelling and by inhibiting activation of RANK 
it inhibits osteoclast formation, differentiation, activation and survival, 
preventing bone resorption.  It is expressed by endothelial cells, VSMC’s and 
osteoblasts.112 In experimental animal models, osteoprotegerin deficiency is 
associated with accelerated medial vascular calcification and these animals 
also develop severe osteoporosis. Replacement of osteoprotegerin leads to 
reversal of the osteoporosis, but had no effect on the vascular calcification.113 
Recently an anti RANKL antibody has been licensed for the treatment of post 
menopausal osteoporosis.114 In humans, osteoprotegerin levels are 
significantly higher in patients with CKD and ESKD than in those without CKD 
and osteoprotegerin levels are higher at lower levels of renal function.115 The 
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role of osteoprotegerin in vascular calcification in CKD is unclear. 
Observational studies in patients with normal renal function116 and in 
haemodialysis patients have shown a positive association between 
osteoprotegerin levels and severity and progression of vascular calcification117, 
118 and osteoprotegerin levels were predictive of future cardiovascular 
events.119, 120  In a large cohort of renal transplant recipients osteoprotegerin 
has recently been independently associated with renal events, cardiovascular 
events and mortality.121 The role of osteoprotegerin in the pathogenesis of 
vascular calcification in these studies is unclear but it has been suggested that 
osteoprotegerin levels increase as a defensive response to rapidly progressive 
mineral deposition in the vessel wall.122 
 
Pyrophosphate 
Pyrophosphate is a potent inhibitor of vascular calcification and exerts its 
effect by directly preventing hydroxyapatite formation.  It is produced by 
arterial smooth muscle and is hydrolysed and inactivated by alkaline 
phosphatase.123  O’ Neill et al. have demonstrated that plasma pyrophosphate 
is negatively associated with vascular calcification in ESKD and CKD.124  
Experimental studies have shown that administration either subcutaneously125 
or intraperitoneally126 of pyrophosphate can inhibit vascular calcification in the 
uremic setting without adversely affecting bone formation. 
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In summary, vascular calcification in CKD is a highly regulated process, initiated 
by injury to the VSMC, and involves a complex interplay between promoters 
and inhibitors of vascular calcification.127 (Figure 1.3)  This process shares 
many similarities with the process of bone mineralization.    
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Figure 1.3: Pathogenesis of Vascular Calcification in Chronic Kidney Disease.
                             
Figure 1.3: Model shows VSMC phenotypic adaptation in response to mineral 
dysregulation in CKD. VSMCs that fail to adapt to a synthetic phenotype and release 
vesicles to protect against Calcium overload will eventually undergo necrosis. In 
contrast, VSMCs that release vesicles do not succumb to intracellular Calcium 
overload but deposit Calcium in the extra cellular matrix, which eventually calcifies. 
This process eventually results in apoptosis of VSMCs. Reproduced with permission 
from “Chronic mineral dysregulation promotes vascular smooth muscle cell 
adaptation and extracellular matrix calcification.” Shroff R C et al. JASN 2010; 21:103-
112103 
VSMC, Vascular Smooth Muscle Cell, CKD, Chronic Kidney Disease, P, Phosphate, Gla-
MGP, Matrix Gla protein, ALK, Alkaline Phosphatase, PPi, Pyrophosphate, Runx2, Runt 
-related transcription factor 2, required for osteoblast differentiation. 
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Assessment of Vascular Calcification 
A number of non-invasive methods are available to assess vascular 
calcification and arterial stiffness.  The presence of vascular calcification or 
increased arterial stiffness using each of these modalities is associated with an 
increased risk of adverse consequences and cardiovascular mortality both in 
CKD and ESKD. 
 
Plain Radiography 
Plain radiography is a useful non-invasive and inexpensive tool for detecting 
the presence of vascular calcification, both in the general population and in 
CKD.  The pattern of calcification seen on the radiograph can help to 
differentiate between intimal and medial calcification, with the former 
typically demonstrating patchy, discontinuous lesions.  Medial calcifications 
are seen as linear “tram-track” lesions along the course of the vessel wall. 
However, the pattern is not sufficiently diagnostic to allow any of the available 
imaging modalities to reliably distinguish between the two forms. 
Both types of calcification are associated with increased mortality.  Blacher et 
al showed an association between arterial calcification and survival in patients 
on haemodialysis, with mortality increasing with higher number of arterial 
sites demonstrating calcification on plain radiograph.128  Kauppila at al 
introduced a semi-quantitative scoring system for vascular calcification using 
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lateral radiographs of the lumbar spine.  Using this system, calcifications along 
the anterior and posterior margins of the aortic contour, adjacent to the 4 
lumbar vertebrae are scored 0 to 3. A score of zero represents no evidence of 
calcification, 1 represents calcification extending less than one third the length 
of the adjacent vertebra, a score of 2 represents calcification extending for 
more than one third, but less than two thirds the length of the vertebra and a 
score of 3 represents calcification extending more than two thirds the length 
of the vertebra.  This system, applied to each of the lumbar aortic segments, 
results in a composite score of between 0 and 24.129  This scoring system was 
used in a study of 515 dialysis patients which showed the presence of aortic 
calcification to be predictive of all cause and cardiovascular mortality.130 The 
KDIGO group recommended in 2006 that lateral abdominal radiography be 
used as a screening tool for the detection of vascular calcification.33 
 
Aortic Pulse Wave Velocity 
Carotid – Femoral (Aortic) Pulse Wave Velocity measures the speed with which 
the arterial pulse travels down the aorta and thus is a measure of aortic 
stiffness.  Using this technique, Doppler waveforms are obtained 
transcutaneously over the common carotid and femoral arteries, in sequence.  
Pulse Wave Velocity is calculated as the distance between the suprasternal 
notch and the femoral artery recording site, measured over the body surface.  
This distance is divided by the time taken for the pulse wave to travel between 
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the two arterial sites.131  Time delay is measured using the R wave on 
continuous ECG monitoring as a timing reference. Pulse Wave Velocity is 
expressed as meters/second.  This method is supported by a large number of 
epidemiological studies which show that aortic stiffness is an independent 
predictor of all cause and cardiovascular mortality in patients with various 
levels of cardiovascular risk, 132 including ESKD.133 
 
Computed Tomography  
While plain radiographs provide a semi-quantitative assessment of vascular 
calcification and Pulse Wave Velocity provides an assessment of the resultant 
aortic stiffness, Electron Beam (EBCT) and Multi Slice Computed Tomography 
represent the gold standard in the detection of vascular calcification although 
they are not universally available. The extent and degree of calcification can be 
precisely quantified using Agatston and volumetric scoring systems.  Multi 
Slice CT scanners can acquire up to 64 simultaneous slices with thickness of 
the slices as low as 0.5mm, allowing precise quantification of vascular 
calcification. Newer software systems can facilitate low radiation dose 
protocols with similar diagnostic results.  While CT scanning cannot distinguish 
between intimal and medial calcification, the detection of vascular calcification 
by CT is associated with reduced survival in dialysis patients.134  Due to its 
precision, CT has also been used to monitor vascular calcification and to assess 
the effect of therapeutic interventions in slowing its progression.135        
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Relationship between Bone Abnormalities and Vascular Calcification 
Bone disease and vascular calcification are both multifactorial, complex 
processes. Vascular calcification is a highly regulated process which resembles 
bone mineralization.  Several epidemiological studies in the general population 
have demonstrated a relationship between decreased bone mineral density 
and increased vascular calcification.  In the Framingham Heart Study, Kiel et al. 
demonstrated that there was a significant association between percentage 
change in Bone Mineral Density (measured by metacarpal relative cortical area 
(MCA)) and progression of abdominal aortic calcification (measured by lateral 
lumbar radiograph) in women though not men over a 25 year follow up 
period.136  Similarly, in a cross-sectional study of 2348 post-menopausal 
women, Schluz et al. found aortic calcification scores were inversely related to 
bone mineral density (both parameters determined by CT).  This study also 
reported that the Odds Ratios (95% Confidence Interval) for vertebral and hip 
fractures in those women with calcification were 4.8 (3.6 – 6.5) and 2.9 (1.8 – 
4.8) respectively, compared to those without evidence of calcification.  In a 
subgroup analysis of 228 women with available longitudinal data, this study 
also demonstrated a significant graded association between progression of 
vascular calcification and bone loss, where women with the greatest increase 
in vascular calcification had 4 times greater yearly bone loss than women of 
similar age in the lowest vascular calcification quartile.137  In a larger 
prospective study of 624 men and women over the age of 50 years, Naves et 
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al. showed that progression of aortic calcification (determined by lateral 
lumbar radiograph) was associated with the rate of decline in Bone Mineral 
Density (determined by DXA) over 4 years of follow-up.  This relationship 
remained significant following adjustment for age, gender, smoking history 
and diabetic status.138 
This relationship has also been demonstrated in patients on dialysis, a 
population with markedly elevated risks of bone fracture and cardiovascular 
events.  London et al. showed an inverse relationship between arterial 
calcification and bone activity, determined by bone biopsy.  This study found 
that subjects with adynamic bone disease on bone biopsy had the greatest 
degree of arterial calcification, while active bone was associated with less 
vascular calcification.131  This finding is consistent with the theory that low 
turnover bone disease impairs the ability of the bone to buffer minerals and 
they are then deposited in soft tissues and vasculature.  It was also noted in 
this study that patients with a greater degree of arterial calcification had lower 
PTH levels, indicating that over-suppression of PTH predisposes to vascular 
calcification. Similarly the Treat to Goal study showed that treatment with the 
non-calcium containing phosphate binder sevelemar slowed progression of 
aortic calcification 139 and vertebral bone loss, 140 compared to calcium based 
phosphate binders (both p = 0.01).      
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The pathogenesis of both bone disease and vascular calcification in CKD is 
closely inter-related.  Both conditions are stimulated by abnormal mineral 
homeostasis, particularly abnormally high levels of phosphate. In addition a 
number of proteins involved in bone formation have been identified at sites of 
arterial calcification, such as alkaline phosphatase, bone sialoprotein, 
osteocalcin, along with hydroxyapatite, the same crystal found in bone. FGF 23 
which is secreted by osteocytes and whose primary function is the regulation 
of phosphate homeostasis has been associated with increased risk of Left 
Ventricular Hypertrophy,141 cardiovascular events and mortality across a wide 
range of renal function.142, 143  As discussed previously, abnormal mineral 
metabolism also stimulates differentiation of the VSMC into osteoblast-like 
cells, capable of mineralisation. While the mechanisms underlying the 
relationship between abnormal bone health and vascular calcification in CKD 
are incompletely understood, based on current evidence it appears likely, 
though it remains unproven, that minimizing abnormalities in phosphate, 
calcium, PTH and Vitamin D metabolism may help to prevent bone loss and 
cardiovascular morbidity and mortality.             
                             
Post Transplant Bone Disease and Vascular Calcification. 
Successful renal transplantation restores effective endogenous renal function 
to patients with ESKD and improves survival, but it fails to restore either 
normal longevity or health.98, 144  Cardiovascular disease accounts for up to 
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50% of all-cause mortality in renal transplant recipients145 and mortality rates, 
while substantially lower than that of the dialysis population,144 are 
approximately four times that of the age matched general population.146  Risk 
factors for cardiovascular disease after renal transplant include traditional risk 
factors common to the general population, such as older age, pre-existing 
diabetes mellitus, hypertension, hypercholesterolemia and Left Ventricular 
Hypertrophy.  Renal transplant recipients also accrue additional non-
traditional risk factors specific to their post-transplant status namely, often 
suboptimal levels of renal function provided by the allograft, de-novo 
hyperglycaemia and hyperlipidemia due to immunosuppressive agents and 
residual disturbances in mineral metabolism.147 Post-transplant 
hyperparathyroidism improves over the first year post transplant but PTH 
levels stabilize at elevated concentrations in over 50% of patients and in a 
substantial minority of cases are associated with hypercalcaemia.148-151 It is 
typically assumed that with normalization of bone minerals and improvement 
in PTH levels, vascular calcification stabilizes or improves though few studies 
have examined the natural history of arterial calcification post-renal 
transplant.  Several small cross-sectional studies have reported the prevalence 
of vascular calcification in renal transplant recipients, determined by EBCT, to 
be between 65% and 92%, which was similar to the comparative dialysis 
population.152, 153 One prospective study of 23 transplant recipients found no 
evidence of progression of coronary artery or aortic calcification scores, 
53 
 
determined by spiral CT over 15-20 months of follow-up.154 Similarly, several 
small studies (n=36 to 41) have shown improvement in vascular function and 
vascular stiffness following renal transplant.155-157 Conversely, in a recent study of 
281 renal transplant recipients, Marechal et al. demonstrated a significant increase in 
spiral CT measures of coronary artery and thoracic aorta calcification scores over 3.5 
years of follow-up.158 
While cardiovascular risk improves post renal transplantation (compared to 
continuing on dialysis), fracture risk remains elevated and in fact the risk of 
fracture increases further post transplant. 159-161 In contrast to vascular 
calcification, numerous studies have evaluated fracture risk and its predictors 
in the post transplant population. Nikkel et al, in a study of 69,000 renal 
transplant recipients, reported that 22.5% of patients suffered a fracture 
within 5 years.162 The cumulative incidence of any fracture at 15 years post 
transplant was reported by Vautour to be 60%.159 Overall, renal transplant 
recipients have an adjusted incidence ratio for fracture of 4.59 (95% CI 3.29 to 
6.31) compared to the general population, along with an increased risk of all-
cause mortality of 1.6 (95% CI 1.13 to 2.26).163 A high prevalence of fractures 
affecting the extremities has been observed in renal transplant recipients, at 
sites containing a high proportion of cortical bone. 164, 165  
Risk factors for fracture post renal transplant include dialysis vintage prior to 
transplant, severity of pre-transplant hyperparathyroidism, duration since 
transplant, female gender, diabetes mellitus, age greater than 45 years, 
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decreased bone mineral density, prior history of fracture and 
immunosuppressive therapies (corticosteroids and calcineurin inhibitors).165  
Evaluation of Bone Mineral Density by DXA after renal transplant in most 
studies shows rapid bone loss particularly in the first 6 to 12 months post 
transplant.  Sprague et al, in a literature review, reported that 35% of renal 
transplant recipients had low lumbar spine Bone Mineral Density and 21% had 
low Bone Mineral Density at the femoral neck within the first 6 years post 
transplant.  After 6 years, the proportion of patients with low lumbar Bone 
Mineral Density was 22%, while the proportion with low femoral neck Bone 
Mineral Density was essentially unchanged at 22%.150  
Unlike in the ESKD population, Bone Mineral Density assessment by DXA is 
associated with fracture risk in the post transplant population. In a study of 
238 renal transplant patients who underwent DXA scanning of the lumbar 
spine and hip, 13.9% of the participants had osteoporosis, defined as a T-score 
less than -2.5.  The authors found that osteopenia and osteoporosis were 
independent risk factors for fracture with relative risks of 2.7 (95% CI 1.6 to 
4.6) and 3.5(95% CI 1.8 to 6.4) respectively.166 Interestingly, the majority of 
fractures occurred at peripheral sites such as wrist, foot and leg. Assessment 
of a predominantly cortical bone site –such as distal radius- was not included 
in the study; this may have resulted in a higher prevalence of osteoporosis.  
Roe at al. in a study of 134 renal transplant patients reported that the 
proportion of patients diagnosed as having osteoporosis increased from 30% 
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to 41% when DXA examination of the distal forearm was included. In this 
study, the level of PTH, which has preferential catabolic action on cortical 
bone, correlated strongly with Bone Mineral Density at the radial site.167 
While individual components of CKD-MBD, such as residual mineral 
disturbances, fracture risk and vascular calcification, have been examined in 
the post transplant population, whether the complex inverse relationship 
between bone health and vascular calcification seen in CKD and dialysis 
patients persists in the post transplant setting remains poorly described, but 
may influence the long term health of the successful transplant recipient. 
 
Hyperparathyroidism and Health Related Quality of Life 
 
Primary Hyperparathyroidism 
With increased use of routine screening of serum calcium levels, the clinical 
presentation of primary hyperparathyroidism has changed.  The classic 
symptoms of bone pain, nephrolithiasis and significant neuropsychiatric 
disturbance are seen in only 20% of patients presenting with primary 
hyperparathyroidism.168  In a seminal Consensus Conference statement in 
1991,  the National Institute of Health (NIH)  stated that evidence of mineral 
bone loss, a decrease in renal function and classical symptoms were 
indications for surgical correction of primary hyperparathyroidism.169 However 
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most patients with primary hyperparathyroidism exhibit vague, non specific 
manifestations of the disease such as mood swings, irritability, fatigue and 
increased absenteeism from work.170  These symptoms often develop 
insidiously and are under appreciated or attributed to the effects of aging. 
Recognition of these non-classical symptoms has led to the development of a 
disease specific outcome tool for hyperparathyroidism which has been 
validated by a number of studies in symptomatic and asymptomatic 
patients.171, 172 These studies and others173, 174 also demonstrated an 
improvement in symptom score and Health Related Quality of Life following 
surgical treatment of primary hyperparathyroidism. In light of this more recent 
data, the original NIH consensus statement has been revised. A consensus 
statement from the proceedings of the Third International Workshop on 
Asymptomatic Primary Hyperparathyroidism (2008) stated that “the balance 
of available evidence suggests that surgery is appropriate in the majority of 
patients with asymptomatic hyperparathyroidism”.175 
 
Post Renal Transplant Hyperparathyroidism and Quality of Life. 
Secondary hyperparathyroidism is a frequent complication of Chronic Kidney 
Disease (CKD) and End Stage Kidney Disease (ESKD). After successful renal 
transplantation, serum calcium and phosphate values typically normalise.  
However whether hyperplastic parathyroid tissue ever spontaneously 
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involutes is controversial.176  Regardless, the secretion of PTH decreases over 
several weeks to months and usually falls to within the normal reference 
range.  However in up to one quarter of renal transplant recipients the 
restoration of adequate endogenous renal function does not lead to 
normalisation of PTH levels.  Approximately one third to one half of these 
patients also demonstrates mild to moderate hypercalcaemia.148, 165   
The disease specific Parathyroid Assessment of Symptoms tool has been 
utilised in a study of patients with secondary  and tertiary 
hyperparathyroidism due to ESKD, where tertiary hyperparathyroidism was 
defined as persistently elevated PTH six months post successful renal 
transplantation.  This study compared the pre and post-operative disease 
specific tool scores and Quality of Life scores of patients with primary, 
secondary and tertiary hyperparathyroidism with those of a control group with 
non-toxic thyroid disease.  Although the group with tertiary 
hyperparathyroidism (post transplant), was too small (n=10) for meaningful 
statistical analysis, they showed resolution of their symptoms similar to those 
in the primary hyperparathyroidism group.53 
The non-specific symptoms of hyperparathyroidism such as fatigue irritability 
and mood swings are generally assumed to be due to associated 
hypercalcaemia.  However studies have shown that patients with primary 
hyperparathyroidism have significant functional health status impairment 
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independent of the level of serum calcium.  The relative impact of elevated 
PTH levels independent of serum calcium values on the health status of renal 
transplant recipients has not previously been evaluated. 
In summary, abnormalities in mineral metabolism are common complications 
of CKD and are central to the development of bone disorders and vascular 
calcification, which is an undisputed risk factor for cardiovascular mortality, 
the incidence of which is greatly increased even in young people with CKD. 
Disorders of bone health in CKD are closely related to the development and 
progression of vascular calcification and confer a substantially increased risk of 
fragility fractures, with their attendant increases in morbidity and mortality.  
Cardiovascular mortality and fracture risk remain markedly elevated following 
renal transplantation.  The role played by persistent abnormalities in mineral 
metabolism, particularly residual hyperparathyroidism, in these inter-related 
pathologies has not been evaluated, nor has the effect of elevations in PTH 
post transplant on the Health Related Quality of Life and overall well-being of 
the transplant recipient been examined. 
This study was undertaken to examine firstly, risk factors for decreased Bone 
Mineral Density and fracture occurrence in the general population, namely 
renal function and serum sodium levels and secondly to determine if post 
renal transplant hyperparathyroidism and hypercalcaemia are associated with 
increased measures of vascular calcification, abnormal bone turnover, 
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decreased Bone Mineral Density, and decreased measures of Health Related 
Quality of Life. 
 
Study Aims and Hypotheses 
Specific Aim 1a (Chapter 2): To examine the cross-sectional association 
of CKD Stage 2-5 with decreased Bone Mineral Density and fracture 
occurrence within the general population by cross-linking Bone Mineral 
Density measurements from the DXA database at Cork University 
Hospital (CUH) Department of Rheumatology with estimated GFRs 
obtained from Cork University Hospital central biochemistry 
laboratory. 
 Specific Aim 1b (Chapter 3): To examine the cross-sectional 
association of hyponatremia (serum sodium <135mmol/L) with fracture 
occurrence in the general population and to assess if this relationship 
was associated with decreased Bone Mineral Density. 
 
Hypothesis 1 That the presence of mild to moderate quantitative (e.g. a 
reduction in Glomerular Filtration Rate) or qualitative (e.g. reduced serum 
sodium concentration) abnormalities in renal function are independently 
associated with decreased Bone Mineral Density and occurrence of bone 
fracture in the general population. 
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Specific Aim 2: To conduct a cross-sectional observational study of successful 
first renal transplant recipients between 4 months and 12 years post-
transplantation to determine the association of persistent post-transplant 
hyperparathyroidism with CKD Mineral Bone Disorder, in particular: 
Specific Aim 2A (Chapter 4): Prevalent Post-Transplant Measures of 
Bone Health including DXA Bone Mineral Density and indices of bone 
formation and resorption. 
Specific Aim 2B (Chapter 5): Measures of Vascular Calcification as 
measured by Pulse Wave Velocity and radiographic calcification scores. 
Specific Aim 2C (Chapter 6): Measures of Health Related Quality of Life 
as measured by parathyroid disease specific and SF  12 Quality of Life 
surveys.  
Hypothesis 2: That persistent post-transplant hyperparathyroidism is 
associated with decreased Bone Mineral Density, abnormal bone turnover, 
increased measures of vascular calcification, and reduced Health Related 
Quality of Life, all of which are likely to be injurious to the long term health of 
the transplant recipient.   
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Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moderate CKD in Women is Associated with Fracture 
Occurrence Independently of Osteoporosis 
 
 
 
 
 
 
 
This work has been peer reviewed and published as “Moderate Chronic Kidney 
Disease in Women Is Associated with Fracture Occurrence Independently of 
Osteoporosis.” Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA.  
Nephron Clin Pract. 2010 Jul 2; 116(3):c256-c262.  PMID: 20606487  
(Extracts reproduced with permission of the publishers). 
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Introduction    
 
Several recent studies have reported the association of increased fracture risk 
with stage 3 and 4 Chronic Kidney Disease (CKD)177-182, an association that is 
well established in subjects with End Stage Kidney Disease183, 184. Fragility 
fractures are a major public health concern185 and result in prolonged 
hospitalization, disability and substantial mortality.184 Given the prevalence of 
mild to moderate CKD in the general population,186 an independent 
association of CKD with fragility fractures would add substantially to the Public 
Health burden attributable to CKD.  
Fragility fractures are strongly associated with age related osteoporosis, a 
condition that shares many risk factors with CKD.187  Moreover, advanced CKD 
leads to a combination of quantitative and qualitative abnormalities of bone, 
referred to as Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD).188 
The aetiology of CKD-MBD is complex and includes hyperphosphatemia, 
hyperparathyroidism, hypovitaminosis D and uncontrolled acidosis.184, 187, 189 
These factors may co-exist with unrelated pathologies such as age related 
decreased bone mineral density, though distinguishing between these 
processes in advanced CKD is extremely difficult in the absence of a bone 
biopsy.190  A progressive deterioration in many of the factors that predispose 
to CKD-MBD is evident at earlier stages of CKD191 but the extent to which the 
risk of fragility fracture in moderate CKD is mediated by or, alternatively, is 
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independent of the presence of osteoporosis is unclear. We therefore 
conducted the following retrospective study of subjects who had undergone 
routine elective bone mineral density measurement to test the hypothesis that 
stage 3 CKD is associated with fracture occurrence independently of the 
presence of osteoporosis.  
 
Methods 
Study population. Female patients, aged over 18 years who underwent a DXA 
scan at Cork University Hospital between 1st September 2006 and 11th April 
2007 were eligible for inclusion.  To avoid referral bias, as a result of enriching 
the sample with subjects with known decreased renal function who were 
referred for DXA scanning due to a concern for osteoporosis, we excluded 
patients who had been referred from nephrology services.  
 
Bone Densitometry measurement: Dual energy x-ray absorptiometry (DXA) 
measurements were performed at the lumbar sacral spine and both hips using 
a Lunar IDXA™ scanner (General Electric) and expressed as T-scores indicative 
of the number of SDs by which the bone mass value deviated from the mean 
of a group of young normal controls.  In keeping with the World Health 
Organization definition, osteopenia was defined as a lowest reported T-score 
of between -1.0 and -2.5 and osteoporosis as the lowest T-score of  < -2.5.185 
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Data regarding patient demographics, risk factors, current and prior treatment 
regimes for osteoporosis, history of prior fracture and details of co-existent 
medical conditions were obtained from a standardized self-report 
questionnaire, completed at the time of the DXA scan. 
 
Fracture Validation Subgroup: The definition of fracture used in our primary 
analysis was purely based on subjects self report obtained at time of DXA 
scanning. In an attempt to at least partially validate fracture occurrence we 
cross checked self reported fracture occurrence against radiology reports 
and/or fracture clinic attendance at Cork University Hospital. As local patients 
who were referred to Cork University Hospital for DXA scan would also be 
expected to be referred here for fracture care this would be expected to 
confirm many but certainly not all patients with an actual past history of 
fracture. Moreover subjects with spinal collapse fracture would not have been 
referred to the fracture clinic and could have obtained radiological diagnosis at 
a number of other regional radiology units, while alternative fracture services 
are also provided at two other regional public hospitals as well as at a private 
hospital, the records of which we were not able to cross reference. As a result, 
while the absence of fracture confirmation at Cork University Hospital does 
not reliably refute the possibility of a fracture, confirmation does strongly 
support the diagnosis.  
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Calculation of eGFR: The DXA database was manually cross referenced against 
the central laboratory database using agreement of at least 2 of 3 potential 
patient identifiers (name, date of birth, medical record number) to identify 
those subjects who had a serum creatinine within 1 year of the index DXA 
scan. Laboratory results obtained during in-patient admissions were not 
included unless these were similar to previously measured outpatient levels. 
Serum creatinine was assayed at either our main biochemistry laboratory 
(90.4% of samples) or at one of two regional laboratories using the modified 
Jaffe reaction and reported in umol/l.  The estimated Glomerular Filtration 
rate (eGFR) in ml/min/1.73 m2 body surface area was calculated using the 4 
variable Modification of Diet in Renal Disease (MDRD) prediction equation.186  
Due to concerns regarding the precision of eGFR estimates at near normal 
levels of renal function we a priori excluded those subjects whose eGFR was 
greater than 90 ml/min/1.73m2.192,193  Subjects were categorized using eGFR 
cut-offs of 75-89, 60-74, 30-59 and <29 ml/min/1.73m2 body surface area. In 
keeping with National Kidney Foundation Clinical Practice Guidelines subjects 
with an eGFR of 30-60 ml/min/1.73m2 were considered to have moderate 
CKD. We were unable to determine to what extend subjects in the 60-89 
group may have met the definition of CKD as we had no other routinely 
available data regarding the presence of kidney damage such as presence of 
proteinuria. 
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Statistical Considerations: Outlying and clinically implausible values were 
double checked against the original clinical data.  The distribution, central 
tendency and variance of each variable was examined using standard tabular 
and graphical methods. We examined the correlation between the lowest 
recorded T-score per subject – as is used in the clinical definition of 
osteoporosis - and the eGFR using the non-parametric Spearman rank method.  
Tests for linear trend were performed using eGFR expressed as a 3-level 
ordinal dependant variable within the appropriate linear or logistic regression 
model. We examined the presence, strength, significance and independence 
of the association of eGFR category with reduced bone mineral density using 
logistic regression adjusting sequentially for age, osteoporotic risk factors and 
treatments. All regression analyses were also adjusted for the laboratory used 
in order to control for potential inter-laboratory variability. We repeated the 
above analytic strategy to examine the relationship between eGFR and self-
reported fracture occurrence with the T-score being used as an additional 
explanatory variable. Due to their small number (n=13), data from subjects 
with an eGFR <30 ml/min per 1.73m2 are provided for descriptive purposes but 
are not used in statistical tests. Routine model diagnostics included 
assessment of points of high leverage and influence and measurement of the 
overall model ‘Goodness of Fit’ using the method of Hosmer and Lemeshow. 
Analyses were performed using SPSS Version 12.0 software, (Chicago, Illinois, 
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USA) with a 2-sided type 1 error rate of 0.05. The study protocol was approved 
by the Clinical Research Ethics Committee of the Cork Teaching Hospitals. 
 
Results 
Clinical Characteristics: Of the 2900 potential subjects who underwent DXA 
scanning during the study period, 1930 had an available creatinine 
measurement.  Subjects with eGFR greater than 90ml/min per 1.73m2 (n = 
228) were excluded due to concerns regarding the accuracy of the MDRD 
equation at these levels, resulting in a sample size of 1702 participants, Figure 
2.1. Patients with an available serum creatinine were older, less likely to have 
been referred for DXA by their primary care physician, and had less exposure 
to steroids and alcohol; however their occurrence of osteoporosis and 
fractures was similar to those who did not have an available creatinine 
measurement, Table 2.1. Median interval from time of DXA scanning to 
measurement of renal function was 4 weeks, with 69.4% of measurements 
being within 3 months.  
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Figure 2.1: Study Population, 1702 subjects with available DXA and creatinine 
measurement. 
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Table 2.1: Patient Characteristics of women undergoing routine DXA scan, with or 
without an available serum creatinine measurement within 1 year of the scan. 
Characteristic Creatinine Available No Creatinine 
Available 
p value 
Number of Patients 1930 970  
Age (years ), Mean (SD) 61.7 (10.8) 58.6 (11.8) <0.001 
     Range     20 to 97     20 to 88  
T-score, Mean (SD) -2.3 (1.1) -2.3 (1.1) 0.47 
    Range -6.5 to 0.9 -6.4 to 0.9  
Osteoporosis % 46.8 44.0 0.16 
Risk Factors for Osteoporosis  
Amenorrhea % 83.7 76.7 0.01 
Dairy <3 serving/wk % 42.4 40.0 0.34 
Alcohol >5units/wk % 18.2 23.0 0.01 
Steroid Use % 6.3 11.2 <0.01 
Ever Smoked % 18.3 19.6 0.64 
Family History % 10.7 11.3 0.56 
Treatment for Osteoporosis 
Calcium/Vitamin D % 34.7 34.6 0.95 
Antiresorptive % 23.1 19.7 0.06 
HRT % 9.5 10.1 0.6 
Prior Fracture  
None % 71.1 74.0  
0.27 Single % 25.4 23.1 
Multiple % 3.5 2.9 
Referral Source  
General Practitioner % 82.3 91.5  
<0.001 Hospital % 17.7 8.5 
Abbreviations: HRT, Hormone Replacement Therapy 
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The mean (range) age of study participants was 61.7 (23 - 97) years; 29 
subjects (1.7%) were aged less than 35 years. The mean (SD) eGFR was 68.8 
(12.2) ml/min per 1.73m2. The percentage of subjects with eGFR of 75-89, 60-
74, and 30-59 and <30 ml/min per 1.73 m2 was approximately 34%, 45%, 20% 
and 1% respectively, Table 2.2. Eighty-two percent of subjects had been 
referred for the DXA by their primary care physician. Risk factors for 
osteoporosis included amenorrhoea (84%), low dietary intake of dairy 
products (42%), ever having smoked (18%) and a high alcohol intake (18%). 
Over one third of subjects were taking vitamin D / calcium supplementation, 
23% were treated with bisphosphonates or other anti-resorptive agents and 
10% were on hormonal replacement therapy.   As expected, there was a 
strong relationship between older age and reduced renal function, with those 
in the 30-59 ml/min per 1.73m2 category being on average 10 years older than 
those in the 75-89 ml/min per 1.73m2 category. In keeping with their older 
age, lower levels of renal function were also associated with more 
amenorrhoea and with treatment with anti-resorptives agents, and with less 
alcohol use and a lower proportion with a family history of osteoporosis. 
(Table 2.2) Self-reported fracture was associated with older age, more 
amenorrhoea and more calcium and Vitamin D supplementation and anti-
resorptive treatment. (Table 2.3) 
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Table 2.2:  Patient Characteristics of women who met study entry criteria by 
eGFR Category. 
Abbreviations: HRT: Hormone Replacement Therapy.  eGFR: 4 variable MDRD 
estimated Glomerular Filtration Rate. 
* Due to its small sample size data from the eGFR <30 category is provided for 
descriptive purposes only and is not used in calculation of p-values. 
 
 
 
 
 
Characteristic 
 
 
Total 
 
eGFR (ml/min per 1.73m2) 
 
 
p 
trend*  
75-89 60-74 30-59 <30* 
Number of Patients 
(%) 
1702 583 (34.3) 772 (45.4) 334(19.6) 13 (0.8)  
Age (yr) Mean (SD) 61.7(10.8) 57.5(10.6) 62.3(10.1) 67.6(9.6) 67.7(11.9) <0.001  
Range 23 - 97 23 – 88 24 - 97 40 – 89 38 - 83  
Risk Factors for Osteoporosis 
Amenorrhoea % 83.7 77.5 85.8 90.1 76.9 <0.001 
Dairy < 3/week % 42.4 40.8 44.3 41.0 38.5 0.75 
Alcohol intake 
>5units/week % 
18.2 23.5 16.7 12.6 15.4 <0.001 
Steroid Use % 6.3 5.7 5.4 9.3 7.7 0.06 
Ever Smoked % 18.3 19.9 18.8 15.9 23.1 0.31 
Family History % 10.7 12.9 11.3 5.7 7.7 0.001 
Treatment for Osteoporosis 
Calcium/Vitamin D % 34.7 35.3 33.7 36.2 23.1 0.91 
Antiresorptive % 23.1 18.7 25.3 26.0 23.1 0.004 
HRT % 9.5 10.1 9.1 9.6 0.0 0.71 
Referral Source 
General Practitioner 
% 
82.3 82.3 84.1 79.6 38.5 
 
0.46 
Hospital % 17.7 17.7 15.9 20.4 61.5 
72 
 
Table 2.3:  Patient Characteristics by Self-Reported Fracture Status. 
 
 
 
 
 
 
 
Characteristic Total Fracture No Fracture p 
Number of Patients (%) 1702 492 1210  
Age (yr) Mean (sd) 61.7(10.8) 65.4 (10.9) 60.3 (10.4) <0.001  
Range 23 - 97 27 - 97 23 - 89  
Risk Factors for Osteoporosis 
Amenorrhoea % 83.7 88.6 81.7 <0.001 
Dairy < 3/week % 42.4 44.9 41.4 0.194 
Alcohol intake >5units/week % 18.2 16.5 18.9 0.240 
Steroid Use % 6.3 6.1 6.4 0.912 
Ever Smoked % 18.3 16.5 19.0 0.240 
Family History % 10.7 11.6 10.3 0.489 
Treatment for Osteoporosis 
Calcium/Vitamin D % 34.7 44.9 30.5 <0.001 
Antiresorptive % 23.1 31.5 19.8 <0.001 
HRT % 9.5 8.1 10.0 0.237 
Referral Source 
General Practitioner % 82.3 76.8 84.5 
<0.001 
Hospital % 17.7 23.2 15.5 
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Association of eGFR with osteoporosis: The mean T-score (SD) was -2.3 (1.1); 
47% of subjects had osteoporosis (T-score <-2.5). The measured site of lowest 
bone mineral density was spinal in 809 (47.5%). There was no association 
between site of lowest bone mineral density and eGFR category. The eGFR 
was weakly though significantly correlated with T-score, Spearman rank 
r=0.14, p<0.001. The risk of osteoporosis was significantly higher at lower 
eGFR, p linear trend <0.001, Table 2.4 and Figure 2.2.  Although an eGFR of 30-
59 and 60-74 as compared to the reference category of 75-89 ml/min per 1.73 
m2 were associated with osteoporosis on univariate logistic regression, with 
adjustment for age, the strength of this relationship was substantially 
attenuated and no longer significant, Table 2.5.  Subsequent sequential 
models, adjusting simultaneously for risk factors and treatments for 
osteoporosis did not alter this finding and eGFR remained non significant (data 
not shown).  
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Table 2.4: Bone Mineral Density and prior history of fracture occurrence among 1702 
women undergoing routine outpatient DXA measurement, by MDRD eGFR category  
 
 
 
 
 
 
 
 
eGFR (ml/min per 1.73 m2) 
 Total 75-89 60-74 30-59 15-30* p-value* 
Bone Mineral Density 
T-Score: Mean 
(SD) 
-2.3 (1.1) -2.2 (1.1) -2.3 (1.1) -2.5 (1.1) 
 
-3.0 (0.9) <0.001 
Osteoporosis 
(%) 
47.1% 47.1% 48.8% 54.2% 84.6% <0.001 
Number of Fractures 
None: n (%) 1210  
(71.1%) 
449  
(77%) 
540  
(69.9%) 
211 
 (63.2) 
10 
 (76.9%) 
 
 
<0.001 
 
One: n (%) 432 
(25.4%) 
119  
(20.4%) 
203  
(26.3%) 
107 
 (32.0%) 
3 
 (23.1%) 
Multiple: n (%) 60 
(3.5%) 
15 
 (2.6 %) 
29  
(3.8%) 
16 
 (4.8%) 
0  
(0%) 
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Figure 2.2: Box plot of lowest measured Bone Mineral Density by MDRD eGFR 
category. 
 
 
 
 
 
 
 
 
 
 
 
 
Boxplot: showing median (solid heavy line), intra quartile range (box) 
and outliers (open circles). Number within box = sample size. 
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Table 2.5: Crude and age adjusted OR (95% CI) for Association of osteoporosis 
with eGFR (ml/min/1.73m2) 
  Unadjusted Model Age Adjusted Model 
eGFR 75 - 89 1 (Reference) 1 (Reference) 
eGFR 60 - 74 1.44 (1.16 - 1.80) *** 1.02 (0.80 - 1.29) 
eGFR 30 - 59 1.79 (1.36 - 2.35) *** 0.83 (0.61 - 1.12) 
Age (10 yrs)   - 2.33 (2.07 – 2.6) *** 
***p < 0.001 
 
 
Fracture Occurrence:  Overall, 492 patients (28.9%) reported a total of 554 
fractures; 60 (3.5%) subjects had 2 or more prior fractures, Table 2.4. The 
percentage of patients with a prior self-reported fracture was significantly 
higher at lower levels of eGFR, p linear trend <0.001 The percentage of 
patients with multiple prior fractures also increased across lower eGFR 
categories from 2.6% in 75-89 ml/min per 1.73m2 category to 4.8% in the 30-
59 ml/min per 1.73m2 category, p chi square <0.001. In 94 cases, the site of 
fracture was not recorded; of the remainder, 125 (27%) were lower limb, 243 
(53%) were upper limb and 92 (20%) involved the axial skeleton. The site of 
fracture did not significantly differ by eGFR category. 
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Patients with eGFR 60-74 and 30-59 ml/min per 1.73m2 had a significantly 
increased crude Odds Ratio (95% CI) of  fracture occurrence, 1.4 (1.1-1.8) and 
1.9 (1.4-2.5) respectively, as compared with the reference group (eGFR 75-
89ml/min per 1.73m2), Table 2.6. In the 60-74 ml/min per 1.73m2 category the 
OR, adjusting sequentially for age and T-score (model 2), osteoporosis risk 
factors (model 3) and osteoporosis treatments (model 4) remained 
persistently elevated at 1.2 but it was no longer statistically significant. 
However, the 30-59 ml/min per 1.73m2 category was both significantly and 
independently associated with fracture occurrence in the fully adjusted model 
(model 4, Table 2.6), having a statistically significant (p=0.03)  approximately 
40% increased odds of fracture relative to the 75-89 ml/min per 1.73m2 
category. T score (per unit decrease), adjusted OR (95% CI) 1.26 (1.12, 1.41) 
and age (per decade) adjusted OR 1.38 (1.21, 1.57) were both significant and 
independent predictors of fracture occurrence. In order to examine whether 
the association of chronic kidney disease on fracture varied according to the 
site of lowest bone mineral density (spinal vs. non spinal) we repeated the 
above regression model adding the relevant multiplicative interaction term, 
however there was no evidence of a significant interaction (p interaction 
=0.42) 
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Table 2.6: Crude and adjusted OR (95% CI) for Association of Fractures with 
eGFR Category 
eGFR 
(ml/min per 1.73 
m2) 
Model 1 
Crude OR 
Model 2 
Adjusted OR 
Model 3 
Adjusted OR 
Model 4 
Adjusted OR 
75 – 89 1 (Reference) 1(Reference) 1 (Reference) 1 (Reference) 
60 – 74 1.44  (1.13-.84)** 1.20 (0.93-1.55) 1.20 (0.93-1.55) 1.20 (0.93-1.55) 
30 – 59 1.95 (1.46-.62)***  1.34 (0.97-1.84) † 1.37 (1.0-1.89)* 1.37 (1.0-1.89)* 
 
† p<0.1, *p <=0.05, **p <= 0.01 
Model 1: Unadjusted. 
Model 2: Adjusted for age (decades), and T-score. 
Model 3: Adjusted for age (decades), T-score,  amenorrhoea, fewer than 3 
diary servings per week, corticosteroid use, ever having smoked, known family 
history of osteoporosis. 
Model 4: Adjusted as per model 3 above plus treatment with calcium/vitamin 
D, use of bisphosphonate / other anti-resorptive agents or hormonal 
replacement therapy.    
 
In the validated fracture subgroup, 431 fractures could be confirmed by review 
of radiology reports or by fracture clinic attendance at Cork University 
Hospital.  The adjusted odds ratio (95% CI) for fracture occurrence at eGFR of  
75-89, 60-74 and 30-59 ml/min per 1.73m2 were similar to the main analysis, 
namely  1 (reference), 1.18 (0.89-1.55) p=0.26, and 1.34 (0.95-1.89) p=0.09 
with age and the presence of osteoporosis both remaining significant 
independent predictors of fracture.   
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Discussion  
We report that amongst Irish women referred for routine DXA, moderate CKD 
is associated with fracture occurrence independently of bone mineral density. 
The utility of DXA scanning in predicting fractures in the dialysis population has 
been questioned, however in our study of patients at earlier stages of CKD 
bone mineral density remained unambiguously associated with fracture risk. 
These data also suggest that within the population that we studied, at least 1 
in 5 subjects had an additional independent risk factor for fracture, in the form 
of CKD, which in most cases was probably neither recognized nor actively 
managed. The improved recognition of this association may provide important 
opportunities to improve both renal and long-term bone health in this patient 
group.    
Several analyses have suggested an association between diminished renal 
function and decreased Bone Mineral Density.194-197 In an analysis of 885 
women in the Cardiovascular Health Project, renal function defined by 
quartiles of Cystatin C, was associated with a decrease in bone mineral density 
over time on univariate but not multivariate analyses.196 Hsu et al. using the 
Third National Health And Nutrition Examination Survey (NHANES III) 1988-
1994 dataset similarly found that Cockcroft-Gault estimated creatinine 
clearance, though associated with femoral bone mineral density on univariate 
analysis, was attenuated and no longer significant following adjustment for 
subject demographics.197 We also find that CKD is associated with low BMD on 
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univariate analysis but not following adjustment for age. Thus, while chronic 
kidney disease is associated with osteoporosis, this is mainly due to 
confounding by age, with patients who have CKD being older. 
 End Stage Kidney Disease has been independently associated with increased 
fracture risk and with worse patient outcomes post fracture in several 
studies.183, 198 Several 177-182 though not all 199 recent reports have suggested 
that earlier stages of renal dysfunction are also associated with increased 
fracture risk. The extent to which this observation may be the result of 
coexistent osteoporosis remains inadequately explored. In an analysis of the 
NHANES III dataset the adjusted odds ratio (95% CI) for self reported fracture 
for subjects with an eGFR below as compared to those above 60 ml/min per 
1.73m2  was  2.32 (1.13 – 4.74) and was independent of history of 
osteoporosis.180 In a case cohort study nested within a large observational 
cohort of osteoporosis, baseline bone mineral density was measured at the 
calcaneus using single photon absorptiometry and at the lumbar spine and 
femoral neck using standard DXA scanning on average 2.2 years later.177 
Decreased renal function was associated with fracture risk when adjusting for 
the calcaneal but not for femoral bone mineral density.177 There remains 
therefore substantial uncertainty as to the role that osteoporosis plays in 
fracture risk in patients with CKD.  Yenchek et al. in a recent longitudinal study, 
analyzed the effect of CKD on fracture risk prediction by DXA in a cohort of 
2754 community dwelling older adults, followed for a median of 11.3 years.  
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This study demonstrated that low BMD by DXA predicted fracture occurrence 
in patients with and without CKD, even following adjustment for mineral and 
bone abnormalities (elevated PTH and low Vitamin D levels). The majority of 
patients with CKD in this cohort had CKD Stage 3, eGFR 45-59.9mls/min.41 In 
distinction to the above, our data suggests that while part of the increased 
fracture risk seen in the unadjusted analysis results from decreased bone 
mineral density, a significant component of it is independent of this. The 
reasons for these disparate results in the limited literature that has to date 
examined this issue are unclear and may relate to different study designs or 
populations studied. Additional prospective studies are required to better 
delineate the independent role of early CKD in fragility fractures.  
The cause of increased fracture risk in CKD is speculative; it may be related to 
progressive development of bone mineral disorders in subjects with CKD. As 
serum PTH and vitamin D levels are not routinely measured in general practice 
we were unable to examine to what extent the association with CKD is 
mediated by derangements in these parameters. Alternatively part of this risk 
may be mediated not only by increased bone fragility but also by an increased 
risk of suffering a fall or injury. Decreasing renal function is associated with 
increased levels of fragility, anaemia and deconditioning as well as specific 
alterations in muscle function all of which may predispose an osteoporotic 
subject to fall and suffer an injury resulting in a fragility fracture.185  
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Several limitations apply to our study. Due to its cross sectional nature it is 
susceptible to incidence-prevalence bias, especially given the association of 
hip fracture with increased mortality200, however if present, survival bias 
would tend to enrich the prevalent population with subjects who had not 
suffered from a fracture and would thus tend to attenuate the association 
between CKD and fracture. Only two thirds of DXA screenees had an available 
serum creatinine within 1 year of DXA measurement and were eligible for 
inclusion in our study. These subjects were significantly older and more likely 
to have been referred for DXA scanning from hospital and may thus have had a 
higher burden of comorbidity and possibly more CKD than in those with no 
available creatinine measurement. This may have contributed to the relatively 
high prevalence of osteoporosis and of fracture within the study population 
though this possibly also represents the historically limited availability and 
resulting underutilization of DXA scanning in Ireland. The prevalence of CKD 
amongst DXA screenees may be less in countries where there is a greater 
utilization of DXA screening in the general healthy population. Our diagnosis of 
fracture in our primary analysis was based on patient recall; however patient 
recall has been shown to be reasonably reliable with regard to fractures of hip, 
wrist and upper arm201, while we found a similar relationship in the subgroup 
in which a history of fracture could be confirmed. Parathyroid hormone has 
differing effects on trabecular than on cortical bone, however we did not 
detect any interaction between CKD category and site of lowest bone mineral 
83 
 
density on fracture risk. Strengths of our study include its large sample size 
and the fact that it is predominantly based on a primary care rather than a 
hospital based or formal research setting.   
In conclusion, our data supports that CKD is present in over 1 in 5 Irish women 
who had a creatinine measurement within the previous year and who 
underwent routine DXA scanning.  CKD was an independent risk factor for 
fracture occurrence and its presence should potentially influence the decision 
to treat decreased bone mineral density. The nature of the association of CKD 
with fracture risk requires confirmation and warrants further evaluation into 
its mechanism(s). A better understanding of its pathogenesis may allow for 
focused secondary preventative measures and may thereby serve to reduce 
the risk of fragility fracture in CKD with all of its attendant complications. 
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Chapter 3 
 
 
 
 
 
 
 
 
Hyponatremia Independently of Osteoporosis is 
Associated with Fracture Occurrence  
 
 
 
 
This work has been peer reviewed and published as “Hyponatremia independently of 
Osteoporosis is associated with fracture occurrence”. Kinsella S, Moran S,           
O’Sullivan M, Molloy MG, Eustace JA. Clin J Am Soc Nephrol 2010 5: 275-280. PMID: 
20056759. (Extracts reproduced with permission of the publishers). 
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Introduction 
In the previous chapter we found that moderate CKD in women was 
associated with fracture occurrence, independently of Bone Mineral Density.  
Numerous factors in addition to bone mineral density influence fracture risk as 
renal function declines. Additionally, CKD is associated with increased levels of 
frailty, Vitamin D deficiency, deterioration in muscle function and general 
deconditioning which predispose to an increased risk of falls with subsequent 
fragility fracture.36-38 In this chapter we examine hyponatremia as a potential 
novel risk factor for falls which may also exert direct effects on bone mineral 
density and thus predispose to fragility fracture by both direct and indirect 
mechanisms. 
 
Background 
Severe hyponatremia is a well recognised cause of increased patient morbidity 
and mortality, although milder degrees of hyponatremia -serum sodium levels 
of 130-134 mmol/L- are usually devoid of obvious symptoms.202 However 
recent evidence suggests that mild chronic hyponatremia is associated with 
subtle central nervous system impairment including gait and attention deficits 
that may lead to an increased risk of falling.203, 204  Furthermore, two case 
control studies have  reported the association of mild asymptomatic 
hyponatremia with bone fracture in the ambulatory elderly,20,21  although 
neither study was able to control for the presence of osteoporosis, a major 
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potential confounder of this relationship, as the prevalence of both 
osteoporosis and hyponatremia increase with older age.  Evidence also 
suggests that hyponatremia itself contributes to bone loss. Approximately one 
third of total body sodium is stored in bone.  Bergstrom et al. demonstrated in 
1954 that acute hyponatremia in experimental animals resulted in release of 
sodium from bone22, 23, analogous to bone resorption and calcium efflux from 
bone in settings of hypocalcaemia. More recent studies by Verbalis et al. 
confirmed that chronic hyponatremia (>3 months) significantly reduced Bone 
Mineral Density compared with normonatremic rats.  Histomorphometric 
analyses in these animals indicated that hyponatremia markedly increased 
both cortical and trabecular bone resorption and decreased bone formation. 24 
Using the NHANES III dataset, Verbalis et al. also reported a significant 
association between mild hyponatremia (<135mmol/L) and increased odds 
ratio of osteoporosis at the hip (OR 2.85, 95% CI 1.03-7.86, p<0.01).24 
 
We therefore conducted the following analysis in order to quantify the 
presence, strength and significance of the association of hyponatremia with 
fracture occurrence -based on the hypothesis that hyponatremia predisposes 
to falls with an attendant increase in fracture risk- and in particular to assess 
whether this relationship is associated with osteoporosis.  
 
87 
 
Methods 
This is a secondary analysis of data collected for a retrospective study 
examining the association of chronic kidney disease with self reported fracture 
occurrence. Concise methods have been published elsewhere 205 and are 
described in detail in Chapter 2. Briefly, female patients, aged over 18 years 
who underwent a DXA scan at Cork University Hospital between 1st September 
2006 and 11th April 2007 and who had an available serum creatinine level 
measured within 1 year of the DXA scan were eligible for inclusion. Subjects 
who were referred from nephrology services (in order to avoid referral bias) 
and those with an eGFR greater than 90 ml/min per 1.73m2 (due to concerns 
regarding the accuracy of the MDRD equation at these levels) were excluded. 
For the current analysis we additionally a priori excluded 203 subjects who did 
not have an available serum sodium, 79 patients whose fracture could not be 
validated (see below) and 11 subjects who had a vertebral collapse fracture, 
resulting in a sample size of 1408 participants. (Figure 3.1) Patients with 
vertebral collapse fractures were excluded as they are frequently non 
traumatic and our hypothesis centred on hyponatremia leading to an 
increased risk of falls with resulting fracture.   
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Figure 3.1: Study Population, 1408 subjects with available DXA and sodium 
level 
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Dual energy x-ray absorptiometry (DXA) measurements were performed at the 
lumbar sacral spine and both hips using a Lunar IDXA™ scanner (General 
Electric) and expressed as T-scores indicative of the number of SDs by which 
the bone mass value deviated from the mean of a group of young normal 
controls.  In keeping with the World Health Organization definition, 
osteoporosis was defined as a T-score of  less than -2.5.185  Data regarding 
patient demographics, risk factors, current and prior treatment regimes for 
osteoporosis, history of prior fracture and details of co-existent medical 
conditions were obtained from a standardized self-report questionnaire, 
completed by the subject at the time of the DXA scan. 
The DXA database was manually cross referenced against the central 
laboratory database at Cork University Hospital, as outlined in Chapter 2 to 
identify those subjects who had a serum creatinine measured within 1 year of 
the index DXA scan. Serum creatinine was assayed using the modified Jaffe 
reaction and reported in umol/l.  The estimated Glomerular Filtration Rate 
(eGFR) in ml/min per 1.73 m2 body surface area was calculated using the 4 
variable Modification of Diet in Renal Disease (MDRD) prediction equation.186 
Subjects were categorized using a modified National Kidney Foundation 
staging system with  eGFR cut-offs of 75-89, 60-74, 30-59 and <29 ml/min per 
1.73m2. Serum sodium concentrations were measured by an ion selective 
electrode and reported in mmol/l.  Hyponatremia was defined as [Na+] < 
135mmol/L and mild hyponatremia as a value between 130-134 mmol/L. 
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In an attempt to partially validate fracture occurrence we cross checked self 
reported fracture against radiology reports and/or fracture clinic attendance 
at Cork University Hospital.  
Statistical Considerations: Outlying and clinically implausible values were 
double checked against the original clinical data.  The distribution, central 
tendency and variance of each variable was examined using standard tabular 
and graphical methods.  The study population was categorised by serum 
sodium levels and characteristics were compared using the Mann-Whitney 
test for continuous variables and chi-square for categorical variables.  We  
examined the presence, strength, significance and independence of the 
association of hyponatremia with fracture occurrence using logistic regression, 
adjusting sequentially for age, osteoporotic risk factors (amenorrhoea, family 
history, regular steroid use, smoking history, alcohol use, history of liver 
disease and low calcium diet) and osteoporosis treatments (calcium and 
vitamin D supplements, antiresorptives and hormonal replacement therapy). 
To examine if there was a relationship between values within or above the 
normal reference range with fracture occurrence, we additionally repeated 
the above multivariate logistic regression model, expressing the serum sodium 
as a 6 level categorical variable, namely <135, 136-137, 138-140 (reference), 
141-142, 143-145 and > 145 mmol/L. All analyses were performed using SPSS 
Version 12.0 software, (Chicago, Illinois, USA) with a 2-sided type 1 error rate 
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of 0.05. The study protocol was approved by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals. 
 
Results 
Clinical Characteristics: 
The mean (sd) age of the 1408 subjects analyzed was 61 (11) years and mean 
(sd) eGFR was 69 (12) ml/min per 1.73m2, Table 3.1. The mean T-score (SD) 
was -2.3 (1.1); 45% of subjects had osteoporosis (T-score < -2.5). Serum 
sodium was normally distributed with a mean (sd) of 140.6 (3.0) mmol/L, 
Figure 3.2. Hyponatremia was present in 59 patients (4.2%) and was mild in 53 
(3.8%).   
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Figure 3.2: Distribution of Serum Sodium Values in 1408 women undergoing 
DXA scanning.  
 
 
Subjects with, as compared to those without, hyponatremia were significantly 
older, had a lower bone mineral density and a higher prevalence of 
osteoporosis but similar eGFR. The use of antiresorptive agents, calcium and 
vitamin D and hormonal replacement therapy was not significantly different 
between the two groups, Table 3.1.  
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Table 3.1: Subject Characteristics by Serum Sodium Level 
Characteristic Total Na < 135mmol/l Na >135mmol/l p 
No. of Patients (%) 1408 59 (4.2) 1349 (95.8)  
Mean (sd), Age (years)  
Range 
61.4 (10.7) 
23 to 97 
67.8 (13.0) 
32 to 97 
61.1 (10.5) 
23 to 89 
<0.001 
Mean (sd), T-score  
Range 
-2.3 (1.1) 
-6.5 to 0.9 
-2.6 (1.2) 
-5.6 to -0.2 
-2.3 (1.1) 
-6.5 to 0.9 
0.03 
Osteoporosis (%) 
(T-score < -2.5) 
44.9% 57.6% 44.3% 0.04 
OP Risk Factors (%) 
Amenorrhoea 
Dairy Servings<3/wk 
Alcohol >5units/week 
Maintenance Steroids 
Ever Smoked 
Family History 
Liver Disease 
 
83.9% 
42.3% 
18.0% 
6.4% 
18.3% 
10.3% 
0.7% 
 
81.4% 
25.4% 
8.5% 
3.4% 
18.6% 
5.1% 
1.7% 
 
84.0% 
43.0% 
18.5% 
6.5% 
18.3% 
10.5% 
0.7% 
 
0.59 
<0.01 
0.05 
0.34 
0.95 
0.18 
0.36 
Treatment for OP (%) 
Calcium 
Vitamin D 
Antiresorptive 
HRT 
 
33.0% 
8.3% 
21.9% 
9.6% 
 
39.0% 
13.6% 
28.8% 
11.9% 
 
32.8% 
8.1% 
21.6% 
9.5% 
 
0.32 
0.14 
0.19 
0..54 
Mean (sd) 
[Na+](mmol/l)  
Range 
140.6 (3.0) 
127 to 153 
132.2 (1.8) 
127 to 134 
141.0 (2.4) 
135 to 153 
<0.001 
Mean (sd), eGFR 
(ml/min/1.73m2)  
Range 
 
68.8 (12.3) 
20 to 89 
 
66.9 (14.4) 
29 to 88 
 
68.9 (12.2) 
20 to 89 
 
0.43 
Abbreviations: OP, Osteoporosis, HRT, Hormone Replacement Therapy, eGFR, 
estimated Glomerular Filtration Rate. 
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Overall 254 (18.0%) subjects had at least one prior fracture.  Hyponatremia 
was present in 8.7% of those with a fracture versus 3.2% of those without a 
fracture, p (chi square) <0.001.  Patients with hyponatremia had a 2.86 fold 
increased unadjusted Odds Ratio for fracture occurrence as compared to non 
hyponatremic subjects, p<0.001, Table 3.2. On adjusting simultaneously for 
age and T-score the Odds Ratio (95% CI) for fracture occurrence remained 
significantly elevated at 2.06 (1.14 – 3.65).  In the fully adjusted model 
(simultaneously adjusting for age, T-score, Chronic Kidney Disease stage, 
osteoporotic risk factors and osteoporosis treatments, as listed  in Table 3.1), 
there continued to be a significantly increased Odds Ratio (95% CI) of fracture 
occurrence in the hyponatremic group of 2.25 (1.24 - 4.09). When serum 
sodium was entered into the above multivariate model as a 6 level categorical 
variable and using the 138-140 mmol/L category as the reference group, the < 
135mmol/L category was independently associated with fracture while the 
confidence intervals for categories above 135mmol/L largely overlapped each 
other and were not significantly different to reference, Figure 3.3.   
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Table 3.2: Crude and Adjusted Odds Ratio for Association of Hyponatremia 
with Fracture Occurrence. 
 Odds Ratio 95% CI p 
Model 1 2.86 1.66 – 4.94 <0.001 
Model 2 2.06 1.14 – 3.65 0.02 
Model 3 2.06 1.15 – 3.71 0.02 
Model 4 2.25 1.24 – 4.09 0.01 
 
Model 1: unadjusted 
Model 2: Adjusted for age (years), and T-score. 
Model 3: Adjusted for age (years), T-score and CKD stage. 
Model 4: Adjusted for age (years), T-score, CKD stage, osteoporotic risk factors 
(amenorrhoea, low dietary diary intake, high alcohol intake, maintenance 
steroids, ever having smoked, family history of osteoporosis and history of 
liver disease)  and treatment  (use of calcium, vitamin D , anti-resorptive 
therapy, hormonal replacement therapy).  
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Figure 3.3: Odds Ratio (95% Confidence Interval) of fracture occurrence by 
[Na+] category, adjusting simultaneously for age (years), T-score, CKD stage, 
osteoporotic risk factors amenorrhea, low dietary calcium intake, high alcohol 
intake, maintenance steroids, ever having smoked, family history of 
osteoporosis, and history of liver disease), and osteoporosis therapy (use of 
calcium, Vitamin D, antiresorptive therapy, hormonal replacement therapy). 
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In a sensitivity analysis, we excluded hyponatremic subjects with serum 
sodium below 130mmol/L in order to examine whether the observed 
association with fracture was driven by the small number of extreme values. 
The unadjusted OR (95% CI) for mild hyponatremia (130-134mmol/L) versus 
those with serum sodium of 135mmol/L or greater was 2.92 (1.65 – 5.18), 
p<0.001. This remained significant following sequential models with the 
adjusted OR (95% CI) as per model 4, table 3.2 being 2.2 (1.18 – 4.13) p= 0.014 
 
Discussion 
We report that mild hyponatremia, of a degree that is often ignored in clinical 
subjects is significantly associated with fracture occurrence independently of 
bone mineral density. Renneboog et al. have shown that mild chronic 
hyponatremia is associated with gait and attention deficits and with an 
increased risk of falls. They also found that hyponatremia caused more 
attention deficits than did a serum alcohol level of 0.6g/L in an age and sex 
matched control group.203 In a preliminary report of an additional study the 
threshold for gait and attention deficits induced by hyponatremia were 134 
and 132 mEq/L respectively. 204  Furthermore, a case control study by Kengne 
et al demonstrated that mild asymptomatic hyponatremia (mean serum 
sodium 131 mmol/L) was associated with bone fracture following incidental 
fall in the ambulatory elderly, with an adjusted OR of 4.16 (95% CI 2.24 – 
7.71)20 with a similar significant association reported in a recent additional 
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study.21 A limitation of both these studies was the inability to fully adjust for 
bone mineral density, which as demonstrated in our analysis partially -though 
incompletely- attenuates the association seen in unadjusted analyses. 
Advanced chronic kidney disease is associated with a range of qualitative 
abnormalities of bone turnover. However the majority of subjects in our 
analysis had well preserved renal function (mean eGFR 69 ml/min per 1.73 
m2), while the association of hyponatremia with fracture was independent of 
the presence of Chronic Kidney Disease. As well as predisposing to falls 
through disturbance of balance and gait, hyponatremia has been shown to 
contribute to abnormalities in underlying bone health by a direct effect on 
bone turnover.24 Unfortunately we were unable to examine this issue in this 
retrospective study.  
 
The term ‘symptomatic hyponatremia’ has been used to refer to the presence 
of overt complications of hyponatremia, typically gastrointestinal and neuro-
psychiatric in nature. This is on occasion associated with seizures and indeed 
the initial report of hyponatremia associated fracture occurred in a subgroup 
of post-menopausal women with severe hyponatremia who presented with 
fracture following seizure activity.206 Mild chronic hyponatremia, which lacks 
these overt symptoms, is typically considered asymptomatic; however subtle 
alterations in gait and balance are unlikely to be volunteered by patients and 
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may often be attributed to concomitant conditions such as old age.  Whether 
the range of clinical complications associated with mild chronic hyponatremia 
is limited to disturbances of gait and balance or is more extensive is unknown, 
as is its impact on quality of life. In view of these uncertainties the suitability of 
the term ‘asymptomatic hyponatremia’ is open to question. 
 
Fragility fractures, occurring after minor trauma or falls, are a major public 
health concern due to their attendant morbidity and mortality.207 Recurrent 
incidental falls result in bone fracture in 4 – 6% of cases, with up to 2% of 
these patients dying.208 Effective treatment and preventative strategies for 
recurrent falls remains highly limited.209 Mild chronic hyponatremia is a 
common electrolyte imbalance with a reported prevalence of 2-4% in the 
general population, rising to 7-11% in the ambulatory elderly, 210,211 and to 
42% in hospitalized subjects. 211  The potential importance of the association 
of mild hyponatremia with fracture relates to this high prevalence of the 
condition, especially in groups who have a high risk of fracture following falls, 
such as the elderly.  In addition, hyponatremia commonly complicates 
advanced cardiac and liver failure, in both of which conditions it has well 
recognized prognostic import, 212, 213 though the hyponatremia per se is usually 
considered to be asymptomatic. It is of interest that advanced cardiac failure 
has been recently associated with an increased incidence of fracture,214 and it 
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has been speculated that this may be mediated in part through the 
development of hyponatremia. 215  
 
Two common reversible causes of hyponatremia are the use of thiazide type 
diuretics216 and Selective Serotonin Reuptake Inhibitor (SSRI)217 
antidepressants, both of which are in widespread clinical use.  Thiazide 
diuretics are widely used as first line agents in the treatment of hypertension 
but are complicated in up to 14% of subjects by hyponatremia.218, 219 Among 
subjects aged 65 years and older resident in a nationally representative 
sample of US nursing homes, thiazide use was associated with increased 
fracture risk over 1 year of follow-up.220 However, thiazide type diuretics in 
addition to their antihypertensive effect, also decrease urinary calcium 
excretion and promote a positive calcium balance, thereby helping to maintain 
and improve bone mineral density.221,222,223 It is possible that the potential 
uses of thiazide diuretics for this indication may have led to their selective use 
in subjects with pre-existing osteoporosis and thus confound the association of 
thiazide induced hyponatremia with fracture in ours and in other studies 
examining this relationship. However, against this, thiazide type diuretics have 
not been widely used in this indication in Irish clinical practice (Prof MG 
Molloy, Professor of Rheumatology, Cork University Hospital, personal 
communication). Pending further studies, our results would urge caution in 
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the use of thiazide type diuretics for bone protection in those subjects who 
develop hyponatremia, as the benefits of a positive calcium balance may be 
offset by the potential increase in falls risk. In addition, it may be prudent to 
routinely screen serum sodium levels following initiation of thiazide diuretics, 
especially in those at high risk for developing hyponatremia such as elderly 
females.  
 
Depression and the use of centrally acting agents are recognized as being 
associated with increased risk of falls and of fracture. Available evidence 
suggests that some of this increased risk is due to the agents independently of 
the presence of depression.224 Of the studied agents the highest risk of falls 
has been associated with selective serotonin reuptake inhibitors (SSRI’s), 225  
with peak fracture risk occurring in the first 2 weeks after initiation of therapy. 
This risk of fracture mirrors the increased risk of hyponatremia in SSRIs as 
compared to alternative agents and the time course in which hyponatremia 
typically occurs226,224 however the potential role of hyponatremia in 
predisposing to fracture in this population remains unstudied.  
 
The mainstay of treatment for persistent hyponatremia, where the syndrome 
is either irreversible or where the iatrogenic cause cannot be readily altered, 
centres on fluid restriction, the severity of which depends on the degree of the 
102 
 
diluting defect; however this is difficult to maintain and patient adherence is 
often incomplete. As a result, the goal of such therapy is often to limit the 
severity of the dysnatremia rather than to fully correcting it, mild 
hyponatremia being seen as an acceptable clinical compromise between the 
dangers of severe hyponatremia and the inconvenience of aggressive therapy. 
Thus the perception of mild hyponatremia as being devoid of clinical 
significance in many cases tempers the aggressiveness of therapy. Of the 
available medical adjuncts to fluid restriction, loop diuretics are of limited 
efficacy, oral urea is unpalatable and demeclocycline is potentially 
nephrotoxic.227 The recent development of selective oral vasopressin V2 
receptor antagonists may facilitate the more complete correction of 
hyponatremia in patients with persistent hyponatremia,228  but whether such 
therapy would reduce the occurrence of falls and low impact fractures in 
susceptible individuals is to date unknown.229  
Several limitations apply to our analysis, serum sodium measurement was not 
available at the actual time of fracture but was instead related to the bone 
density measurement, while this may have resulted in a degree of non 
differential misclassification, this would tend to reduce the observed 
association toward the null hypothesis and attenuate the effect size of any 
association. Indeed the magnitude of the association we found is less than that 
described by other authors, this may relate in part to different populations 
examined, ours was relatively young and may therefore be less severely 
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affected by mild gait disturbances as compared to older subjects. Moreover 
serum sodium levels measured following a fall, would be potentially 
influenced by both complications of the fall (such as development of 
dehydration) or to initial therapeutic measures such as intravenous fluid 
infusion initiated prior to venupuncture, either of  which may systematically 
distort the measurement serum sodium level relative to the true pre-fall level. 
In addition our effect size is also partially attenuated as it is adjusted for bone 
mineral density. A major limitation on the inferences that can be drawn from 
this study is that, as with all observational research, it can at best only provide 
support for the above hypothesis but cannot prove it. Both unmeasured 
confounders such as unreported co-morbid conditions, sedative drug use or 
the presence of malignancy may impact on the described relationship of 
hyponatremia with fracture. Nevertheless, there exists a plausible mechanism 
to explain this putative association and as in our work the observed 
relationship has been independent of a wide range of relevant confounders, 
including the presence of osteoporosis. In an editorial commentary, Ayus et al. 
summarise that bone abnormalities should be viewed as an additional 
complication of chronic hyponatremia.230 The increased risk of falls and 
subsequent fracture in hyponatremic patients is magnified by hyponatremic-
induced bone loss; therefore chronic hyponatremia should be viewed as a 
modifiable risk factor for fracture. This view is supported by an increasing body 
of literature from epidemiological and experimental studies.231-234  
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Nevertheless, controlled interventional trials are essential in order to reliably 
estimate the true attributable risk of hyponatremia with falls and fracture 
occurrence. 
 
In conclusion, mild chronic hyponatremia is a significant independent risk 
factor for bone fracture. In keeping with recent studies our data suggests that 
mild chronic hyponatremia is neither a benign nor an inconsequential 
condition.  If confirmed in prospective studies the prevention, identification 
and effective management of this relatively common condition may provide an 
important opportunity to reduce the risk of recurrent falls and repeated 
fractures and lead to alterations in a wide range of current clinical practices.  
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Chapter 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Burden of Chronic Kidney Disease - Mineral Bone 
Disorder (CKD-MBD) in Successful Renal Allograft 
Recipients: The ABC-HEART Study. 
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Introduction 
 
Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) is the term 
introduced by the Kidney Disease–Improving Global Outcomes (KDIGO) 
international consensus group to encompass the closely interrelated processes 
of abnormal bone mineral homeostasis, Vitamin D and parathyroid hormone 
(PTH) dysregulation, derangements of bone turnover, mineralization and 
volume  and aberrant vascular and soft tissue calcification that develop as 
complications of CKD.33 These complex interrelated processes have been 
extensively studied in subjects with End Stage Kidney Disease treated with 
dialysis, while in recent years there has been increased awareness that the 
genesis of the disorder occurs from early on in the natural history of CKD.46 
Successful renal transplantation restores effective endogenous renal function 
to patients with End Stage Kidney Disease and improves survival but it fails to 
restore either normal longevity or health.144, 147, 235 Furthermore, it is 
associated with persistent and on occasion progressive morbidities that result 
from the combined sequelae of prior native CKD, de novo transplant-related 
complications and consequences of the often suboptimal level of kidney 
function provided by the allograft.150, 151, 167, 236-239 To date several reports have 
examined the prevalence of individual components of CKD-MBD in transplant 
recipients. Post-transplant hyperparathyroidism improves over the first year 
post transplant but remains highly prevalent occurring in over 50% of patients 
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and in a substantial minority of cases is associated with hypercalcaemia.148-151  
Vitamin D levels are typically low due to ultraviolet light avoidance –resulting 
from concerns regarding cutaneous malignancy- and limited use of vitamin D 
supplements – resulting from concerns over exacerbating hypercalcaemia and 
promoting nephrolithiasis.149, 240, 241  In addition, transplant recipients have 
unambiguously been shown to have increased fracture risk relative to the 
general population,159, 161, 163, 165 while the limited available bone biopsy data 
suggests widespread derangements of normal bone architecture, turnover and 
mass.151, 242-245 Despite its acknowledged limitations, areal bone density 
measurement is widely measured in renal transplant recipients and is 
recommended by current renal transplant guidelines.246, 247 There is only 
sparse available data regarding the presence and natural history of vascular 
mineralization post transplantation using either radiographic or functional 
measurements such as pulse wave characteristics.156, 157, 248-250  
However, to date the overall burden of CKD-MBD experienced by successful 
renal allograft recipients in routine medical practice has not been 
comprehensively examined in the same transplant population. With improved 
allograft and recipient survival rates, the presence and severity of CKD-MBD is 
likely to prove to be increasingly important in influencing the long term health 
and quality of life of successful renal allograft recipients and to assume an 
increasing priority in both the medical management and research agenda 
within this population.   As most interventions simultaneously influence 
108 
 
multiple components of CKD-MBD it is relevant, and indeed necessary, to 
evaluate the occurrence of the disorder in its entirety. We therefore 
conducted the following observational study to comprehensively examine the 
occurrence and severity of CKD-MBD within successful renal allograft 
recipients and to examine the relationship of severity of the disorder with 
their level of transplant function.        
 
Methods  
We enrolled a convenience sample of 90 prevalent renal transplant recipients 
into a prospective cohort study the working title of which was; the ‘Association 
of Bone and Cardiovascular HEalth After Renal Transplantation’ (ABC HEART) 
study, in order to examine the interaction of bone and vascular health within 
this population.  The current report uses baseline data at study entry. Subjects 
who were waiting to be reviewed at their routine follow-up clinic were 
approached and invited to participate, only 4 potential subjects declined, 
citing time constraints. To be eligible subjects had to be between 0.5 and 12 
years post-transplant and to have a current transplant eGFR >30 ml/min per 
1.72m2 and to be in their usual state of health. All study procedures were 
performed on an outpatient basis. One subject had a prolonged hospitalization 
closely following enrolment and subsequently died without undergoing any of 
the study specific procedures and was therefore excluded from analysis.   
Informed written consent was obtained from all subjects; the study was 
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approved by the Clinical Research Ethics Committee of the Cork Teaching 
Hospitals.   
Information on demographics, clinical details and past medical and fracture 
history were obtained by patient self-report and abstracted from the medical 
record.  Serum creatinine was measured using the Jaffé reaction on the 
Olympus 5400 analyser. The method was changed to an IDMS traceable form 
in October 2009.  eGFR (ml/min per 1.73 m2 body surface area) was calculated 
using the 4-variable MDRD equation1 and categorized as Transplant CKD Stage 
1T-2T for eGFR >60 ml/min, Stage 3AT for 45-59 ml/min and Stage 3BT for 30-
44 ml/min Serum calcium was measured by the Arsenazo 111 method on the 
Olympus 5400 analyser. Serum albumin was measured by the bromocresol 
purple method up to October 2009. Bromocresol green was then used. The 
laboratory participates in the UK national external quality assessment 
(UKNEQAS) scheme for clinical chemistry analytes  Albumin adjusted serum 
calcium was calculated as the measured serum calcium plus 0.2 *(40-serum 
albumin). Uncuffed venous samples for ionised calcium and venous pH were 
collected anaerobically in a heparinised syringe and immediately analysed on 
the GEM 4000 blood gas analyser in the main biochemistry laboratory.  An 
additional urine sample for measurement of calcium-creatinine ratio and 
simultaneous serum calcium was measured on 85 subjects several months 
after the study entry blood draw and so was not contemporaneous with the 
other study tests.  
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Blood samples and second void urine samples were collected following an 8 
hour fast. The blood was centrifuged and serum and urine samples  aliquoted 
and frozen at -800C and -200C respectively, within 1 hour of collection and 
subsequently analysed in batch for biochemical markers of bone turnover that 
have been validated in CKD.251. Bone Specific Alkaline Phosphatase (Bone ALP), 
a marker of bone mineralisation and maturation was measured by an enzyme-
linked immunosorbent assay (ELISA) (Immunodiagnostic Systems Ltd, Boldon, 
Tyne and Wear, UK) with inter-assay coefficients of variation of 2.3% (at 10.95 
ug/L and 39.77 ug/L) and intra-assay coefficients of variation of -6.9% (at -
12.43 µg/L) and -5.1% (at -35.9 µg/L) respectively. Tartrate- Resistant Acid 
Phosphatase 5b(TRACP5b)  a marker of bone resorption was determined by 
ELISA (IDS Ltd) with - inter-assay coefficients of variation of 1.58% (at 1.46 U/L) 
and 0.74% (at 4.18 U/L) and intra-assay coefficients of variation of -2.53% (at -
2.37 U/L), 3.42% (at 4.62 U/L and -1.44% (at 13.36 -U/L) respectively.  Urinary 
N-Terminal cross-linking telopeptide of Type 1 collagen (NTx-I) was measured 
using ELISA (Osteomark, Ostex International Inc., Seattle, USA-) with an inter- 
assay coefficient of variation of 4.7% (at 1503.9 nmol BCE) and intra-assay 
coefficients of variation of 9.54% (at 457 nmol BCE) and 8.18% (at 1142 nmol 
BCE) respectively.  Assay values are corrected for urine concentration by 
indexing to urinary creatinine level and expressed in nanomoles of bone 
collagen equivalents per millimole of creatinine per litre (nM BCE per mM/L).  
Serum 25-hydroxyvitamin D (25(OH) D) was measured by a competitive 
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radioimmunoassay (IDS). Interassay coefficients of variations were 6.2% and 
7.7% at concentrations of 28.8 nmol/l and 105.4 nmol/l, respectively. The 
intra-assay coefficients of variations were 3.0% and 2.7% at concentrations of 
28.9 nmol/l and 73.9 nmol/l, respectively. Optimal values were considered to 
be over 50 nmol/l73. Biochemical markers of bone turnover and 25-OH Vitamin 
D assays were performed in the Metabolism Laboratory in St Vincent’s 
University Hospital under the supervision of Dr. Jennifer Brady.  Intact PTH was 
measured using a Roche Elecsys assay. This is a second generation PTH assay, 
which is the most widely used in clinical practice in Europe. These assays use 2 
separate antibodies, one is directed against the C-terminal fragment of the 
PTH molecule and the second is directed against the N-terminal fragment.  
These assays were initially thought to quantify only the full-length, biologically 
active 1-84 PTH molecule.  It is now known that they also measure other large 
PTH fragments, predominantly 7-84 PTH, the biological activity of which is 
uncertain. 
Areal Bone Mineral Density was measured at the lumbar sacral spine, the 
femoral neck and total femur of both hips and the non-dominant forearm, 
using a Lunar IDXA scanner (General Electric) and expressed as a T-score.  
Osteoporosis was defined as a lowest T-score of -2.5 or less and osteopenia as 
a T-score of 1.5-2.49. Carotid Femoral Pulse Wave Velocity was performed by a 
single investigator (SK) experienced in the performance of the technique using 
a dedicated Pulse Trace 400 PWV system (Viasys Healthcare) following the 
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method described by London.131  Aortic calcification and vertebral collapse 
fractures were independently assessed by 2 radiologists blinded to the clinical 
study detail.  Aortic vascular calcification was quantified from lateral lumbar 
spine radiographs using the Framingham method, scoring on a scale of 1-3 the 
presence of calcification along the anterior and posterior margin of the 
expected aortic contour adjacent to the 4 lumbar vertebrae, resulting in a 
composite score of between 0-24.129 
 
Statistical analysis: 
Clinically implausible and outlying data were checked against the original 
clinical record. Normality was examined using boxplots and Shapiro-Wilks test 
and distribution described using mean (sd) or median (intra quartile range 
[IQR]) as appropriate.  Non-parametric analytic methods were exclusively used 
including Spearman rank correlation and Mann-Whitney U test. The 
relationship of variables across eGFR stage was assessed using a hierarchical 
approach initially testing for a linear trend across groups, which if not 
significant was followed by comparison between groups using the non-
parametric Kruskal-Wallis test. The relationship of vitamin D with iPTH 
stratified by the presence or absence of an elevated total serum calcium was 
modelled using restricted cubic spline plots. The association of osteoporosis 
(lowest DXA T-score less than -2.5) with iPTH was examined using multivariate 
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logistic regression analysis, adjusting sequentially and simultaneously for age, 
gender, ESKD vintage (cumulative time spent on dialysis and post transplant), 
current corticosteroid use, serum 25-OH Vitamin D and TCO2 level. Routine 
model diagnostics included assessment of points of high leverage and 
influence and measurement of overall “Goodness of Fit”, using the model of 
Hosmer and Lemeshow. Analysis was conducted using SPSS (Chicago, Illinois) 
V16 with a 2 sided type one error rate of 0.05.  
 
Results 
Of the 141 transplant clinic attendees who met study entry criteria, 89 
participated in the study. The demographics of the study sample are shown in 
Table 4.1. Our study sample was broadly representative of our overall 
transplant population, the latter being 56% male, with a mean (sd) age of 42.8 
(17.8) years, mean (sd) eGFR of 55.5 (16.7) ml/min/1.73m2 and a median (IQR) 
duration of transplantation of 3.5 (1.6, 6.6) years. The proportion of post-
transplant hyperparathyroidism (available from routine clinical records in 128 
patients) and of hypercalcaemia in the overall transplant population was 
77.9% and 37.4% respectively.   
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Table 4.1: Patient Characteristics of 89 enrolled renal transplant recipients by 
CKD-T Stage 
 
Abbreviations: eGFR, estimated Glomerular Filtration Rate, ESKD, End Stage Kidney 
Disease, IQR, Intra Quartile Range, GN, Glomerulonephritis, PCKD, Polycystic Kidney 
Disease, DM, Diabetes Mellitus, ASCVD, Atherosclerotic Cardiovascular Disease. 
1Excluding 6 pre-emptive transplants who were never dialyzed.  
2Variables with fewer than 10 events are provided for information purposes only and 
are not compared statistically 
p values for continuous variables denoted †were calculated using linear test for trend. 
All other continuous variables were examined using Kruskal Wallis non-parametric 
test. Categorical variables were examined using Pearson’s Chi square test  
 Enrolled Study Population 
All subjects Stage T1-2 Stage T3A Stage T3B p-value 
N 89 32  27 30  
Mean (sd) eGFR (ml/min per 
1.73m2) 
53.9 (16.5) 72.2 (10.0) 51.2 (4.3) 36.8 (4.6) <0.001† 
Age, years,  Mean (sd) 46.8 (12.7) 39.9 (14.2) 48.9 (10.4) 52.3 (9.5) <0.001 
Sex, Male, n (%) 53 (59.6%) 21 (65.6%) 19 (70.4%) 13 (43.3%) 0.08 
Cause ESKD, n (%) 
    GN 
    PCKD/Alports 
    DM 
    Other 
 
29 (34.9) 
22 (26.6) 
7 (8.4) 
25 (30.1) 
 
15 (55.6) 
3 (11.1) 
2 (7.4) 
7 (26.0) 
 
8 (29.7) 
9 (33.3) 
4 (14.8) 
6 (22.2) 
 
6 (20.7) 
10 (34.5) 
1 (3.4) 
12 (41.1) 
 
 
0.05 
Duration pre-ESKD renal care 
(yrs), Median (IQR) 
4.8  
(1.9 - 9.0) 
3.3  
(1.1 -8.8) 
4.0  
(1.6 -9.1) 
5.7 
(2.9 – 12.8) 
0.30 
Dialysis Modality n (%): 
    Haemodialysis  
    Peritoneal dialysis 
    Pre-emptive transplant 
 
49 (55.1%) 
34 (38.2%) 
6   (6.7%) 
 
19 (59.4%) 
11 (34.4%) 
2 (6.2%) 
 
11 (40.7%) 
15 (55.6%) 
1 (3.7%) 
 
19 (63.3%) 
8 (26.7%) 
3 (10.0%) 
 
 
0.23 
Duration Dialysis (yrs)1, 
Median (IQR) 
2.3  
(1.5 – 3.2 ) 
2.1 
(1.3 – 2.9) 
2.6 
(1.7 – 3.6) 
2.3 
(1.4 – 3.8) 
0.45 
Duration Transplant (yrs),  
median (IQR) 
2.6  
(1.0, 6.3) 
2.4  
(1.0 – 7.3) 
3.0  
(2.2 – 5.2) 
2.1  
(0.7 – 5.9) 
0.52 
Acute cellular rejection n (%) 10 (11.2) 2 (6.2) 5 (18.5) 3 (10) 0.43 
ASCVD 8 2 2 4 N/A2 
Tacrolimus n (%) 
[Median serum level, mg/dl]  
75 (84.3) 
[8.9] 
26 (81.2) 
[9.0 ] 
25 (92.6) 
[8.5] 
24 (80.0) 
[9.1] 
0.36 
0.77 
Mycophenolate n (%) 
[median total dose, g/day]   
71 (79.8) 
[1g/day] 
23 (71.9) 
[1g/day] 
24 (88.9) 
[1g/day] 
24 (80.0) 
[0.75 g/day]  
0.27 
Corticosteroid: n (%) 
[median total dose, mg/day]  
34 (38.2%) 
[5mg/d ] 
12 (37.5%) 
[5mg/day] 
8 (29.6%) 
[3mg/day ] 
14 (46.7%) 
[5mg/day ] 
0.42 
Parathyroidectomy n (%) 7 (7.9) 2 (7.4) 3 (11.1) 2 (7.1) N/A2 
Cinacalcet n (%) 11 (12.4) 4 (12.5) 1 (3.7) 6 (20) 0.175 
One alpha Vitamin D n (%) 6 0 1 5 N/A2 
Bisphosphonates n (%) 7 (7.9) 0 (0) 2 (7.4) 5 (17.2) N/A2 
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The mean (sd) eGFR of the 89 study subjects at enrolment was 53.9 (16.5) 
ml/min/1.73m2; allograft function was stage 1T-2T in 36%, stage 3AT in 30% 
and stage 3BT in 34%. Reduced levels of kidney function were associated with 
older age and female gender (Table 4.1). The commonest cause of ESKD was 
chronic glomerulonephritis, occurring in over one third of subjects. Thirteen 
subjects (15%) had diabetes; the attributed cause of ESKD in 7, while it 
developed post-transplantation in 5. Six subjects had undergone pre-emptive 
transplantation. The median duration of dialysis was 2.3 years and was similar 
for haemodialysis and peritoneal dialysis subjects.  Eighty subjects received a 
single cadaveric allograft, 2 a dual cadaveric transplant, 3 a combined kidney-
pancreas transplantation and 4 a living related transplant.  The majority of 
subjects were initially treated with triple immunosuppressive therapy, 
including tacrolimus in 84% and mycophenolate mofetil in 88%. Sixty-two 
percent of subjects had had their corticosteroids successfully withdrawn post 
transplantation; the median dose in the remainder was 5mg/day.   Eight 
subjects had a past history of atherosclerotic cardiovascular disease, including 
3 who had undergone a coronary revascularization procedure.  Nine subjects 
had undergone a total parathyroidectomy prior to transplant - all of whom had 
a forearm parathyroid implant.  Medication use of note included Cinacalcet® 
(n=9), loop diuretics (n=9), bisphosphonates (n=7), calcium supplementation 
(n=6) and 1-OH vitamin D supplementation (n=5).  
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Eighty-two percent of subjects had a post-transplant iPTH level >65ng/ml; the 
median (IQR) iPTH was 100ng/ml (75-148).  Subjects in stage T3B CKD had 
significantly higher iPTH than those in stage T1-2; moreover the majority of 
patients in all 3 CKD categories had an iPTH that was above the normal 
reference range, Table 2, Figure 4.1. iPTH was positively correlated with serum 
calcium (vide infra), and negatively correlated with serum phosphate (r= -0.43, 
p<0.001).  
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Table 4.2: Bone Turnover Parameters of Study Population by CKD-T Stage 
 All subjects Stage T1-2 Stage T3A Stage T3B p-value 
N 89 32 27 30  
PTH and Vitamin D 
iPTH  ng/ml, Median (IQR) 100 (75, 148) 99 (76,119) 91 (69, 
109) 
144 (82, 197) 0.003† 
iPTH >65ng/ml,  n (%) 73 (82%) 27 (84.4%) 21 (77.8%) 25 (83.3%) 0.84 
25 (OH) Vitamin D nmol/l 
Median (IQR) 
41.3 
(29., 52.5) 
40 
(28.4, 51.5) 
42.1 
(33.1, 52.3) 
39.7  
(30.2, 52.1) 
0.51 
25 (OH) Vitamin D <50nmol/l n (%) 63  
(70.8%) 
22  
(68.8%) 
20  
(74.1%) 
21  
(70%) 
0.9 
Calcium and Phosphate 
Serum Calcium, mmol/L 
Mean, sd 
2.57 (0.16) 2.58 (0.13) 2.53 (0.18) 2.61 (0.2) 0.4 
Albumin Corrected Serum Calcium 
mmol/L  
Mean (sd) 
2.63 
(0.16) 
2.60  
(0.12) 
2.59  
(0.17) 
2.61  
(0.16) 
0.14 
Serum Calcium >2.62mmol/l n (%) 34 (38.2%) 11 (34.4%) 9 (33.3%) 14 (46.7%) 0.52 
Urine Ca:Cr ratio (mmol/ mmol), 
Median (IQR) 
0.16 
(0.09, 0.24) 
0.18 
 (0.8, 0.32) 
0.16 
 (0.1, 0.22) 
0.12  
(0.09, 0.29) 
0.68 
Serum Phosphate (mmol/L), Mean 
(sd) 
1.02 (0.2) 1.02 (0.23) 0.98 (0.17) 1.1 (0.2) 0.24 
Serum Phosphate 
 <0.7 mmol/L, n (%) 
11 (12.4%) 5 (15.6%) 4 (14.8%) 2 (6.7%) 0.52 
TCO2 and pH 
Serum TCO2 (mmol/L) 
Mean (sd) 
24.6 
(2.7) 
25.2  
(2.7) 
25 
(2.3) 
23.6 
(3.0) 
0.03† 
Serum TCO2 <24mmol/L, n (%) 29 (33%) 8 (25%) 6 (22%) 15 (50%) 0.05 
pH, Mean (sd) 7.34  (0.04) 7.36 (0.06) 7.33 (0.03) 7.33 (0.03) 0.03† 
Bone Turnover 
Alkaline Phosphatase (mmol/L), 
Mean (sd) 
103.3 
(45.8) 
117.4 
(53.1) 
91.6  
(33.5) 
98 
(44.3) 
0.12 
Bone ALP  (ug/L)1 
Median (IQR) 
20.3 
(14.5, 30.3) 
26.1 
(20.5, 37.5) 
15.7 
(13.4, 21.9) 
18.9  
(13.1, 32.5) 
0.01 
 
TRACP5b (U/L)2  
Mean (sd) 
4.1 (1.7) 4.8 (1.8) 3.3 (1.1) 4.0 (1.7) 0.01 
NTx-I (nM BCE per mM/L)3 Median 
(IQR) 
49.0 (31.6, 
92.6) 
71.0  (41.7, 
119.3) 
40.4 (29.3, 
55.5) 
72.3 (28.6, 
105) 
0.01 
Abbreviations: iPTH, intact parathyroid hormone, Bone ALP, Bone Specific Alkaline 
Phosphatase, TRACP5B, Tartrate Resistant Acid Phosphatase 5b, NTx-I, Urinary N-Terminal 
cross-linking telopeptide of Type 1 collagen.  
p values for continuous variables denoted  †were calculated using linear test for trend. All 
other continuous variables were examined using Kruskal Wallis non-parametric test. 
Categorical variables were examined using Pearson’s Chi square  
1
Reference Range, Male (7.2 – 15.0ug/L), Female (6.1 -11.8ug/L)  
 
2
Reference Range, Male (1.3 – 4.82 U/L), Female (1.03 – 4.15U/L) 
3
Reference Range (25.5 – 72.4 nM BCE per mM/L) 
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Figure 4.1: Boxplot of iPTH level by National Kidney Foundation stage of 
Chronic Kidney Disease 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Boxplot of iPTH level by National Kidney Foundation stage of 
Chronic Kidney Disease in 89 prevalent renal transplant recipients. The solid 
line within the box indicates the median value, the box the intra-quartile range 
and open circles outliers. The horizontal line denotes the upper limit of normal 
of iPTH (65ng/ml). 
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Seventy-one percent of subjects had suboptimal 25(OH) vitamin D levels, 
which were uniformly low across the 3 CKD categories - median values of 40-
42nmol/l, Table 4.2, Figure 4.2. Eighty-seven percent of subjects with a 
suboptimal Vitamin D had an elevated iPTH >65ng/ml vs. 68% of those with 
adequate vitamin D, p=0.06.  
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Figure 4.2: Boxplot of 25-OH Vitamin D level by National Kidney Foundation 
stage of Chronic Kidney Disease 
 
Figure 4.2: Boxplot of 25-OH Vitamin D level by National Kidney Foundation 
stage of Chronic Kidney Disease in 89 prevalent renal transplant recipients. 
The solid line within the box indicates the median value, the box the intra-
quartile range and open circles outliers.  The horizontal line denotes a 25-OH 
Vitamin D level of 50nmol/L 
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We further examined the relationship of 25-OH vitamin D with iPTH stratified 
by the presence or absence of hypercalcaemia having first excluded the 5 
patients treated with activated vitamin D.  In those subjects with an elevated 
total serum calcium there was no association between iPTH and 25-OH vitamin 
D level (r2=0.06, p=0.35). However, in those subjects who were 
normocalcaemic the 25-OH Vitamin D level was significantly associated with 
iPTH, in keeping with a tendency to  secondary hyperparathyroidism (p=0.003; 
r2 =0.31) Figure  4.3.   
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Figure 4.3: Restricted Cubic Splines plot of iPTH with 25-OH vitamin D in 
successful renal allograft recipients with (panel A) or without (panel B) 
hypercalcaemia. 
Figure 4.3A 
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Figure 4.3B 
 
Figure 4.3: Restricted Cubic Splines plot of iPTH with 25-OH vitamin D in 
successful renal allograft recipients with (panel A) or without (panel B) 
hypercalcaemia. Five subjects who were treated with activated vitamin D are 
excluded. The vertical dashed line denotes a 25 OH Vitamin D level of 
50nmol/L 
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The mean (sd) serum calcium and albumin corrected serum calcium was 2.57 
(0.16) mmol/l and 2.63 (0.16) mmol/L respectively. Ionized calcium was 
available for 83 study subjects for whom the median (IQR) was 1.16 (1.08, 
1.22) mmol/L. The median (IQR) of ionized calcium expressed as a proportion 
of total calcium and of albumin corrected serum calcium was 0.45 (0.43, 0.47) 
and 0.44 (0.42, 0.46). Whereas no subject had a subnormal serum calcium by 
either total or albumin corrected calcium measurement, 25% had a subnormal 
ionized calcium (< 1.15mmol/l) level.  The percentage of subjects with 
hypercalcaemia by the 3 methods was:  total calcium (38.2%), albumin 
corrected calcium (49.4%) and ionized calcium (10.8%). The Spearman Rank 
correlation of iPTH with the above 3 measures of calcium was r=0.29 (p <0.01), 
r=0.23 (p=0.03) and r=0.44 (p<0.001) respectively.   
The median (IQR) spot urine calcium-creatinine ratio was 0.16 (0.09, 0.24) 
mmol/mmol. The ratio was not correlated with the concomitant total serum 
calcium (r=0.12, p=0.27). Spot urine calcium creatinine ratios were higher in 
subjects treated with cinacalcet at the time of measurement (n=9) vs. not so 
treated: median (IQR) 0.32 (0.20 - 0.68) vs. 0.14, (0.08 - 0.24) mmol/mmol, 
p=0.01. The median ratio for those on 30mg cinacalcet (n=6) was 0.27 
mmol/mmol and for those on 60mg/day (n=3) 0.67 mmol/mmol.  Spot urine 
calcium creatinine ratios also tended to be higher in subjects treated vs. not 
treated with loop diuretics (n=9):  0.39 (0.98, 0.63) vs.  0.15 (0.08, 0.24) 
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mmol/mmol, p= 0.07 respectively. Three subjects were on both cinacalcet and 
a loop diuretic. 
Mean (sd) phosphate levels were 1.02 (0.2) mmol/L; only 1 subject was 
hyperphosphatemic (with a value of 1.51 mmol/L), whereas 11 subjects had 
hypophosphatemia of whom 10 had concomitant suboptimal 25(OH) vitamin 
D and 9 an iPTH >100 ng/mL. The median iPTH was significantly higher in 
subjects with vs. those without hypophosphatemia (177ng/ml vs. 94ng/ml, 
p=0.007) whereas measures of calcium were similar.   
Acidosis was present in up to one third of study subjects with a venous TCO2 
below 24 mmol/L being present in 29 (33%) and a level of below 22 mmol/L in 
11 (12.4%); venous pH was below 7.33 in 22/69 subjects (32%). Venous pH 
correlated with eGFR (r=0.25, p=0.04) and was negatively correlated with iPTH 
(r= -0.36, p<0.005) and albumin corrected serum calcium (r= -0.37, p<=0.005).  
Of the 9 subjects with a past history of parathyroidectomy, the median (range) 
iPTH was 94 ng/ml (22 – 197); 5 had post transplant hyperparathyroidism and 
8 had suboptimal vitamin D levels. Of 8 subjects treated with cinacalcet the 
median (IQR) iPTH was 151 ng/L (82-290), 3 had persistent hypercalcaemia 
and none were hyperphosphatemic. 
Eight-five subjects had an available areal bone mineral density measurement, 
of whom 22 (26%) had osteoporosis and 28 (31%) had osteopenia. In 8 cases 
the distal one third of the radius was the only site in which the T-score was 
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below 2.5. T-scores did not significantly differ across different stages of CKD, 
Table 4.3.  There were significant differences in T-scores by site examined 
(Friedman p <0.001), with the lumbar spine being considerably higher than 
other sites, Figure 4.4. Significant correlations were found between T-score at 
the neck of femur and distal radius with age (r=-0.28 and -0.22 respectively) 
and iPTH r= -0.20 and -0.31 respectively.  25(OH) vitamin D level only 
correlated with T-score at the distal forearm (r=0.36, p=0.001).  
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Table 4.3: Bone and Vascular Health Parameters by CKD-T Stage 
 
p values for continuous variables denoted  †were calculated using linear test 
for trend. All other continuous variables were examined using Kruskal Wallis 
non-parametric test. Categorical variables were examined using Pearson’s Chi 
square test  
 
 
 
 
 
 
 All subjects Stage T1-2 Stage T3A Stage T3B p-value 
N 89 32 27 30  
Areal Bone Mineral Density  
T-Score, L1-4,  Mean (sd) -0.22  (1.6) -0.44 (1.55) 0.42 (1.34) -0.55(1.82) 0.06 
T-Score, Total femur, Mean 
(sd) 
-0.73 (1.4) -0.6 (1.57) -0.39 (1.29) -1.14 (1.26) 0.16 
T-Score Neck of femur, 
Mean (sd) 
-0.83 (1.29) -0.56  (1.52) -0.55 (1.0) -1.28 (1.17) 0.03† 
T- score Distal 1/3 radius, 
Mean (sd) 
-1.2  (1.36) -1.08 (1.3) -0.95 (1.0) -1.52 (1.64) 0.4 
Lowest T-score, Mean (sd) -1.73 (1.19) -1.67 (1.25) -1.28 (0.9) -2.2 (1.22) 0.01 
Osteoporosis, n (%) 22 (24.7) 8 (28.6) 2 (7.7) 12 (41.4) 0.15 
Osteopenia, n (%) 27 (30.3) 9 (32.1) 9 (34.6) 9 (31) 1.0 
Fractures 
Appendicular Fracture,  
n (%) 
14 (15.7) 7 (21.9)  3 (11.1) 4 (13.3) 0.54 
Spinal collapse fracture,  
n (%) 
8 (9) 3 (11.1) 4 (16.7) 1 (3.8) 0.34 
Vascular Health 
Pulse Wave Velocity, m/s 
median (IQR) 
5.5 
(3.1, 9.5) 
6.5  
(4.0, 9.9) 
5.7  
(2.8, 9.3) 
4.7  
(3.2, 7.8) 
0.38 
Pulse pressure, mmHg, 
Mean (sd) 
57.3  
(13.3) 
52.4  
(10.7) 
58.8  
(12.4) 
60.8  
(15.7) 
0.01† 
Aortic calcification n (%) 43  (48) 11 (39.3) 14 (56) 18 (69.2) 0.09 
Calcification score, Median 
(IQR) 
1.0  
(0,6) 
0.0 
(0, 1) 
1.0  
(0, 3) 
3.0 
(0, 9) 
0.04 
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Figure 4.4: Boxplot of areal Bone Mineral Density by site studied 
 
Figure 4.4: Boxplot of areal Bone Mineral Density at different sites in 85 
prevalent renal transplant recipients. The solid line within the box indicates 
the median value, the box the intra-quartile range and open circles outliers.    
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 The 3 markers of bone turnover, Bone ALP, TRACP5b, and NTx-I were closely 
correlated with each other (correlation coefficients of 0.6 - 0.77, all p<0.001).  
None of the markers correlated with age and only TRACP5b correlated with 
eGFR, (r=0.23, p=0.04).  Bone ALP and NTx-I both correlated with iPTH (r=0.52 
and 0.53 respectively, both p<0.001) and negatively with 25(OH) vitamin D (r= 
-0.42 and -0.38 respectively, both p<0.001); the above correlations for 
TRACP5b were weaker but similar in direction, (iPTH: r= 0.26, p=0.02 and 
25(OH) Vitamin D: r= -0.20, p=0.08 respectively).   All 3 bone turnover markers 
correlated negatively with lowest measured T score, with correlations of -0.32 
for Bone ALP, -0.45 for TRACP5b and -0.43 for NTx-I, all p< 0.005, Figure 4.5.  
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Figure 4.5: Scatterplots of 3 biomarkers of bone turnover with areal Bone 
Mineral Density 
 
 
Figure 4.5a: Scatterplot of Bone Specific Alkaline Phosphatase (ug/L) with areal 
Bone Mineral Density 
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Figure 4.5b: Scatterplot of Urinary N-Telopeptide (nMBCE per mM/L) with areal 
Bone Mineral Density 
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Figure 4.5c: Scatterplot of Tartrate Resistant Acid Phosphatase (TRACP5b) (U/L) 
with areal Bone Mineral Density 
 
 
 
Figure 4.5: Scatterplots of 3 biomarkers of bone turnover with areal bone mineral 
density in 85 prevalent renal transplant recipients. Open circles indicate those 
subjects with an iPTH <=100ng/ml, asterisks those >100 ng/ml.  The dashed line 
represents the cut-off for osteoporosis (T-score <-2.5), the solid horizontal lines 
represent the biomarker reference range within the general population. 
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Forty-two (47%) of subjects had evidence of calcification based on lateral 
lumbar radiographs; 39%, 56% and 69% in stage T1-2, T3A and T3B 
respectively, p trend = 0.03. In those with detectable aortic calcification the 
severity of the calcification also tended to be higher at higher CKD stage, with 
median calcification score of 1, 3 and 6.5 respectively. Vascular calcification 
was associated with a history of prior atherosclerotic cardiovascular events 
(p=0.06).  Median pulse wave velocity was 5.5m/sec; 19.1% had a pulse wave 
velocity of ≥ 10m/sec.  Pulse wave velocity did not significantly differ by aortic 
calcification status but was significantly higher in those with past history of 
atherosclerotic cardiovascular disease than in those without such a history, 
11.3 (6.2 – 17.8) vs. 5.1 (3.1 – 8.9) m/sec, p=0.02.    
Fourteen subjects (15.7%), 9 men and 5 women, suffered from a low impact 
peripheral fracture post transplantation. The fracture occurred at the wrist (5 
cases), digit (4 cases), knee (2 cases), tibia (1 case), ankle (1 case), and rib (1 
case). Fracture sufferers’ median age was 42.4 years, median eGFR was 59 
ml/min/m2; their median duration of transplantation and of dialysis was 3.2 
and 2.2 years respectively. Their median lowest T score (-1.9), median iPTH 
(119ng/ml) and 25(OH) Vitamin D levels (33nmol/l) were not significantly 
different compared to the overall study population.  Eight subjects had a 
prevalent lumbar collapse fracture evident on lateral lumbar radiograph which 
involved 2 or more vertebrae in 4 patients.  
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Overall 91% of  renal transplants with eGFR >30ml/min/m2 had an elevated 
iPTH and/or suboptimal vitamin D level,  54% had aortic calcification and 42% 
osteoporosis, a prevalent vertebral collapse fracture or a post-transplant 
peripheral fragility fracture, Figure 4.6 .  Of the 75 subjects with complete data 
27% had all 3 types of abnormalities, while 97% had at least one element of 
CKD-MBD present. Even in those with an eGFR >60 ml/min/m2 23% had all 3 
and 96% at least 1 abnormality present. 
25%
27%
Aortic
Calcification
5%
23%
High PTH/Low Vitamin D
16%
1%Osteoporosis/
Fragility Fracture/
Vertebral Collapse Fracture
 
Figure 4.6: Venn diagram of the prevalence of either hormonal dysregulation 
(iPTH > 65 ng/L and/or 25 hydroxy Vitamin D <50nmol/L), aortic calcification 
and bone pathology (osteoporosis, prevalent vertebral collapse fracture or 
post-transplant peripheral fragility fracture) in 89 prevalent renal allograft 
recipients with an eGFR > 30 ml/min/1.73m2 
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On univariate logistic regression analysis the presence of osteoporosis (DXA T-
score less than -2.5) was significantly associated with iPTH (per 10ng/ml 
increment), Odds Ratio (95% Confidence Interval), 1.13 (1.05, 1.22).  On 
multivariate logistic regression analysis, adjusting simultaneously for age, 
gender, ESKD vintage (cumulative time on dialysis and post transplant), eGFR, 
current corticosteroid use, 25-OH Vitamin D and TCO2 level, the presence of 
osteoporosis remained independently associated with PTH. (Table 4.4). 
 
 
Table 4.4: Logistic Regression Crude and Adjusted Association of Osteoporosis 
with iPTH (per 10ng/ml increment), Odds Ratio (OR), (95% Confidence Interval) 
 OR 95% Confidence 
Interval 
p 
Model 1 1.13 1.05, 1.22 0.001 
Model 2 1.15 1.06, 1.26 0.001 
Model 3 1.15 1.05, 1.25 0.002 
Model 4 1.15 1.04, 1.27 0.006 
 
 
Model 1: Crude Association of Osteoporosis (Lowest DXA T-score <-2.5) and 
intact PTH (per 10ng/ml increment). 
Model 2: Adjusted for Age (decades), Gender, ESKD vintage (years) and MDRD 
eGFR (ml/min/1.73m2)  
Model 3: Adjusted for Age (decades) and Gender, ESKD vintage (years), MDRD 
eGFR (ml/min/1.73m2) and current corticosteroid use 
Model 4: Adjusted for Age (decades), Gender, ESKD vintage (years), MDRD 
eGFR (ml/min/1.73m2), current corticosteroid use, 25-OH Vitamin D level 
(nmol/L) and TCO2 level (mmol/L) 
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Discussion 
In this chapter we report that CKD-MBD remains highly prevalent post renal 
transplantation; 91% of our study population had an elevated iPTH and/or 
suboptimal Vitamin D level. We found iPTH to be independently associated 
with the presence of osteoporosis, a well recognized risk for fracture 
occurrence.  The burden of CKD-MBD in successful renal allograft recipients is 
overwhelming and may be a major mechanism contributing to the persistent 
elevation in morbidity and mortality in this population. The prevalence of CKD-
MBD differs substantially post transplantation to that reported in native 
kidney CKD at an equivalent level of renal function.44  Unfortunately the 
successful restoration of renal function fails to restore normal bone and 
vascular health. The clinical consequences of this are underscored by high 
prevalence of both lumbar collapse fractures and peripheral fragility fractures 
as described previously and as evident in our population.159, 161, 163, 165, 167 
Post-transplant hyperparathyroidism appears central to the presence of 
deranged bone mineral homeostasis. Although higher than in several reports, 
the prevalence of post transplant hyperparathyroidism in our study is similar 
to that found by Marcen who described a prevalence of 77% amongst 509 
renal transplant recipients.238  The  pathophysiology of post transplant 
hyperparathyroidism may relate to both persistent autonomous PTH 
production from hyperplastic parathyroid glands and/or from a degree of 
secondary hyperparathyroidism in setting of diminished renal function, 
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vitamin D deficiency and diminished vitamin D receptor activation as occurs in 
the setting of native CKD.236  Alternatively, in the setting of hypercalcaemia the 
condition more closely resembles primary hyperparathyroidism with 
associated hypophosphatemia and is relatively independent of the 25(OH) 
Vitamin D level. Given the literature of often subtle complications of minor 
elevations in PTH and calcium seen in patients with primary 
hyperparathyroidism252, there is surprisingly little data, particularly on the non 
skeletal consequences, of such autonomous hyperparathyroidism post 
transplantation. Borchhardt et al reported that -the off label- use of cinacalcet 
post transplantation was associated with a persistently increased urinary 
calcium excretion253, a finding that could theoretically predispose to transplant 
nephrolithiasis and which may therefore support prospective monitoring of 
urinary calcium excretion in this setting.  
The clinical relevance of post-transplant hyperparathyroidism even with 
regard to skeletal health remains to date uncertain. The extent and time scale 
over which the skeletal resistance to PTH that exists in CKD stage 5D resolves 
following transplantation is unknown, as is the optimal iPTH target post 
transplantation and the extent to which factors such as the type and severity 
of dialysis associated CKD MBD should influence this target.   
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 PTH is known to reduce bone mineral density especially at sites with a high 
proportion of cortical bone such as the distal forearm. It is thus noteworthy 
that while iPTH did not correlate with lumbar BMD, it strongly correlated with 
the forearm site and to a lesser extent with femoral site. In keeping with 
current recommendations for primary hyperparathyroidism –though not 
specifically discussed in current transplant guidelines- the assessment of bone 
mineral density post transplantation if conducted by DXA should routinely 
include examination of the distal forearm. Failing to do so would have resulted 
in missed diagnosis of osteoporosis in over one third of osteoporotic subjects 
within our study. Our findings broadly agree with those of Roe and colleagues 
who in a study of 134 prevalent male transplant recipients found a 72% 
prevalence of hyperparathyroidism, the level of which strongly correlated with 
areal bone mineral density at the radial site and with the proportion of men 
diagnosed as having osteoporosis rising from 30 to 41% with examination of 
the radial site.167 The clinical significance of this is further underscored by the 
high frequency of distal upper and lower limb fracture seen in renal transplant 
recipients.   We report the significant and independent association between 
osteoporosis and iPTH despite adjustment for multiple confounders which 
may adversely influence bone health. While we cannot in this cross-sectional 
study assess the extent that the presence of osteoporosis may have resulted 
from pre-transplant as distinct to post transplant levels of PTH, the strong 
correlation of iPTH seen with biochemical markers of bone turnover, with their 
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short half-life, supports the hypothesis that hyperparathyroidism in at least 
some of these subjects is exerting an ongoing active and possibly maladaptive 
influence on bone turnover. However, the limited available data from post-
transplant bone biopsies have reported disparate results, with two such 
studies finding no correlation between bone turnover and PTH.245, 254 
 We found a substantially higher prevalence of hypocalcaemia by measuring 
ionized calcium rather than total calcium based measurements. Evenepoel and 
colleagues recently reported similar poor agreement between ionized and 
total calcium although in their study total calcium overestimated ionized 
calcium in only 5% of subjects and underestimated it in 35%.255  
We report the significant association of relatively mild acidosis with 
hyperparathyroidism and hypercalcaemia as has previously been shown by 
Yakupoglu et al.256  The broader effects of even mild acidosis on bone health 
and renal survival of transplant recipients is worthy of additional prospective 
study.    
 While vascular calcification was not associated with Pulse Wave Velocity in 
this cross-sectional data there was a trend for both to be associated with past 
history of atherosclerotic cardiovascular events.  The lack of association of 
Pulse Wave Velocity with vascular calcification may relate to imprecision in the 
assessment of vascular calcification using lateral radiographs of the lumbar 
spine, our limited sample size and to incidence-prevalence bias resulting from 
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the cross sectional nature of the analysis, whereby those subjects with greater 
degrees of vascular damage may have been more likely to have died and 
thereby not be available for study enrolment. Follow-up of these outcomes 
over time may help clarify these issues.  Additional limitations of our study is 
that it is based in a single Irish institution and is susceptible to local  practice 
patterns and possibly genetic predispositions occurring within Ireland, 
nevertheless the observed relationships between different CKD-MBD 
parameters should be reasonably generalizable.  We do not have FGF-23 
measurements which may contribute to the presence of hypophosphatemia, 
although available data suggests that this is most influential in the first year 
post transplant,257, 258 and therefore would be relevant in only 25% of our 
study population.  
 In conclusion, while the severity of CKD-MBD varies with the post 
transplantation level of renal function, it is regardless highly prevalent even in 
those with excellent allograft function.  Both autonomous iPTH secretion and 
vitamin D deficiency are likely to contribute to its perpetuation.  Post 
transplant hyperparathyroidism may independently contribute to the 
development of osteoporosis and subsequent fracture risk. Finally the 
presence of persistent vascular and bone pathology may represent an 
essential mechanism in driving post-transplant morbidity and mortality. These 
data support the need to limit the initial development of these abnormalities 
at earlier stages of kidney disease through appropriate preventative measures 
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and call for research into the optimal management and secondary prevention 
of CKD-MBD in renal transplant recipients.   
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Chapter 5 
 
 
 
 
 
 
The Association of Hyperparathyroidism and Bone 
Mineral Density with Vascular Calcification after Renal 
Transplantation 
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Introduction 
Vascular calcification independently predicts cardiovascular disease, which 
accounts for up to 50% of all-cause mortality  in renal transplant recipients.145  
Mortality rates, while substantially lower than that of the dialysis 
population144, remain markedly elevated after renal transplantation.146 Risk 
factors for cardiovascular disease after renal transplantation include the 
traditional risk factors common to the general population, such as; older age, 
pre-existing Diabetes Mellitus, hypercholesterolemia, hypertension and Left 
Ventricular Hypertrophy.  Post renal transplant status confers additional 
cardiovascular risk factors namely the often suboptimal levels of renal function 
provided by the allograft, de-novo hyperglycaemia and hyperlipidemia due to 
immunosuppressive agents and residual disturbances in mineral 
metabolism.147 Parameters of mineral metabolism typically improve over the 
first year post renal transplantation, although in a substantial proportion of 
patients PTH concentrations remain elevated, albeit at lower levels, and are 
frequently associated with hypercalcaemia.148, 150, 151  It is typically assumed 
that with normalisation of bone mineral parameters and improvements in PTH 
levels, vascular calcification stabilizes or improves.  However, few studies have 
examined the natural history of vascular calcification post renal 
transplantation and results have been conflicting.  The prevalence of vascular 
calcification post transplantation, determined by Electron Beam Computed 
Tomography (EBCT) has been reported to be between 65% and 92%, which 
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was similar to comparative dialysis populations.152, 153  Moe et al., in a 
prospective study of 23 renal transplant recipients found no evidence of 
progression of vascular calcification scores, determined by spiral CT over 15-20 
months of follow-up.  Several other small studies have shown improvements 
in vascular function and vascular stiffness following transplantation.  More 
recently, Marechal et al. demonstrated significant increases in spiral CT 
determined vascular calcification scores in 281 renal transplant recipients over 
3.5 years of follow up.158  
In contrast to vascular calcification, the natural history of disorders of bone 
metabolism and fracture risk are well described post renal transplantation. 
Fracture risk is elevated in Chronic Kidney Disease and End Stage Kidney 
Disease and the risk of fracture further increases post transplantation.  The 
cumulative incidence of any fracture post transplantation is reported to be as 
high as 60%159 and is accompanied by an increased risk in all-cause mortality 
compared to the general population.163  Risk factors for fracture post 
transplantation include dialysis vintage prior to transplant, severity of pre-
transplantation hyperparathyroidism, duration since transplant, female 
gender, diabetes mellitus, older age, decreased Bone Mineral Density, prior 
history of fracture and immunosuppressive therapies (corticosteroids and 
calcineurin inhibitors).165 
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Bone metabolism and vascular calcification are both complex, multifactorial 
processes.  Vascular calcification is a highly regulated process which closely 
resembles bone mineralization.  Several epidemiological studies in the general 
population have demonstrated a relationship between decreased Bone 
Mineral Density and increased measures of vascular calcification.136, 137, 259  
This relationship has also been observed in the CKD population260 and in 
patients treated with dialysis.261 However, while individual components of 
CKD-MBD, such as residual mineral disturbances, fracture risk and vascular 
calcification, have been examined in the post transplant population, whether 
the complex inverse relationship between bone health and vascular 
calcification seen in CKD and dialysis patients persists in the post transplant 
era remains poorly described, but may influence the long term health of the 
successful transplant recipient. In this chapter we present cross-sectional data 
examining the presence, strength, independence and significance of (1) iPTH 
and (2) Bone Mineral Density with vascular calcification in a cohort of 
successful renal transplant recipients. 
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Methods 
We examine the association of Bone Mineral Density and osteoporosis with 
measures of vascular calcification in 90 subjects prospectively enrolled in the 
Association of Bone and Cardiovascular Health after Renal Transplantation 
(ABC-HEART) study, by the author as described in detail in Chapter 4. The 
current report uses baseline data at study entry on 64 patients who 
underwent CT assessment of aortic vascular calcification and bone mineral 
density.  In brief, to be eligible subjects had to be between 0.5 and 12 years 
post transplant and to have a current transplant eGFR>30ml/min/1.73m2 and 
to be in their usual state of health.  All study procedures were performed on 
an outpatient basis. Informed written consent was obtained from all 
participants and the study protocol was approved by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals. 
Information on demographics, clinical details and past medical history were 
obtained by patient self-report and abstracted from the medical record. 
Biochemical measures of renal function and of bone metabolism were 
obtained as described in detail in Chapter 4. In addition, previously stored 
samples were analysed in batch for serum osteoprotegerin and Fetuin A. 
Osteoprotegerin was measured using an ELISA assay (Biomedica, Austria), and 
expressed in pmol/L. Fetuin A was measured using Human Fetuin A ELISA 
(Epitope Diagnostics, Inc, USA) and expressed in g/L. 
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Assessment of Bone Mineral Density 
Areal bone mineral density was measured at the lumbar spine, the femoral 
neck and total femur of both hips and the non-dominant forearm, using a 
Lunar IDXA scanner (General Electric) and expressed as a T-score.  
Osteoporosis was defined as a lowest T-score of -2.5 or less and osteopenia as 
a T-score of -1.5-2.49.16  
 
Assessment of Vascular Calcification 
Consenting patients also underwent a non-contrast CT scan using a 64 slice 
General Electric Medical Systems Lightspeed VCT XTE CT scanner.  A helical 
series from the L1 to L4 vertebral bodies was performed in all patients. An 
acquisition slice thickness of 0.625 mm was utilised. Calcification was scored 
using the semi-quantitative Aortic Calcification Index (ACI). The Aortic 
calcification index (ACI) is a semi-quantitative score where the cross section of 
each of 10 slices of the abdominal aorta is divided into 12 radial sectors. The 
number of sectors showing calcification in each slice is counted, and the total 
number of calcified sectors in the 10 slices is summed. All detectable 
calcifications ≥100 Hounsfield units are included, and the sum is then divided 
by 120 and multiplied by 100 to be expressed as a percentage.262 
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Aortic vascular calcification was quantified from plain lateral lumbar spine 
radiographs using the Framingham method, scoring on a scale of 1-3 the 
presence of calcification along the anterior and posterior margin of the 
expected aortic contour adjacent to the 4 lumbar vertebrae, resulting in a 
composite score of between 0-24.129  
Carotid Femoral Pulse Wave Velocity (PWV) was measured using a dedicated 
Pulse Trace 400 PWV system (Viasys Healthcare) by a single investigator (SK) 
following the method described by London.131 Participants were studied in the 
supine position after approximately 5 minutes of rest.  Brachial systolic and 
diastolic blood pressure was recorded on 3 separate occasions at 5 minute 
intervals during the examination using an oscillometric device.  Doppler 
ultrasound with simultaneous ECG recording was used to assess the pulse 
wave between the carotid and femoral sites.  Pulse wave transit distances 
were recorded from the suprasternal notch to the femoral recording site.  The 
velocity of the pulse wave between the carotid and femoral site was recorded 
during 10 – 15 ventricular contractions and the average PWV was calculated 
by the system software and expressed as meters per second.   
 
Statistical Analysis 
Clinically implausible and outlying data were checked against the original 
clinical record.  Normality was examined using box-plots and Shapiro-Wilks 
149 
 
test and distribution described using mean (sd) or median (intra quartile range 
(IQR)) as appropriate.  Non parametric analytic methods were exclusively used 
including Spearman rank correlation and Mann-Whitney U test.  We examined 
the independence of the association of iPTH and osteoporosis (DXA T-score 
less than -2.5) with measures of vascular calcification, (PWV, lateral lumbar 
radiograph and Aortic Calcification Index) using multivariate linear regression, 
adjusting sequentially for age, smoking history, mean arterial blood pressure, 
renal function and history of Diabetes Mellitus.  Analysis was conducted using 
SPSS (Chicago, Illinois) V16, with a 2-sided Type one error rate of 0.05. 
 
Results 
Data on 64 subjects who underwent CT scan were included for analysis. The 
baseline clinical characteristics of the included study population are shown in 
Table 5.1 and were similar to the baseline characteristics of the 26 subjects 
who did not undergo CT scanning.  Mean age (sd) of the study participants was 
47.3 (12.9) years, 61% were male and mean (sd) MDRD eGFR was 54.1 (17.6) 
ml/min/1.73m2. Median (IQR) duration of dialysis and transplantation was 2.2 
(1.4, 3.3) and 3.7 (0.9, 8.1) years respectively.  Mean (sd) osteoprotegerin was 
4.09 pmol/L (1.37) (Reference Range 0.6 – 6.9pmol/L). Mean (sd) Fetuin-A was 
0.51 g/L (0.19), (Reference Range 0.35 – 0.95g/L). Using the CT determined 
Aortic Calcification Index (ACI), 62.5% of the study population had evidence of 
vascular calcification. Presence of vascular calcification was associated with 
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older age, lower level of renal function, longer dialysis vintage prior to 
transplantation, higher mean arterial blood pressure, prior cardiovascular 
event and higher total serum cholesterol, but not iPTH level. (Table 5.1) 
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Table 5.1: Characteristics of Study Population by Aortic Calcification Index 
Calcification Status 
Characteristic Total 
N=64 
No Calcification 
N = 24 
Calcification 
N =40 
p- value 
Age (years) (sd) 47.3 (12.9) 35.8 (8.5) 52.3 (9.6) 0.001 
Male (%) 39 (61) 18 (75) 21 (52.5) 0.074 
eGFR (ml/min/1.73m2) (sd) 54.1 (17.6) 57.8 (14.8) 48.3 (14.9) 0.002 
CKD Stage, N (%) 
Stage 1T-2T 
Stage 3AT 
Stage 3BT 
 
22 (34.4) 
20 (31.2) 
22 (34.4) 
 
14 (58.3) 
6 (25) 
4 (16.7) 
 
8 (20) 
14 (35) 
18 (45) 
 
 
0.006 
Cause ESKD, N (%) 
 GN 
PKD/Alports 
DM 
Other 
 
22 (34.4) 
13 (20.3) 
6   (9.4) 
23  (35.9) 
 
7 (29.2) 
3 (12.5) 
2 (8.3) 
12 (50) 
 
15 (37.5) 
10 (25) 
4 (10) 
11 (27.5) 
 
 
0.466 
Dialysis Modality, N (%) 
Haemodialysis 
Peritoneal Dialysis 
Pre-emptive  
 
39 (60.9) 
23 (35.9) 
2 (3.2) 
 
15 (62.5) 
8 (33.3) 
1  (4.2) 
 
24 (60) 
15 (37.5) 
1 (2.5) 
 
0.954 
Median Duration of Dialysis, (years) 
(IQR) 
2.2  
(1.4, 3.3) 
1.6 
 (0.8, 2.0) 
3.0  
(1.7, 3.8) 
 
0.034 
Median Duration of Transplant, 
(years), (IQR) 
3.7  
(0.9, 8.1) 
3.2  
(0.9, 8.8) 
4.1  
(0.9, 7.1) 
 
0.398 
Mean Arterial Blood Pressure, mmHg 102.7 (9.7) 100.0 (8.8) 104.7 (8.9) 0.012 
Ever Smoked, n (%) 28 (43.8) 8 (33.3) 20 (50) 0.193 
Diabetes, n (%) 10 (15.6) 3 (12.5) 7 (17.5) 0.594 
Cardiovascular  Event, n 6 0 6 0.046 
Tacrolimus, n (%) 56 (87.5) 21 (87.5) 35 (87.5) 1.0 
Mycophenolate mofetil, n (%) 52 (81.2) 17 (70.8) 35 (87.5) 0.098 
Current Steroid Use, n (%) 28 (43.8) 10 (41.7) 18 (45) 0.795 
Previous Parathyroidectomy, n 8 3 5 1.0 
Current Vitamin D Use, n 5 1 4 0.642 
Median intact PTH, ng/ml  
(IQR)  
91.5  
(73, 168) 
106.5  
(83.5, 175) 
86.5  
(57, 128) 
 
0.846 
Mean 25 OH Vitamin D, nmol/L (sd) 44.9 (18.1) 47.7 (20.1) 45.2 (19.8) 0.430 
Mean Total Calcium, mmol/L (sd) 2.57 (0.17) 2.52 (0.16) 2.63 (0.17) 0.062 
Mean Haemoglobin, g/dl (sd) 13.3 (1.8) 13.3 (1.9) 13.2 (1.9) 0.972 
Mean LDL Cholesterol, mmol/L (sd) 2.7 (0.9) 2.3 (0.8) 2.9 (0.9) 0.052 
Mean HDL Cholesterol, mmol/L (sd) 1.35 (0.4) 1.27 (0.35) 1.44 (0.46) 0.211 
Mean Total Cholesterol, mmol/L (sd)  4.7 (1.1) 4.2 (0.9) 5.0 (1.0) 0.006 
Mean Osteoprotegrin, pmol/L (sd) 4.09 (1.37) 4.2 (1.8) 4.2 (1.3) 0.776 
Mean Fetuin A, g/L (sd) 0.51 (0.19) 0.51 (0.23) 0.47 (0.15) 0.441 
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Using Spearman rank correlation the Aortic Calcification Score correlated 
significantly with the Lateral Lumbar Radiograph Calcification score (r = 0.91, 
p< 0.001) (Figure 5.1). The correlation of Aortic Calcification Score with Pulse 
Wave Velocity was weaker but similar in direction, r = 0.29, p = 0.02. 
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Figure 5.1: Scatter-plot of Correlation of Aortic Calcification Index with Lateral 
Lumbar Radiograph Calcification Score 
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On univariate linear regression, PWV was significantly associated with prior 
history of cardiovascular event (ß (95% Confidence Interval), 5.4 (2.4, 8.4)) and 
history of diabetes mellitus (ß (95% Confidence Interval), 3.1 (0.54, 5.56). 
Lateral Lumbar Radiograph Calcification Score and Aortic Calcification Index 
were both univariately associated with age, prior cardiovascular event, mean 
arterial blood pressure, osteoprotegerin, and lower DXA measures of Bone 
Mineral Density but not iPTH. (Table 5.2) 
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Table 5.2: Linear Regression Univariate Associations of Measures of Vascular 
Calcification with demographic, clinical and laboratory variables. 
 ß (95% Confidence Interval) 
Parameter Pulse Wave 
Velocity 
Lateral Lumbar 
Radiograph 
Calcification Score 
Aortic Calcification 
Index 
Age (decades) 0.469 ( -0.268, 
1.206) 
1.81 (1.04, 2.6) 
p<0.001 
10.49 (6.91, 14.08) 
p <0.001 
ESKD Vintage (years) 0.076  
(-0.159, 0.311) 
0.076  
(-0.198, 0.35) 
0.636  
(-0.77, 2.04) 
History of Prior CV 
event 
5.4 
(2.4, 8.4) 
p=0.001 
4.67 
(1.22, 8.05) 
p = 0.008 
30.86  
(12.76, 48.96) 
p = 0.001 
History of Smoking 0.55  
(-1.33, 2.43) 
1.75 
 (-0.42, 3.92) 
10.09  
(-1.21, 21.39) 
History of Diabetes 
Mellitus 
3.1  (0.54, 5.56) 
p = 0.018 
0.658 (-2.46, 3.78) -0.796  
(-16.63, 15.04) 
Mean Arterial Blood 
Pressure (mmHg) 
0.057  
(-0.032, 0.145) 
0.111  
(0.005, 0.217)  
p = 0.04 
0.928 
(0.371, 1.48) 
p =0.001 
25 OH Vitamin D 
(nmol/L) 
0.003  
(-0.053, 0.058) 
0.001  
(-0.066, 0.068) 
-0.077 
 (-0.394, 0.241) 
FetuinA (g/L 4.19 (-0.91, 9.28) 0.663 (-6.05, 7.37) 2.57 (-27.75, 32.89) 
Osteoprotegerin 
(pmol/L) 
0.226  
(-0.56, 1.01) 
1.05  
(0.131, 1.96) 
p = 0.026 
4.68  
(0.015, 9.34) 
p = 0.049 
eGFR 
(ml/min/1.73m2) 
0.034  
(-0.02, 0.09) 
-0.05  
(-0.118, 0.019) 
-0.298  
(-0.62, 0.022) 
Phosphate (mmol/L) 3.36  
(-1.12, 7.8) 
3.89  
(-1.26, 9.04) 
13.71  
(-12.02, 39.45) 
Total Calcium 
(mmol/L) 
-5.72  
(-11.63, 0.186) 
4.3  
(-2.47, 11.07) 
7.29  
(-27.54, 42.13) 
Total Cholesterol 
(mmol/L) 
-0.5  
(-0.95, 0.85) 
0.324  
(-0.699, 1.35) 
-0.91  
(-6.29, 4.47) 
iPTH (ng/ml) -0.004  
(-0.17, 0.008) 
0.006  
(-0.008, 0.02) 
0.041  
(-0.028, 0.110) 
Prior 
Parathyroidectomy 
-1.62  
(-4.71, 1.48) 
0.794  
(-2.78, 4.37) 
1.49  
(-15.89, 18.87) 
Cinacalcet Use -0.84  
(-3.7, 2.0) 
4.43  
(1.48, 7.38) 
p =0.004 
16.04  
(-0.864, 32.94) 
Lowest T-score 0.615 (-0.2, 1.43) -1.43 (-2.3, -0.56) 
p = 0.002 
-6.25 (-11.2, -1.29) 
p = 0.014 
Osteoporosis (Lowest 
T-score <-2.5) 
-1.078  
(-3.13, 1.158) 
3.79 (1.43, 6.16) 
p= 0.002 
20.48 (8.46, 32.5) 
p = 0.001 
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On multivariate linear regression analysis osteoporosis (defined as a DXA T-
score less than -2.5) was significantly associated with Lateral Lumbar 
Radiograph Calcification Score, even with simultaneous adjustment for age, 
gender, mean arterial blood pressure, smoking history, and intact PTH 
(adjusted ß (95% confidence Interval), 3.27 (0.88, 5.66), p =0.008). (Table 5.3, 
Model 5) 
Similarly, on multivariate linear regression analysis, osteoporosis was 
independently associated with Aortic Calcification Index, even following 
adjustment for the above variables, (adjusted ß (95% Confidence Interval), 
12.45 (1.16, 23.75), p = 0.031). (Table 5.3, Model 5)  With further adjustment 
for osteoprotegerin in addition to the variables in Model 5, the relationship 
between osteoporosis and Aortic Calcification Index was substantially 
attenuated an no longer statistically significant (adjusted ß (95% Confidence 
Interval), 7.17 (-5.3, 19.6), p = 0.25). Similarly, with adjustment for Fetuin A, in 
addition to the variables in Model 5 the relationship between osteoporosis 
and Aortic Calcification Index was no longer significant, (adjusted ß (95% 
Confidence Interval), 8.77 (-2.7, 20.3), p = 0.13). 
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Table 5.3: Linear Regression Crude and Adjusted Association of Osteoporosis 
with measures of Vascular Calcification, ß (95% Confidence Interval) 
 
Model 1: Crude Association of Osteoporosis (Lowest DXA T-score <-2.5) and measure 
of Vascular Calcification. 
Model 2: Adjusted for Age (decades) and Gender 
Model 3: Adjusted for Age (decades), Gender and Mean Arterial Blood Pressure 
Model 4: Adjusted for Age (decades), Gender, Mean Arterial Blood Pressure and 
history of smoking  
Model 5: Adjusted for Age (decades), Gender, Mean Arterial Blood Pressure, history 
of smoking   and intact PTH (ng/ml) 
 
Intact PTH showed no significant association with Pulse Wave Velocity or with 
either of the calcification scores on univariate or any of the above mentioned 
multivariate models.  
 
 
 Pulse Wave 
Velocity 
Lateral Lumbar 
Radiograph 
Calcification Score 
CT Aortic 
Calcification Index 
Model 1 -1.08  
(-3.3, 1.16) 
p = 0.340 
3.79  
(1.43, 6.16) 
p = 0.002 
20.48  
(8.47, 32.5)  
p =0.001 
Model 2 -1.35  
(-3.64, 0.935) 
p = 0.243 
2.81  
(0.68, 4.94)  
p = 0.011 
12.63 
(2.71, 22.55)  
p = 0.014 
Model 3 -1.18  
(-3.33, 0.97)  
p = 0.278 
2.76  
(0.62, 4.91) 
p = 0.012 
11.74  
(1.5, 21.9)  
p= 0.025 
Model 4 -1.26  
(-3.44, 0.93) 
p = 0.256 
2.58  
(0.41, 4.75)  
p = 0.02 
10.4  
(0.26, 20.57)  
p= 0.045 
Model 5 -0.93  
(-3.33, 1.47) 
 p =0.443 
3.27  
(0.88, 5.66)  
p = 0.008 
12.45  
(1.16, 23.75)  
p = 0.031 
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Discussion 
We report that in a cohort of successful renal transplant recipients, the 
presence of osteoporosis but not the prevalent intact PTH is associated with 
measures of vascular calcification.  This relationship was independent of 
potential confounders; age, gender mean arterial blood pressure, smoking 
history and PTH level. We found that vascular calcification is highly prevalent 
post-transplant, 62.5% of our study population had evidence of abdominal 
aortic calcification, determined by CT. While lower than the prevalence of 80-
95% in the CKD and haemodialysis population,260, 263, 264 our findings are similar 
to those of by Rosas et al. who reported evidence of vascular calcification to 
be present in  65% of 79 incident renal transplant recipients, determined by CT 
measures of Coronary Artery Calcification.152  The lower prevalence of vascular 
calcification seen in renal transplant recipients compared to those with CKD 
and ESKD still on dialysis may reflect selection or survival bias in those patients 
evaluated and successfully listed for renal transplantation, for whom severe 
vascular disease would be a relative contra-indication. 
Vascular calcification is an independent predictor of cardiovascular disease 
and in patients with End Stage Kidney Disease, the presence of vascular 
calcification is predictive of both all cause and cardiovascular mortality.128, 130  
While originally thought to be an unregulated process due to passive mineral 
deposition in the vascular wall, evidence from human and animal studies have 
demonstrated that vascular calcification is an active, cell-mediated process 
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which closely resembles bone mineralisation.  However, while bone 
mineralisation is a physiological process, vascular calcification is a pathological 
process with important clinical consequences, both in the general population 
and in patients with renal disease.  
Several epidemiological studies in the general population have reported 
associations between vascular calcification and decreases in bone mineral 
density.  In the Framingham Heart Study, Kiel et al. demonstrated that there 
was a significant association between percentage change in Bone Mineral 
Density (measured by metacarpal relative cortical area (MCA)) and progression 
of abdominal aortic calcification (measured by lateral lumbar radiograph) in 
women though not men over a 25 year follow up period.136  Similarly, in a 
cross-sectional study of 2348 post-menopausal women, Schluz et al. found 
aortic calcification scores were inversely related to bone mineral density (both 
parameters determined by CT).  This study also reported that the Odds Ratios 
(95% Confidence Interval) for vertebral and hip fractures in those women with 
calcification were 4.8 (3.6 – 6.5) and 2.9 (1.8 – 4.8) respectively, compared to 
those without evidence of calcification.  In a subgroup analysis of 228 women 
with available longitudinal data, this study also demonstrated a significant 
graded association between progression of vascular calcification and bone 
loss, where women with the greatest increase in vascular calcification had 4 
times greater yearly bone loss than women of similar age in the lowest 
vascular calcification quartile.137  In a larger prospective study of 624 men and 
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women over the age of 50 years, Naves at al. showed that progression of 
aortic calcification (determined by lateral lumbar radiograph) was associated 
with the rate of decline in Bone Mineral Density (determined by DXA) over 4 
years of follow-up.  This relationship remained significant following 
adjustment for age, gender, smoking history and diabetic status.138 
This relationship between vascular calcification and bone metabolism has also 
been demonstrated in patients with CKD and End Stage Kidney Disease treated 
with dialysis.  In a cross-sectional study of 48 patients with NKF Stage 3 CKD 
(mean eGFR 35ml/min/1.73m2), Toussaint et al. demonstrated an inverse 
association between superficial femoral artery vascular calcification score 
(measured by CT) and femoral T-scores (measured by DXA).260 London et al 
reported, in a cross-sectional study of 58 haemodialysis patients, that the 
extent of vascular calcification, assessed by ultrasonography and plain 
radiography at 4 separate anatomical sites was associated with low bone 
turnover and adynamic bone disease on bone histomorphometry.261   
Few studies have examined whether the complex relationship between bone 
metabolism and vascular calcification persists in the post-transplant setting.  In 
the present study, we report that measures of vascular calcification, 
determined both by lateral lumbar radiographs and by CT, were associated 
with presence of osteoporosis, defined as a lowest DXA T-score less than -2.5.  
These relationships remained significant even following adjustment for age, 
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gender, mean arterial blood pressure, history of smoking, and PTH. Although 
cross-sectional, these data broadly concur with the earlier observation by 
Schulz at al.137  and Naves et al.138 In the general population, the associations 
between increased vascular calcification and decreased bone mineral density 
occur in the absence of disorders of mineral metabolism and are often 
considered a degenerative consequence of aging. In CKD, the prevalence of 
vascular calcification increases with progressively decreasing renal function, 
even in young patients and is greater than in the general population.  The 
associations between vascular calcification and bone health observed in the 
CKD population occur in the context of abnormal bone mineral homeostasis, 
Vitamin D and PTH dysregulation and disruptions in the complex inter-play 
between promoters and inhibitors of vascular calcification.  In the current 
study we did not observe an association between measures of vascular 
calcification and PTH, Vitamin D or serum calcium and phosphate levels which 
may indicate that these factors are not of clinical importance in a well 
functioning renal allograft or that the presence of vascular calcification was 
dominated by the historical –during dialysis- rather than ambient 
derangements in mineral metabolism. Alternatively given out modest sample 
size it is possible that the lack of association may represent a type II statistical 
error.  
However, we did observe a univariate association between osteoprotegerin 
levels and measures of vascular calcification. Osteoprotegerin is a glycoprotein 
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member of the tumour necrosis factor (TNF) receptor family. Osteoprotegerin 
is an important modulator of bone remodelling and by inhibiting activation of 
RANK it inhibits osteoclast formation, differentiation, activation and survival, 
preventing bone resorption.  It is expressed by endothelial cells, VSMC’s and 
osteoblasts.112 Osteoprotegerin levels are significantly higher in patients with 
CKD and ESKD than in those without CKD and osteoprotegerin levels are higher 
at lower levels of renal function.115 Observational studies in haemodialysis 
patients have shown a positive association between osteoprotegerin levels 
and severity and progression of vascular calcification117, 118 and 
osteoprotegerin levels were predictive of future cardiovascular events.119, 120 
In a large cohort of renal transplant recipients osteoprotegerin has recently 
been independently associated with renal events, cardiovascular events and 
mortality.121 The role of osteoprotegerin in the pathogenesis of vascular 
calcification in these studies is unclear but it has been suggested that 
osteoprotegerin levels increase as a defensive response to rapidly progressive 
mineral deposition in the vessel wall.122  With the addition of osteoprotegerin 
to our multivariate linear regression model, the observed relationship 
between osteoporosis and vascular calcification was attenuated and no longer 
significant. A similar effect was seen with the addition of Fetuin A to the 
statistical model. Fetuin A is an extracellular protein which is an inhibitor of 
calcium-phosphate precipitation.  It is a negative acute phase protein, with 
reduced circulating levels during inflammation. Fetuin A acts both systemically 
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and locally to potently inhibit vascular calcification.  The effect of 
osteoprotegerin and Fetuin A, 2 potent calcification inhibitors, on our results 
may represent incident-prevalence bias in this cross sectional study –whereby 
the elevated osteoprotegerin and Fetuin A levels may result as a consequence 
of rather than as a cause of the vascular calcification.  
The presence and severity of vascular calcification strongly predicts 
cardiovascular morbidity and mortality in patients with CKD in whom Electron 
Beam CT (EBCT) or Multi Slice CT (MSCT) is considered the gold standard for 
the detection and quantification of vascular calcification.  However, these CT 
based techniques are expensive and not as readily available as plain 
radiography.  The KDIGO clinical practice guideline for the diagnosis, 
evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and 
Bone Disorder (CKD-MBD) suggest that a lateral abdominal radiograph can be 
used to detect the presence or absence of vascular calcification as a 
reasonable alternative to CT based imaging.39  We performed lateral lumbar 
radiographs in our study and applied the semi-quantitative scoring system for 
vascular calcification, originally described by Kauppila.129 We found a strong 
correlation between this scoring system and the CT derived Aortic Calcification 
Index, Spearman Rank Correlation, r = 0.91, p <0.001. Similarly, in multivariate 
linear regression models, the adjusted relationship between osteoporosis and 
vascular calcification, using both these outcome variables showed comparable 
results, suggesting that semi-quantitative determination of vascular 
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calcification by lateral lumbar radiograph is a valid alternative to CT based 
measures. 
In conclusion, osteoporosis but not intact PTH was significantly and 
independently associated with CT and radiographic measures of aortic 
calcification in this cross-sectional study of renal transplant recipients.  
Whether the relationship between these two important conditions persists 
over time warrants further prospective evaluation as vascular calcification and 
fracture remain extremely deleterious to the long-term health of the 
successful renal transplant recipient.  
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Chapter 6 
 
 
 
 
 
 
Association of Hyperparathyroidism and Health Related 
Quality of Life Post Renal Transplantation 
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Introduction 
Renal transplantation is the treatment of choice for advanced Chronic Kidney 
Disease.265 The risk of death for a successful renal transplant recipient is less 
than half of that for dialysis patients.266 Patient and allograft survival rates 
following renal transplantation have improved dramatically over the past 30 
years; one year allograft survival rates currently exceed 88% for deceased 
donor allografts and 95% for living donor allografts. One year patient survival 
exceeds 94% for deceased donor allografts and 98% for living donor 
allografts.267 With this improvement in allograft and recipient survival rates, 
recent attention has increasingly focused on minimizing the long-term 
complications related to immunosuppression and cardiovascular risk and 
optimizing the Health Related Quality of Life and functional health status of 
transplant recipients. 
Secondary hyperparathyroidism (SHPT) is a common complication of Chronic 
Kidney Disease (CKD) and End Stage Kidney Disease (ESKD).  
Hyperparathyroidism typically develops early in the course of CKD and is 
initially compensatory, serving to help maintain a normal serum calcium and 
phosphate level.  However, over time, prolonged secondary 
hyperparathyroidism may result in nodular hyperplasia and autonomous 
parathyroid hormone secretion, termed tertiary hyperparathyroidism.  Such 
tertiary hyperparathyroidism is distinct to the secondary condition and 
resembles primary hyperparathyroidism in that in the setting of a functioning 
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kidney it may lead to actual hypercalcaemia and phosphate wasting.  
Successful renal transplantation restores endogenous renal function and in the 
absence of tertiary hyperparathyroidism serum calcium and phosphate values 
typically normalize over weeks to months.  However, whether hyperplastic 
parathyroid tissue ever spontaneously involutes is controversial176, 268 and 
renal transplantation frequently does not lead to normalization of parathyroid 
hormone levels despite adequate renal function.150, 238 
Primary hyperparathyroidism has classically been associated with symptoms of 
bone pain, nephrolithiasis and neuropsychiatric disturbance.  In recent years, 
with increased routine screening of serum calcium levels, the presentation of 
primary hyperparathyroidism has changed.  Most patients with primary 
hyperparathyroidism exhibit vague non-specific manifestations of the disease 
such as mood swings, irritability, fatigue and increased absenteeism from 
work.170  These non-classical manifestations of primary hyperparathyroidism 
are associated with decreased measures of Health Related Quality of Life 
which demonstrate an improvement following appropriate treatment.171-173 
Both primary and secondary hyperparathyroidism have been associated with 
abnormal bone turnover, decreased bone mineral density and increased 
cardiovascular risk but the relationship between these outcomes and elevated 
parathyroid hormone post-transplantation is unclear.  Moreover, the effect of 
residual hyperparathyroidism on the quality of life and over-all well-being of 
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the renal transplant recipient has not been examined.  We conducted the 
following study to examine the relationship of post transplant 
hyperparathyroidism with parathyroid associated symptoms and Health 
Related Quality of Life in patients with good allograft function. 
 
Methods 
We examine the association of health related Quality of Life with 
hyperparathyroidism in 90 subjects enrolled in the Association of Bone and 
Cardiovascular Health after Renal Transplantation (ABC-HEART) study, as 
described in detail in chapter 4. The current report uses baseline data at study 
entry on 90 patients who completed Parathyroid Assessment of Symptoms 
and Short Form 12 Quality of Life questionnaires at study entry.  In brief, to be 
eligible subjects had to be between 0.5 and 12 years post transplant and to 
have a current transplant eGFR>30ml/min/1.73m2 and to be in their usual 
state of health.  All study procedures were performed on an outpatient basis. 
Informed written consent was obtained from all participants and the study 
protocol was approved by the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals. 
Information on demographics, clinical details and past medical history were 
obtained by patient self-report and abstracted from the medical record.  
Serum creatinine was measured using the modified Jaffe reaction on the 
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Olympus 5400 analyser.  The method was changed to an IDMS traceable form 
in October 2009 and was used in the last 10 subjects recruited into the study.  
eGFR (ml/min/1.73m2) was calculated using the 4-variable MDRD prediction 
equation2 and categorized as Transplant CKD Stage 1T-2T for eGFR >60, Stage 
3AT for 45-59 and Stage 3B for 30-44ml/min/1.73m2.  Parathyroid hormone 
(PTH) was measured by several different methods.  Intact PTH, which uses a 
second generation PTH assay, was initially measured in all subjects by 
electrochemical luminescence (ECLIA) immunoassay on the Roche E170 
modular analyzer.  Second generation PTH assays, which are the most widely 
used in clinical practice in Europe, use 2 separate antibodies.  One is directed 
against the C-terminal fragment of the PTH molecule and the second is 
directed against the N-terminal fragment.  These assays were initially thought 
to quantify only the full-length, biologically active 1-84 PTH molecule.  It is now 
known that they also measure other large PTH fragments, predominantly 7-84 
PTH, the biological activity of which is uncertain. Additional samples were 
taken at the same blood draw, centrifuged, aliquoted and frozen.  In a 
subgroup of 70 patients these samples were subsequently analyzed in batch, 
under the supervision of Dr Paula O’ Shea, Department of Clinical 
Biochemistry, University College Hospital, Galway), using a third generation 
“Whole” PTH assay (Scantibodies™) which only measures the biologically 
active 1-84 PTH as well as a separate measurement of the “Total” PTH, which 
measures both Whole (1-84) PTH and the 7-84 N-truncated PTH fragment. The 
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Scantibodies™ third generation PTH assays also use a two-antibody technique 
but in these assays one antibody is radio-labelled and directed only against the 
first six N-terminal amino acids of 1-84 PTH, while the second antibody binds 
to the C-terminal region of 1-84 PTH. These assays are more sensitive and 
specific for the measurement of biologically active 1-84 PTH.  Typically, mean 
measured PTH levels are 30-60% lower using the third generation PTH assay as 
compared to a second generation assay77 and current guidelines for 
therapeutic targets in patients with renal disease were developed using 
second generation assays.   
Serum 25-hydroxyvitamin D (25(OH) D) was measured by a competitive 
radioimmunoassay (IDS). Inter assay coefficients of variations were 6.2% and 
7.7% at concentrations of 28.8 nmol/l and 105.4 nmol/l, respectively. The 
intra-assay coefficients of variations were 3.0% and 2.7% at concentrations of 
28.9 nmol/l and 73.9 nmol/l, respectively. Optimal values were considered to 
be over 50 nmol/l.73 Serum calcium was measured by the Arsenazo 111 
method on the Olympus 5400 analyzer. 
Subjects completed the standard 4-week recall Short Form 12. (SF-12v2™ 
Health Survey © 2002 Quality Metric Incorporated). This is a multipurpose 
short form survey with 12 questions selected from the Short Form 36 Health 
survey.  It is a generic measure of health status and does not target a specific 
age or disease group. It is used to assess the physical, functional, emotional 
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and social dimensions of Health Related Quality of Life.  It was developed to 
provide a shorter but valid alternative to the Short Form 36.  The Short Form 
12 covers 8 health domains, with one or two questions per domain. The 
domains covered are Physical Functioning, Role-Physical, Bodily Pain, General 
Health, Vitality, Social Functioning, Role-Emotional and Mental Health. These 
dimensions are scored on a scale with a low of 0 and a high of 100.  General 
population norms are used to facilitate direct comparisons across different 
health domains. For example, using the 0-100 scoring, the Physical Function 
scale General population norm is between 80 and 90, while the Vitality general 
population norm is approximately 60 on the 100 point scale. A software 
algorithm computes these standardized domains as well as a composite 
Physical Function Component and a Mental Health Component score using a 
standardized mean score of 50 and a standard deviation of 10. All of the health 
domains contribute to the scoring of both the Physical and Mental Component 
Summary scores, although to a varying extent.  The Physical Function, Role 
Physical, Bodily Pain and General Health domains contribute more to the 
Physical Component Score, while the Vitality, Social Functioning, Role 
Emotional and Mental Health domains contribute more to the Mental 
Component Score.  Higher scores represent higher functioning, a clinically 
relevant reduction in Health related Quality of Life is defined as  a group mean 
that  is below 47.269 
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Patients also completed the Parathyroid Assessment of Symptoms (PAS) 
questionnaire; this tool documents the patients symptoms using a Visual 
Analog Scale ranging from 0 (no experience of the symptom) to 100 
(experiencing the most extreme aspect of the symptom) for 13 disease specific 
items.  Symptoms evaluated are bone pain, fatigue, mood swings, depression, 
abdominal pain, weakness, irritability, joint pain, forgetfulness, difficulty 
getting out of a chair or car, headaches, itchy skin and being thirsty.  This 
disease specific tool has been validated by a number of studies in patients with 
symptomatic and asymptomatic primary hyperparathyroidism and has been 
utilized in a study of patients with both secondary and tertiary 
hyperparathyroidism due to ESKD. 53, 171, 270 
 
Statistical Analysis 
Clinically implausible and outlying data were checked against the original 
clinical record.  Normality was examined using box-plots and Shapiro-Wilks 
test and distribution described using mean (sd) or median (intra quartile range 
(IQR)) as appropriate.  Non parametric analytic methods were exclusively used 
including Spearman rank correlation. Clinical characteristics and laboratory 
results in those above and below the sample median for iPTH were compared 
using the Mann-Whitney U test or Chi square test as appropriate.  Short Form 
12 scores were initially compared to the general population norms, stratified 
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by age and gender. Subsequently, univariate relationships of clinical 
characteristics and laboratory data for subjects with Physical Component 
Score and Mental Component Score above or below the sample median value 
for the respective distribution were quantified using linear regression. We 
examined the presence, strength, significance and independence of the 
association of iPTH with SF 12 domain and composite scores using logistic 
regression, adjusting sequentially for age, gender, eGFR, haemoglobin, serum 
calcium and co-morbidities (prior cardiovascular event and diabetes mellitus).  
The relationship of Parathyroid Assessment of Symptoms score and PTH was 
examined using linear regression modelling.  Routine model diagnostics were 
performed on all final models and included assessment of points of high 
leverage and/or influence and for logistic regression models measurement of 
overall ‘Goodness of Fit’ using the Hosmer and Lemeshow test. All analyses 
were conducted using SPSS (Chicago, Illinois), V16, with a 2 sided type one 
error rate of 0.05. In keeping with methodological approach usually taken in 
Quality of Life studies we do not adjust the type I error rate for multiple 
comparisons across the different Quality of Life domains but instead report 
the nominal p value in a non selective fashion for all of the domains examined.  
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Results 
Data on 90 subjects were included for analysis.  The clinical characteristics of 
the study sample are shown in Table 6.1 and were broadly representative of 
our prevalent transplant population. The median (IQR) iPTH was 100ng/ml, 
(73-148), with 45 subjects above and 45 below this value. Significantly more 
patients with CKD Stage 3BT had an iPTH level above the median of 100ng/ml 
(44.4% vs 24.4%, p = 0.045. The documented cause of ESKD was also 
significantly different between patients with iPTH above or below 100ng/ml, p 
chi square = 0.045, with more chronic glomerulonephritis and less Diabetes, 
Polycystic Kidney Disease and Alports syndrome in the higher iPTH group. 
Subjects with iPTH >100ng/ml also had spent significantly longer on dialysis 
prior to transplantation (2.7 vs 1.7 years, p = 0.0012),   but had no significant 
difference in transplant vintage.  
Seventy percent of subjects had sub-optimal 25 OH Vitamin D levels 
(<50nmol/L). Subjects with elevated iPTH, (>100ng/ml, Roche) had significantly 
lower mean 25 OH Vitamin D levels, (37.4 Vs 50.6 nmol/L, p<0.001).  
We  observed a small but significant difference in mean total calcium and 
haemoglobin levels between the two groups, The percentage of patients with 
a total serum calcium level above the upper limit of normal (>2.6mmol/l) was 
37.8%.  Mean (sd) phosphate was 1.03 (0.2) mmol/L. Only 1 patient was 
hyperphosphatemic (which was marginal at 1.51mmol/L), whereas 11 patients 
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(12.2%) were hypophosphatemic (<0.8mmol/L) of whom 9 had an iPTH level 
>100ng/ml.   
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Table 6.1: Patient Characteristics by iPTH level 
Characteristic Enrolled Study Population p- 
value 
 Total 
 N=90 
Intact PTH 
<100ng/ml 
N = 45 
Intact PTH 
>100ng/ml 
N = 45 
 
Age (years) (sd) 46.4 (12.6) 46.5  (13.3) 46.3 (12.1) 0.954 
Male (%) 54 (60) 30 (66.7) 24 (53.3) 0.197 
eGFR (ml/min/1.73m2) (sd) 53.6 (16.6) 55.9 (16.0) 51.3 (17.1) 0.188 
CKD Stage, N (%) 
Stage 1T-2T 
Stage 3AT 
Stage 3BT 
 
31 (34.3) 
28 (32.9) 
31 (32.9) 
 
15 (33.3) 
19 (42.3) 
11 (24.4) 
 
16 (35.3) 
  9 (20.0) 
20(44.4) 
 
 
0.045 
Cause ESKD, N (%) 
 GN 
PKD/Alports 
DM 
Other 
 
28 (31.0) 
21 (23.3) 
8 (9.0) 
33 (36.7) 
 
12 (26.7) 
14 (31.1) 
7 (15.5) 
12 (26.7) 
 
16 (35.6) 
7 (15.6) 
1 (1.1) 
21 (46.7) 
 
 
0.044 
Dialysis Modality, N (%) 
Haemodialysis 
Peritoneal Dialysis 
Pre-emptive  
 
40 (57.1) 
25 (35.7) 
5   (7.2) 
 
23 (67.6) 
9 (26.5) 
2 (5.9) 
 
17 (47.2) 
16 (44.4) 
3 (8.3) 
 
 
0.196 
Median Duration of Dialysis  
(IQR) 
2.5 
(1.4 – 3.2) 
1.7  
(0.74 – 3.2) 
2.7  
(1.9 – 3.6) 
0.012 
Median Duration of Transplant 
(IQR) 
2.5  
(1.1 – 6.4) 
3.4  
(1.7 – 6.6) 
2.0  
(0.7 -  5.6) 
0.084 
Tacrolimus, N (%) 59 (84.3) 38 (84.4) 38 (84.4) 1.0 
Mycophenolate mofetil, N (%) 56 (80.0) 33 (73.3) 39 (86.7) 0.114 
Current Steroid Use, N (%) 28 (40.0) 20 (57.1) 15 (42.9) 0.280 
Previous Parathyroidectomy, N 9 4 5 1.0 
Current Vitamin D Use, N 6 4 2 0.677 
Median intact PTH, (Roche assay) 
ng/ml (IQR)  
100 
(70 – 143) 
73 
(57 -85) 
148  
(116 – 193) 
 
<0.001 
Intact (Total) PTH (Scantibodies 
Assay) pg/ml (IQR) 
65.9  
(49.4 – 111.8) 
48.6  
(38.8 – 62.7) 
111.8  
(80.4 – 158.1) 
0.4 
Whole (1-84) PTH (Scantibodies 
Assay) pg/ml (IQR) 
51.6  
(36.8 – 78.0) 
34.5  
(26.9 – 47.9) 
78  
(56.5 – 106.2) 
0.547 
Mean 25 OH Vitamin D, nmol/L 
(sd) 
42.7 
(15.8) 
50.6  
(18.2) 
37.4 
(14.5) 
<0.001 
Mean Total Calcium, mmol/L (sd) 2.57 (0.16) 2.5 (0.17) 2.6 (0.18) 0.015 
Mean Haemoglobin, g/dl (sd) 13.3 (1.6) 13.6 (1.6) 12.9 (1.6) 0.043 
Median SF 12 Physical Component 
Score (IQR) 
52.6  
(44.8 – 58) 
56.1  
(44.8 – 58.4) 
52.2  
(44.8 – 57.1) 
0.008 
Median SF 12 Mental Health 
Component Score (IQR) 
54.9  
(50.8 – 57.9) 
54.6  
(49.9 – 57.4) 
57.3  
(52.2 – 59.2) 
0.001 
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In 70 patients with the necessary data, median (IQR) Scantibodies™ Whole (1-
84) PTH and Total Intact PTH were 51.6 (36.8-78) and 65.9 (49.4 -111.8) pg/ml 
respectively.  Spearman Rank correlation of iPTH (Roche) and Scantibodies™ 
Whole (1-84) PTH was r =0.924, p<0.001, (Figure 6.1).  
 
Figure 6.1: Scatter-plot of Correlation of iPTH (ng/ml) with Whole (1-84) PTH 
(pg/ml) 
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Comparison of Short Form 12 Scores with General Population 
Median (IQR) Physical Component Short Form 12 Score (standardized to a 
general population mean score of 50) was 53.6 (44.8 – 57.6). Median (IQR) 
Mental Component Short Form 12 score was 55.6 (51.0 – 59.1); -General 
population median score, 50.  Short Form 12 mean individual domain scores 
for the total study population are shown in Figure 6.2. 
Figure 6.2: SF 12 domain and composite scores for Study Population (n= 90) 
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Physical Function scores were slightly lower than that of the general 
population.  Other dimensions were similar to general population norms, with 
Mental Health dimensions (Mental Component Score, Vitality, Social 
Functioning, Role Emotional and Mental Health) scoring slightly higher than 
the general population average.) Overall 38.5% of subjects had a Physical 
Component Score below 50; the general population average and 23% had a 
Mental Component Score below 50. 
 When stratified by gender (Figure 6.3) scores in all dimensions for male 
transplant recipients were similar to the general population.  Female 
transplant recipients had lower Physical Function scores than the general 
population average, (44.8 Vs 50, p = 0.003) however scores for Mental 
Component Score (55.4 Vs 50, p<0.001), Social Functioning (53.7 Vs 50 
p<0.001 and Role Emotional (53.7 Vs 50, p=0.001) were significantly higher.  
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Figure 6.3: SF 12 Domain and Composite Scores for Study Population (n =90) 
stratified by Gender 
 
Comparison of Short Form 12 Scores within the sample population 
Lower MDRD eGFR (ml/min/1.73m2) were significantly associated with SF 12 
scores below the sample median for the General Health, Vitality, and Physical 
Component domains, mean eGFR approximately 48 Vs 56 ml/min/1.73m2, all 
p<0.05.  Distribution of demographic, clinical and laboratory variables for 
subjects with SF 12 scores below and above the sample median for the 
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Physical and Mental Component Scores are summarized in Tables 6.2 and 6.3 
respectively.  
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Table 6.2: Distribution demographic, clinical and laboratory variables for 
subjects with SF 12 Physical Component Score below Vs above the sample 
median value of 53.6 
 
Abbreviations: sd, standard deviation, IQR, Intra-Quartile Range, ESKD, End 
Stage Kidney Disease, MDRD eGFR, Modification of Diet in Renal Disease 
estimated Glomerular Filtration Rate, PTH, Parathyroid Hormone, SB, 
Scantibodies™. 
 
 
 
 
 
 
 
 
 
 
Total 
N=90 
PCS <53.6 
N = 45 
PCS >53.6 
N= 45 
p 
Male, n (%) 54 (60) 24 (53.3) 30 (66.7) 0.20 
Mean (sd)Age, yrs  46.4 (12.6) 52.3 (11.6) 40.6 (10.9) <0.001 
Median (IQR)ESKD 
Vintage (yrs) 
5.5  
(3.4, 9.2) 
5.4 
(3.6, 9.2) 
5.6  
(3.2, 9.9) 
 
0.96 
History of Diabetes, n 14 8 6 0.53 
Mean (sd)MDRD eGFR 
(ml/min/1.73m2) 
53.6  
(16.6) 
49.9  
(15.8) 
57.3  
(16.7) 
 
0.03 
Mean (sd)Total 
Calcium (mmol/l) 
2.57  
(0.16) 
2.57  
(0.17) 
2.58  
(0.14) 
 
0.71 
Median (IQR) Intact 
PTH (ng/ml) 
99  
(73, 148) 
105  
(82, 182) 
95  
(65, 128) 
 
0.03 
Median (IQR) Whole 
PTH (pg/ml) 
51.3  
(34.5, 78) 
54.2  
(39.7, 100) 
49.6  
(32.9, 65) 
 
0.03 
Median (IQR) Intact 
SB PTH (pg/ml) 
65.7  
(48.6, 111.8) 
73.9  
(50.3, 147.4) 
64.5  
(46.9, 88.3) 
 
0.06 
Mean (sd) 25-OH 
Vitamin D (nmol/l) 
43.9  
(17.6) 
42.8  
(16.3) 
45.1  
(19.1) 
 
0.57 
Mean (sd) 
Haemoglobin (g/dl) 
13.3  
(1.6) 
13.2  
(1.6) 
13.4  
(1.6) 
 
0.44 
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Table 6.3: Distribution of demographic, clinical and laboratory variables for 
subjects with SF 12 Mental Component Score below Vs above the sample 
median value of 55.6 
 
Abbreviations: sd, standard deviation, IQR, Intra-Quartile Range, ESKD, End 
Stage Kidney Disease, MDRD eGFR, Modification of Diet in Renal Disease 
estimated Glomerular Filtration Rate, PTH, Parathyroid Hormone, SB, 
Scantibodies™. 
 
 
 
 
 
 
 
 
 
Total 
N=90 
MCS <55.6 
N = 45 
MCS >55.6 
N= 45 
p 
Male, n (%) 54 (60) 29 (64.4) 25 (55.6) 0.39 
Mean (sd)Age, yrs  46.4 (12.6) 45.9 (11.4) 47.0 (13.9) 0.67 
Median (IQR) ESKD 
Vintage (yrs) 
5.5  
(3.4, 9.2) 
6.6  
(3.6, 9.8) 
5.1  
(2.9, 9.2) 
0.59 
History of Diabetes, 
n 
14 8 6 0.53 
Mean (sd)MDRD 
eGFR 
(ml/min/1.73m2) 
53.6 
(16.6) 
53.3  
(17.0) 
53.9  
(16.3) 
 
0.87 
Mean (sd)Total 
Calcium (mmol/l) 
2.57 
(0.16) 
2.56  
(0.13) 
2.59  
(0.18) 
 
0.42 
Median (IQR)Intact 
PTH (ng/ml) 
99  
(73, 148) 
84  
(61, 122) 
104   
(88, 168) 
 
0.05 
Median (IQR)Whole 
PTH (pg/ml) 
51.3  
(34.5, 78) 
48.6  
(33.2, 65.7) 
64.4  
(47.9, 92.1)  
 
0.35 
Median (IQR)Intact 
SB PTH (pg/ml) 
65.7  
(48.6, 111.8) 
65.5  
(47, 88.1) 
80.1  
(52.3, 130.9) 
 
0.56 
Mean (sd)25-OH 
Vitamin  D (nmol/l) 
43.9 
(17.6) 
45.9  
(17.6) 
41.9  
(17.7) 
 
0.29 
Mean(sd) 
Haemogloblin (g/dl) 
13.3 
(1.6) 
13.2  
(1.6) 
13.4  
(1.7) 
 
0.75 
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Univariate Linear Regression Associations of SF 12 Domain and Composite 
Scores  
Summaries of univariate associations using linear regression for each of the SF 
12 domains with demographic, clinical and laboratory characteristics of the 
study population are shown in Tables 6.4 and 6.5. 
Table 6.4: Univariate Linear Regression of the Associations of SF-12 Physical 
Domains with demographic, clinical and laboratory variables, ß (95% 
Confidence Interval) 
 
 
Physical 
Component 
Score 
Physical 
Functioning 
Physical 
 Role 
Bodily Pain General 
Health 
iPTH (per 
10ng/ml) 
 
1.07 
1.003, 1.138 
p=0.04 
1.09 
1.01, 1.17 
p= 0.02 
1.006 
0.95, 1.07 
1.03 
0.98, 1.09 
1.04 
0.98, 1.1 
Age (years) 
 
 
1.09 
1.05, 1.15 
p <0.001 
1.09 
1.05, 1.14 
P< 0.001 
1.06 
1.02, 1.1 
p = 0.007 
1.08 
1.04, 1.13 
p < 0.001 
1.057 
1.02, 1.10 
p = 0.005 
Gender (Male) 
 
 
1.75 
0.75, 4.1 
3.23 
1.28, 8.14 
p = 0.01 
1.14 
0.45, 2.89 
0.82 
0.34, 1.9 
0.822 
0.34, 1.96 
ESKD Vintage 
(years) 
1.003 
0.90, 1.11 
0.976 
0.88, 1.09 
1.04 
0.93, 1.17 
0.99 
0.88, 1.1 
1.005 
0.901, 1.12 
Previous CV event 
 
7.92 
0.93, 67.3 
p = 0.06 
5.33 
0.63, 45.3 
2.68 
0.62, 11.7 
14.0 
1.64, 119.7 
p = 0.02 
5.38 
1.02, 28.39 
p = 0.05 
Diabetes Mellitus 
 
1.44 
0.46, 4.57 
0.667 
0.21, 2.09 
2.95 
0.92, 9.5 
p = 0.07 
1.78 
0.56, 5.6 
0.366 
0.09, 1.42 
MDRD eGFR  
(ml/min/1.73m2) 
0.97 
0.95, 0.99 
p = 0.04 
0.981 
0.96, 1.01 
0.987 
0.96, 1.02 
0.985 
0.96, 1.01 
0.963 
0.94, 0.99 
p = 0.01 
Total Calcium 
>2.6mmol/L 
1.0 
0.43, 2.34 
0.820 
0.35, 1.94 
1.04 
0.41, 2.66 
0.638 
0.26, 1.56 
0.957 
0.40, 2.29 
Phosphate 
<0.8mmol/L 
1.89 
0.51, 6.97 
2.02 
0.50, 8.17 
2.302 
0.64, 8.34 
1.36 
0.38, 4.85 
1.361 
0.38, 4.85 
 Vitamin D 
<50nmol/L 
0.794 
0.29, 2.09 
0.876 
0.32, 2.4 
0.739 
0.25, 2.14 
0.821 
0.30, 2.24 
0.677 
0.25, 1.83 
Haemoglobin 
(g/dl) 
0.903 
0.70, 1.17 
0.804 
0.61, 1.05 
0.951 
0.72, 1.26 
1.02 
0.78, 1.33 
1.014 
0.78, 1.32 
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Table 6.5: Univariate Linear Regression Associations of SF-12 
Mental/Emotional Domains with demographic, clinical and laboratory 
variables, ß (95% Confidence Interval) 
 
 
 
 
 
 
 
 
MCS Vitality Social 
Function 
Role 
Emotional 
Mental 
Health 
iPTH (per 
10ng/ml) 
0.942 
0.89, 1.00 
1.004 
0.95, 1.06 
1.012 
0.96, 1.07 
0.945 
0.86, 1.04 
0.947 
0.89, 1.01 
Age (years) 
 
 
0.993 
0.96, 1.03 
1.072 
1.03, 1.12 
p =0.001 
1.007 
0.97, 1.04 
0.963 
0.92, 1.01 
1.021 
0.99, 1.06 
Gender (Male) 
 
0.69 
0.29, 1.61 
1.70 
0.72, 3.99 
0.485 
0.19, 1.23 
1.00 
0.32, 3.1 
0.822 
0.34, 1.96 
ESKD Vintage 
 
1.03 
0.93, 1.15 
1.04 
0.93, 1.16 
0.974 
0.87, 1.09 
0.98 
0.84, 1.14 
1.009 
0.91, 1.13 
Previous CV 
event 
1.03 
0.24, 4.38 
4.84 
0.92, 25.5 
2.12 
0.49, 9.13 
1.92 
0.35, 10.64 
2.99 
0.67, 13.42 
Diabetes 
Mellitus 
 
1.027 
0.33, 3.21 
0.707 
0.22, 2.31 
1.11 
0.34, 3.67  
3.61 
1.004, 12.99 
p = 0.49 
1.19 
0.37, 3.78 
MDRD eGFR  
(ml/min/1.73m2) 
0.998 
0.97, 1.02 
0.958 
0.93, 0.99 
p = 0.005 
0.988 
0.96, 1.02 
1.037 
1.004, 1.072 
p = 0.03 
1.007 
0.98, 1.03 
Total Calcium 
>2.6mmol/L 
0.828 
0.35, 1.94 
0.933 
0.39, 2.21 
1.307 
0.54, 3.18 
0.355 
0.09, 1.36 
0.957 
0.40, 2.29 
 Phosphate 
<0.8mmol/L 
0.330 
0.08, 1.34 
0.471 
0.12, 1.91 
1.699 
0.47, 6.09 
1.128 
0.22, 5.84 
0.551 
0.14, 2.24 
Vitamin D 
<50nmol/L 
0.525 
0.19, 1.44 
0.559 
0.21, 1.51 
0.872 
0.31, 2.42 
0.533 
0.16,  1.82 
1.07 
0.39, 2.95 
Haemoglobin 
(g/dl) 
 
0.958 
0.74, 1.24 
0.726 
0.54, 0.97 
p = 0.03 
0.882 
0.67, 1.16 
1.125 
0.80, 1.58 
1.01 
0.78, 1.32 
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Intact PTH (per 10ng/ml increment) was significantly associated with Physical 
Component Score and Physical Functioning but not with any of the other SF 12 
domain scores. (Figure 6.4).  
Figure 6.4: Univariate Linear Regression association of SF 12 Domains (all 
domains) with intact PTH (per 10ng/ml increment)  
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Age was associated with Physical Component Score, Physical Functioning, 
Physical Role, General Health and Vitality on univariate analysis, but not with 
Mental Component Score, Social Function, Emotional Role or Mental Health 
domains.  Gender was univariately associated with Physical Function but not 
with the other SF 12 domains.  
 
Multivariate Logistic Regression Associations of SF 12 Domain and Composite 
Scores 
On multivariate binary logistic regression analysis, Physical Function score 
below the sample median of 53.6 was significantly associated with intact PTH 
(per 10ng/ml increment), even with simultaneous adjustment for gender, 
eGFR, age, haemoglobin and elevated total serum calcium, (adjusted Odds 
Ratio (95% CI), 1.115, (1.009, 1.233, p = 0.03).  With additional adjustment for 
co-morbidities (prior cardiovascular event and history of Diabetes), this 
association was somewhat attenuated, adjusted Odds Ratio (95% CI) 1.107 
(0.999, 1.227, p =0.05). (Table 6.6, Figure 6.5). 
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Table 6.6: Crude and adjusted Odds Ratio (95% Confidence Interval) for 
Association of iPTH (per 10ng/ml) with Physical Domains of SF 12  
 
Model 1: Unadjusted 
Model 2: Adjusted for Gender, MDRD eGFR (ml/min/1.73m2) and Age (years) 
Model 3: Adjusted for Gender, MDRD eGFR (ml/min/1.73m2), Age (years), 
Haemoglobin (g/dl), Total Calcium >2.60 mmol/L. 
Model 4: Adjusted for Gender, MDRD eGFR (ml/min/1.73m2), Age (years), 
Haemoglobin (g/dl), Total Calcium >2.60 mmol/L, History of prior CV event, History of 
Diabetes Mellitus. 
 
 
 
 
 
 
 Model  1 
Crude OR 
Model 2 
Adjusted OR 
Model 3 
Adjusted OR 
Model 4 
Adjusted OR 
Physical 
Component Score 
1.069 
1.003, 1.14 
p = 0.04 
1.063 
0.98, 1.15 
 
1.067 
0.99, 1.16 
 
1.063 
0.98, 1.15 
 
Physical Function 1.089 
1.01, 1.17 
p = 0.02 
1.099 
1.00, 1.21 
p = 0.05 
1.115 
1.01, 1.23  
p = 0.03 
1.107 
0.999, 1.23 
p= 0.05 
Role Physical 1.006 
0.95, 1.07 
0.994 
0.93, 1.06 
0.990 
0.93, 1.06 
1.001 
0.94, 1.07 
Bodily Pain 
 
1.034 
0.98, 1.09 
1.031 
0.97, 1.1 
1.042 
0.97, 1.12 
1.036 
0.96, 1.12 
General Health 1.040 
0.98, 1.10 
1.021 
0.96, 1.09 
1.026 
0.96, 1.10 
1.016 
0.94, 1.09 
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On univariate logistic regression iPTH was not significantly associated with 
Mental Component Score or with any of the domains; on multivariate analysis 
higher iPTH was significantly associated with a better Mental Component 
Score. (Table 6.7, Figure 6.5)  Some of this unexpected association may relate 
to uncontrolled confounding with subjects having a more severe clinical course 
on dialysis having higher post transplant PTH levels and having a greater 
perceived improvement in their quality of life with successful renal 
transplantation.  
 
Table 6.7: Crude and adjusted Odds Ratio (95% Confidence Interval) for 
Association of iPTH (per 10ng/ml) with Mental/Emotional Domains of SF 12  
 
Model 1: Unadjusted 
Model 2: Adjusted for Gender, MDRD eGFR (ml/min) and Age (years) 
Model 3: Adjusted for Gender, MDRD eGFR (ml/min), Age, Haemoglobin (g/dl), Total 
Calcium >2.60 mmol/L. 
Model 4: Adjusted for Gender, MDRD eGFR (ml/min), Age, Haemoglobin (g/dl), Total 
Calcium >2.60 mmol/L, History of prior CV event, History of Diabetes Mellitus. 
 Model  1 
Crude OR 
Model 2 
Adjusted OR 
Model 3 
Adjusted OR 
Model 4 
Adjusted OR 
Mental Component 
Score 
0.942 
0.89, 1.00 
 
0.938 
0.88, 1.00 
 
0.934 
0.873, 1.00 
p = 0.05 
0.918 
0.851, 0.990 
p = 0.03 
Vitality 
 
1.004 
0.95, 1.06 
0.965 
0.91, 1.03 
0.959 
0.90, 1.03 
0.953 
0.88, 1.03 
Social Function 1.012 
0.96, 1.07 
1.011 
0.95, 1.08 
1.002 
0.94, 1.07 
0.985 
0.92, 1.06 
Role Emotional 0.945 
0.86, 1.04 
0.956 
0.86, 1.07  
0.972 
0.87, 1.09 
0.997 
0.88, 1.11 
Mental Health 0.947 
0.89, 1.01 
0.948 
0.89, 1.01 
0.942 
0.88, 1.01 
0.936 
0.87, 1.01 
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Figure 6.5: Multivariate associations of SF 12 Domains (all domains) with intact 
PTH (per 10ng/ml increment) adjusted for Gender, MDRD eGFR (ml/min), Age, 
Haemoglobin (g/dl), Total Calcium >2.60 mmol/L, History of prior CV event, 
History of Diabetes Mellitus. 
 
 
 
 
 
 
 
 
 
Worse Outcomes 
Better Outcomes 
191 
 
Multivariate Logistic Regression Associations of SF 12 Domain and Composite 
Scores with Whole and Total Intact PTH. 
We repeated the above analysis in the subgroup of 70 patients in whom we 
measured Whole 1-84 PTH results as outlined in Methods; examining its 
relationship with each of the SF 12 domain scores. The association of Whole 1-
84 PTH with the Physical Functioning domain of SF 12 was stronger and 
remained significant in the fully adjusted model, adjusted OR (95% CI) 1.399, 
(1.043 – 1.877, p = 0.025) (Table 6.8).  
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Table 6.8: Crude and adjusted OR (95% CI) for Association of Scantibodies™ 
Whole 1- 84 PTH (per 10pg/ml) with SF 12 Domain Scores 
 Crude Adjusted* 
Physical Component 
Score 
1.148 
1.001, 1.316 
p = 0.05 
1.088 
0.916, 1.292 
 
Physical Function 1.358 
1.086, 1.699 
p = 0.007 
1.399 
1.043, 1.877 
p = 0.03 
Role Physical 0.972 
0.87, 1.09 
0.942 
0.83, 1.07 
Bodily Pain 1.076 
0.97, 1.19 
1.070 
0.92, 1.24 
General Health 1.034 
0.94, 1.13 
0.959 
0.83, 1.10 
Mental Component 
Score 
0.959 
0.87, 1.05 
0.932 
0.83, 1.04 
Vitality 
 
1.013 
0.93, 1.11 
0.882 
0.77, 1.02 
Social Function 0.988 
0.99, 1.09 
0.946 
0.83, 1.07 
Role Emotional 0.941 
0.80, 1.10 
0.995 
0.85, 1.16 
Mental Health 0.937 
0.83, 1.05 
0.932 
0.83, 1.05 
* Adjusted for Gender, MDRD eGFR (ml/min), Age, Haemoglobin (g/dl), Total Calcium 
>2.60 mmol/L, History of prior CV event, History of Diabetes Mellitus. 
 
Similarly, Scantibodies Intact PTH (per 10pg/ml increment) was significantly 
associated with SF 12 Physical Functioning Score, even following simultaneous 
adjustment for gender, eGFR, age, haemoglobin level, hypercalcaemia and co-
morbidities (history of cardiovascular event and diabetes) (Table 6.9). 
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Table 6.9: Crude and adjusted OR (95% CI) for Association of Intact PTH 
(Scantibodies Assay) (per 10pg/ml) with SF 12 Domain Scores 
 Crude Adjusted* 
Physical Component 
Score 
1.083 
0.99, 1.189 
1.040 
0.94, 1.15 
Physical Function 1.225 
1.053, 1.424 
p = 0.008 
1.244 
1.024, 1.512 
p = 0.03 
Role Physical 0.980 
0.91, 1.06 
0.959 
0.88, 1.05 
Bodily Pain 
 
1.034 
0.97, 1.10 
1.025 
0.93, 1.13 
General Health 1.023 
0.97, 1.08 
0.976 
0.89, 1.06 
Mental Component 
Score 
0.984 
0.93, 1.04 
0.975 
0.91, 1.04 
Vitality 
 
1.012 
0.96, 1.07 
0.933 
0.86, 1.01 
Social Function 0.984 
0.92, 1.05 
0.960 
0.88, 1.04 
Role Emotional 0.947 
0.84, 1.07 
0.977 
0.875 1.09 
Mental Health 0.980 
0.92, 1.05 
0.973 
0.91, 1.04 
* Adjusted for Gender, MDRD eGFR (ml/min), Age, Haemoglobin (g/dl), Total Calcium 
>2.60 mmol/L, History of prior CV event, History of Diabetes Mellitus. 
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Parathyroid Assessment of Symptoms Score 
Median (IQR) total Parathyroid Assessment of Symptom Score was 100 (31 – 
170). The most commonly reported symptoms were fatigue, forgetfulness, 
joint pain and mood swings. (Figure 6.6) 
 
Figure 6.6: Responses to Parathyroid Assessment of Symptoms Questionnaire 
(n=90) 
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There was no significant difference is Parathyroid Assessment of Symptoms 
Score between patients who had an iPTH level above or below the median 
value of 100ng/ml, (137 vs 127ng/ml, p = 0.7). Similarly there was no 
significant difference in the individual disease specific symptom scores 
between patients who had iPTH levels above or below the median value of 
100ng/ml.  (Figure 6.7) 
 
Figure 6.7: Comparison of individual disease specific symptom scores between 
patients with iPTH value above or below 100ng/ml. 
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There was no correlation between Total Parathyroid Assessment of Symptoms 
Score with either intact PTH or Whole 1-84 PTH. Similarly, there was no 
difference in symptom scores for each of the 13 disease specific items on the 
parathyroid assessment of symptoms questionnaire between patients who 
had iPTH levels above the nominal general population reference range of 
65ng/ml, or between patients who had iPTH values above or below the 
median value of 100ng/ml.   
 
Discussion 
To our knowledge, the current report is the first to demonstrate an 
independent relationship between elevated PTH levels post transplant and 
one element of Health Related Quality of Life. Contrary to our expectation we 
only found PTH levels to be associated with Physical Function Scores below the 
sample median, but not with any other domain or composite of Short Form 12.  
Renal transplantation is the treatment of choice for End Stage Kidney Disease. 
The objective of renal transplantation is to maximise longevity and health 
related quality of life, while minimising the complications of renal disease and 
cost of care.  With increasing graft and patient survival rates, long-term Health 
Related Quality of Life has assumed greater importance as a relevant 
treatment-related outcome. Although published data is limited, studies 
evaluating Health Related Quality of Life after renal transplant have shown 
broadly similar results; Quality of Life substantially improves compared to 
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continuing on dialysis.271-275 A recent meta-analysis has reported that the 
quality of life of renal transplant recipients has been improving over time, with 
significant improvements since the 1980’s, likely reflecting improvements in 
renal transplant care and change in clinical practice and immunosuppressive 
protocols.273 
The most widely employed tool to assess Health Related Quality of Life post 
renal transplant globally is the Short Form 36 questionnaire. Studies have 
reported that SF36 scores across the 8 domains are similar post-
transplantation to that of the general population although there is some 
variability in results.  Griva et al. reported that SF 36 scores in 102 transplant 
recipients with a mean transplant vintage of 8 years were similar to that of the 
general population, with the exception of physical functioning and general 
health perception scores which were slightly lower that population norms.276  
Similarly, Neipp et al. in a cross-sectional study of 139 long-term renal 
transplant recipients (transplant vintage > 15 years) found that SF 36 scores 
were similar to the general population in the domains role physical, social 
functioning, role emotional and mental health, while scores for physical 
functioning, physical pain, general health and vitality were reduced.277 Rebello 
et al. demonstrated that Physical Functioning scores in transplant recipients 
were lower than the general population, but that role emotional and mental 
health scores were higher than the general population for female transplant 
patients.275 To the best of our knowledge no previous study has examined the 
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effect of post transplant hyperparathyroidism with Health related Quality of 
Life. Our study broadly supports these earlier reports, we found that Physical 
Functioning scores were lower than general population norms, and were 
significantly and independently associated with PTH levels. Mental Component 
Scores significantly higher than the general population norm with PTH being 
significantly associated with higher (better) Mental Composite Scores on 
multivariate analysis. Given the observational nature of this study we cannot 
establish causality for any of the above associations, which may relate to 
residual uncontrolled confounding.  
Several factors have been shown to be associated with reduced health related 
quality of life post renal transplantation. In a cross-sectional study of 281 renal 
transplant recipients Neri et al. showed that lower levels of renal function 
were associated with lower measures of Quality of Life, independent of age, 
gender, transplant vintage and co-morbidities (history of diabetes, 
hypertension or cardiovascular disease).278 The immunosuppression protocol 
employed has been associated with improved Health Related Quality of Life 
measures, a number of studies have demonstrated better quality of life scores 
with the use of tacrolimus based protocols compared to cyclosporine.279, 280 
The first of these studies by Shield et al. also reported that patients who had 
experienced an acute rejection episode had lower quality of life scores.279 
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In Chapter 4 of this manuscript, we discuss that the pathophysiology of post 
transplant hyperparathyroidism may relate to a degree of secondary 
hyperparathyroidism in setting of diminished renal allograft function, 
associated vitamin D deficiency and diminished vitamin D receptor activation 
as occurs in the setting of native kidney CKD.236  Alternatively, persistent 
autonomous PTH production from hyperplastic parathyroid tissue may 
resemble primary hyperparathyroidism which is associated with frank 
hypercalcaemia and hypophosphatemia. 
Primary hyperparathyroidism is a biochemical diagnosis often made based on 
routine laboratory assessment of calcium levels in asymptomatic patients.  
Less than 20% of patients display the classic symptoms of bone pain, 
nephrolithiasis and neuropsychiatric disturbance.  Whether the remaining 80% 
of patients are truly asymptomatic is controversial. Several studies have 
reported decreased measures of quality of life and elevated depression scores 
in patients with primary hyperparathyroidism which improves after surgical 
intervention. Weber at al. have recently shown that patients with primary 
hyperparathyroidism had significantly lower SF 36 Physical and Mental 
Component scores compared to a control group of patients with non-toxic 
goitre. SF 36 scores improved significantly over the first 12 months post 
parathyroidectomy.174 In an earlier study the same authors demonstrated that 
patients with primary hyperparathyroidism had significantly lower SF 12 
mental and physical component scores compared to the general population 
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and that mental component scores were significantly higher after 
parathyroidectomy.173 In both these studies, pre-operative calcium levels were 
associated with higher depressive symptom scores. However, a study by 
Burney et al. demonstrated that patients with primary hyperparathyroidism 
have significant functional health status impairment independent of the level 
of serum calcium and that improvements in health related quality of life was 
seen in both the hypercalcaemic and normocalcaemic groups after surgical 
intervention.270  In our study of post transplant patients with relatively well 
preserved renal function we demonstrate that lower levels of physical 
functioning were associated with higher PTH levels, independent  of 
hypercalcaemia.  
The original National Institutes of Health Consensus Conference Statement in 
1991 stated that evidence of mineral bone loss, a decrease in renal function 
and classical symptoms were indications for surgical correction of primary 
hyperparathyroidism.169 However, in light of this more recent data describing 
the more subtle physical and neurocognitive manifestations of the disease, 
which demonstrate improvement following surgical intervention, the original 
NIH recommendation has been revised. A consensus statement from the 
Proceedings of the Third International Workshop on Asymptomatic Primary 
Hyperparathyroidism states that “the balance of available evidence suggests 
that surgery is appropriate in the majority of patients with asymptomatic 
primary hyperparathyroidism”.175 
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Pasieka et al. have developed a disease specific tool for hyperparathyroidism 
which has been validated by a number of studies in both symptomatic and 
asymptomatic patients.171, 172 This disease specific tool has been utilised in a 
single study of patients with secondary  and tertiary hyperparathyroidism due 
to ESKD including 10 renal transplant recipients, where tertiary 
hyperparathyroidism was defined as persistently elevated PTH above the 
normal population reference range six months post successful renal 
engraftment.  This study compared the pre and post-operative disease specific 
tool scores and Quality of Life scores of patients with primary, secondary and 
tertiary hyperparathyroidism with those of a control group with non-toxic 
thyroid disease.  Although the group with tertiary hyperparathyroidism (post 
transplant), was too small (n=10) for meaningful statistical analysis, they 
showed resolution of their symptoms similar to those in the primary 
hyperparathyroidism group.53 We did not find a significant relationship 
between parathyroid assessment score and PTH levels in our study, this may 
relate in part to a type II statistical error given our modest sample size or to 
difficulty in dissecting out direct associations in a transplant population which 
typically has multiple contributing comorbidities which may all influence 
Health related Quality of Life.   In the original studies validating the 
parathyroid assessment of symptoms questionnaire, median symptom scores 
were higher than in our cohort (350 vs 100) and while symptom scores in the 
original studies demonstrated a significant reduction following 
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parathyroidectomy, pre-operative symptom scores did not correlate with pre-
operative PTH values.172  Whether symptom scores in the post transplant 
population would improve following correction of secondary 
hyperparathyroidism, for example with Vitamin D supplementation, warrants 
further study. 
The aetiology of persistent elevations of PTH is multifactorial, with 
autonomous PTH secretion and Vitamin D deficiency likely to contribute to its 
perpetuation.  Regardless of its aetiology, elevated PTH post transplantation 
has been associated with decreased bone mineral density and increased 
fracture risk, with a predilection for cortical bone sites such as the distal 
radius.  This pattern of bone loss is similar to that seen in primary 
hyperparathyroidism, where early bone loss is observed at the radius and is 
frequently asymptomatic.281 
To our knowledge the current study is the first to demonstrate an independent 
relationship between elevated PTH levels and some element of Health Related 
Quality of Life namely physical functioning. Whether these symptom scores 
improve following correction of residual hyperparathyroidism post renal 
transplant is unknown and would require prospective interventional studies.  
While PTH levels typically decline post renal transplant, levels remain elevated 
above the normal range in a substantial proportion of patients despite 
adequate renal function. Given current uncertainty as to the optimal 
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treatment strategy for post-transplant hyperparathyroidism, results of the 
current analysis reinforce the potential benefits of controlling   secondary 
hyperparathyroidism in native CKD and of strategies that prevent the 
development of persistent post transplant hyperparathyroidism.  
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Chapter 7 
 
 
 
 
 
 
 
Conclusions 
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Chronic Kidney Disease (CKD), osteoporosis and mild hyponatremia are all 
prevalent chronic conditions, which may coexist and are often under-
recognized. Mineral-Bone Disorder begins early in the natural history of CKD 
and results in complex abnormalities of bone which ultimately confers a well-
established increased risk of fragility fractures in End Stage Kidney Disease. 
Hyponatremia is a novel, usually renal mediated metabolic perturbation, that 
most commonly occurs independently of the stage of renal dysfunction but 
which may also predispose to increased fracture risk. The extent to which 
either early stages of renal dysfunction or the presence of hyponatremia 
contribute to fracture occurrence in the general population, independently of 
osteoporosis, is unclear. Renal transplantation is the treatment of choice for 
ESKD and although it restores endogenous renal function it typically fails to 
normalize either the long term cardiovascular or fracture risk. One potential 
mechanism contributing to these elevated long-term risks and to diminished 
Health Related Quality of Life is persistent, post-transplant 
hyperparathyroidism.   
In this study we examined the association of renal function and serum sodium 
with Bone Mineral Density and fracture occurrence in a retrospective cohort of 
1930 female members of the general population who underwent routine DXA 
scan.  We then prospectively recruited a cohort of 90 renal transplant 
recipients and examined the association of post transplant parathyroid 
hormone (PTH) level with measures of CKD Mineral Bone Disorder, including, 
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DXA Bone Mineral Density, Vascular Calcification (assessed using both 
abdominal radiograph and CT techniques, as well as indirectly by carotid-
femoral pulse wave velocity) and Quality of Life (using the Short Form-12 and a 
PTH specific symptom score).  
In Chapter 2, we examined the association of renal function with Bone Mineral 
Density and fracture occurrence in a retrospective cohort of 1702 female 
members of the general population who underwent routine DXA scan. 
Osteoporosis and CKD frequently co-exist, a relationship which we found to be 
confounded by age, as both conditions are increasingly more prevalent in 
older people. However, we report that moderate CKD (eGFR 30-
59ml/min/1.73m2), independently of DXA Bone Mineral Density and age was 
associated with the occurrence of self reported fracture with adjusted Odds 
Ratio (95% Confidence Interval), 1.37 (1.0, 1.89).  This study confirms earlier 
reports of increased fracture prevalence in CKD; however we found that this 
association occurs independently of Bone Mineral Density and at moderate 
levels of previously undiagnosed CKD. Osteoporosis and CKD are both 
common chronic conditions associated with fracture risk. Risk stratification 
prediction models for fracture include Bone Mineral Density, but not renal 
function in the assessment of fracture risk. This may under estimate fracture 
risk in the general population, a major public health concern in an ageing 
population. 
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In Chapter 3, we examined the association of mild hyponatremia 
(<135mmol/L) with Bone Mineral Density and fracture occurrence.  Serum 
sodium is a novel marker for bone health and has been associated with gait 
abnormalities, risk of falls and decreased Bone Mineral Density. We report 
that mild hyponatremia, at a level usually regarded as benign, was associated 
with the occurrence of self-reported non-vertebral fracture, adjusted Odds 
Ratio  (95% Confidence Interval), 2.25 (1.24, 4.09), independently of Bone 
Mineral Density.  In an editorial commentary on this work, Ayus et al.230 
suggest that serum sodium should be viewed as a novel marker of bone health 
and should be monitored and corrected when it develops, similar to the 
approach of measuring and correcting Vitamin D deficiency in osteoporotic 
patients.  Subsequent studies have cited and confirmed our findings, Hoorn et 
al.231  found that mild hyponatremia was associated with an increased risk of 
incident fractures, independently of age, gender and Bone Mineral Density, 
adjusted Odds Ratio (95% Confidence Interval), 1.39, (1.11, 1.73). Using the 
NHANES III data, Verbalis et al.24 found a significant relationship between mild 
hyponatremia and risk of osteoporosis at the hip, Odds Ratio (95% Confidence 
Interval), 2.85 (1.03, 7.86).  These studies emphasize the significant public 
health consequences of even mild levels of hyponatremia and the need to 
identify and modify long-term fracture risk. 
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In Chapter 4 we describe the myriad of mineral metabolism, bone turnover 
and vascular calcification abnormalities that are evident in a prospective 
cohort of 90 successful renal transplant recipients. Overall 91% of  renal 
transplants with eGFR >30ml/min/m2 had an elevated iPTH and/or suboptimal 
vitamin D level,  54% had aortic calcification and 42% osteoporosis, a prevalent 
vertebral collapse fracture or a post-transplant peripheral fragility fracture. 
These abnormalities appear to persist despite the restoration of adequate, and 
in some cases excellent, renal function.   While it is likely that some of the long 
term morbidity seen in transplantation results from cumulative damage (e.g. 
vascular calcification or abnormal bone architecture that accrued during the 
period of advanced CKD or on dialysis, we nevertheless  demonstrate an  
independent association of prevalent PTH levels with markers of bone turn 
over and with Bone Mineral Density, adjusted for other potential confounders, 
adjusted Odds Ratio (95% Confidence Interval), 1.15 (per 10ng/ml increment), 
(1.04, and 1.26). This raises the important possibility that in addition to 
previously acquired historical damage, persistent post transplant 
hyperparathyroidism may be actively exerting an ongoing deleterious effect on 
transplant outcomes at least with regard to bone mineral density and risk of 
fragility fracture risk.  If confirmed in prospective studies this observation 
would support the need for interventions aimed at preventing or controlling 
excessive hyperparathyroidism in a post transplantation setting.  
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In Chapter 5, we report that the presence of osteoporosis, but not PTH, was 
independently associated with CT measures of vascular calcification in a 
cohort of 64 successful renal transplant recipients, adjusted ß (95% Confidence 
Interval), 12.45, (1.16, 23.75).  In this cross-sectional study we cannot assess 
the progressive nature of this relationship but ongoing longitudinal 
investigations may further elucidate the nature and extent of this relationship 
and its implications on the long-term excess cardiovascular and fracture risk of 
renal transplant recipients. 
 
In Chapter 6, we evaluate the association of PTH with Health Related Quality 
of Life in 90 subjects with good renal allograft function.  Of the 8 health 
domains and 2 composite scores examined, post-transplant PTH (per 10ng/ml 
increment),  was only significantly and independently associated with reduced 
Physical Functioning,  (95% Confidence Interval), 1.12 (1.01, 1.23). The 
multitude of factors which influence the subjective physical and mental well-
being of patients with chronic disease are diverse and not readily quantifiable. 
To our knowledge the current study is the first to demonstrate an independent 
relationship between elevated PTH levels and some element of Health Related 
Quality of Life namely physical functioning. Whether these symptom scores 
improve following correction of residual hyperparathyroidism post renal 
transplant is unknown and would require prospective interventional studies.   
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Given current uncertainty as to the optimal treatment strategy for post-
transplant hyperparathyroidism, results of the above analyses at the very least 
reinforce the potential benefits of controlling   secondary hyperparathyroidism 
in native CKD and of strategies that prevent the development of persistent 
post transplant hyperparathyroidism and furthermore  support the conduct of 
additional prospective research to better delineate the influence of 
hyperparathyroidism on long term graft and patient outcomes. 
  
In conclusion, Chronic Kidney Disease and hyponatremia are both common 
health problems that may contribute to fracture occurrence in the general 
population, a major on-going public health concern.  PTH may be an important 
mediator of sub-optimal long-term outcomes post renal transplantation, 
influencing bone and vascular health and to a limited extent long term Health 
Related Quality of Life 
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Appendix 1:  Patient Information Sheet and Consent Form Version 4 
 
Clinical Research Ethics Committee Of The Cork Teaching Hospitals 
CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH PROTOCOL 
 
Section A 
Protocol Number: 06 Neph 02.2  Patient Name:     
 
Title of Protocol: Bone Mineral Density and Vascular Calcification in Chronic 
Kidney Disease. 
 
Doctors Directing Research:    
Dr. Joseph Eustace    (Chief Investigator)     Phone:      021 4920199 
Dr. Sinead Kinsella    (Research Co-ordinator)                                  021 4920199           
Dr. Michael Molloy    (Bone Density Laboratory)                               021 4922817    
Dr. Joe Coyle      (Radiology SpR)                          021 4922254 
Prof Michael Maher     (Consultant Radiologist)           021 4922254 
Dr. Denis O Mahony           (Brachial FMD)                                        021 4546400 
         
You are being asked to participate in a research study.  The doctors at University 
College Cork study the nature of disease and attempt to develop improved methods 
of diagnosis and treatment.  In order to decide whether or not you want to be a part 
of this research study, you should understand enough about its risks and benefits to 
make an informed judgment.  This process is known as informed consent.  This 
consent form gives detailed information about the research study, which will be 
discussed with you.  Once you understand the study, you will be asked to sign this 
form if you wish to participate. 
 
Section B 
I. NATURE AND DURATION OF PROCEDURES: 
You are being asked to join a study to look at the effects of high levels of 
parathyroid hormone and calcium on osteoporosis (bone strength) and 
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calcification, (hardening), of blood vessels after a kidney transplant. The study 
will take place in Cork University Hospital. There will be about 90 patients 
involved and it will last for 2 years. 
 
High levels of phosphate, calcium and parathyroid hormone are very common in 
patients on dialysis. Previous research has shown that these high levels are 
associated with a higher risk of suffering a heart attack or stroke. It is also known 
that these high levels can affect the bone strength of people with kidney disease. 
The bones can become more fragile and fracture easily.  
 
In most people the levels of calcium and parathyroid hormone go back to normal 
after a kidney transplant. However, in some people the levels stay above normal, 
even though the kidney transplant is working well. It is not clear whether these 
high levels continue to affect the blood vessels and the strength of the bones or if 
they make any difference to the long-term health of a person with a kidney 
transplant. The aim of this study is to find out if high levels of calcium and 
parathyroid hormone in the blood after a kidney transplant continue to affect the 
blood vessels and bones. 
There are a number of tests that will be carried out as part of the study. Doctors 
and nurses working in Cork University Hospital will do these tests. 
You will be asked to give a blood and urine sample. These samples will be 
repeated every 6 months over a 2-year period. Each time you have a blood 
sample taken, we will withdraw about 30mls (2 tablespoons) of blood. Blood will 
be taken by experienced staff. 
You will then be asked to have a bone density scan done. This will look at the 
strength of the bones of your hips, lower back and forearms.  This is a pain free 
procedure and does not require any special preparation on your part. The scan 
takes about 25 minutes in total. You will be asked to lie still on your back and left 
side. You will be able to breathe normally. 
Next you will be asked to have an X ray of your back done on the same day as the 
bone density scan. This will be done in the Radiology (X Ray) Department of Cork 
University Hospital. 
You will also be asked to have a CT scan done of your abdomen.  This is a detailed 
type of X Ray test which will take about 10 minutes to complete. You will be 
asked to lie on your back on a table, which then moves through the scanning unit. 
You do not need to fast or have any contrast (dye) administered for this test. This 
examination is also done in the Radiology Department of Cork University 
Hospital. 
You will have an ultrasound scan of an artery in your arm. This will not be an 
invasive test. But it will require that a blood pressure cuff be inflated above your 
elbow for 4 minutes before the scan is done.  The amount that your blood vessel 
expands after the blood pressure cuff is taken off will then be measured by 
ultrasound scan. 
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The last test will measure how fast blood moves between 2 blood vessels in your 
body. This is not an invasive test. It involves placing pulse sensors on your skin 
over a blood vessel in your neck and at the top of your leg. You will be asked not 
to move for about 10 seconds while a computer measures how fast your blood is 
moving. You will be able to breathe normally. This test will take 5 to 10 minutes. 
These tests will be done when you start the study and repeated 1 and 2 years 
later. 
You will also be asked to fill in a questionnaire.  This is to find out if you have 
symptoms related to high levels of calcium and parathyroid hormone in the blood 
and if these symptoms are affecting your day-to-day activities. 
 
 
II. POTENTIAL RISKS AND BENEFITS: 
When you have a blood sample taken you may experience some discomfort when 
the needle is being inserted. You may get a bruise at the site of entry of the 
needle. 
During the bone density scan, you may experience some discomfort if you suffer 
from back pain, as you will be asked to lie on your back. The dose of radiation is 
minimal, similar to that experienced on a short haul flight.  The same discomfort 
may be experienced when you have an X Ray of your back done. The dose of 
radiation is higher with an X Ray but still only similar to that experienced on a 
long haul flight. The dose of radiation in the CT scan is similar to that in the X Ray 
of your back. 
You may feel the blood pressure cuff tight on your arm for the 4 minutes before 
the ultrasound scan, but this has not been shown to cause any harm to your arm. 
However it may cause some discomfort while it is inflated and after it is released. 
You might feel pins and needles in your arm for a few minutes. Ultrasound testing 
does not expose you to any harmful radiation and is a non-invasive test. 
Measuring how fast the blood moves between your blood vessels is a non-
invasive test and is not harmful. 
By carrying out this research, we hope to find out if high calcium and parathyroid 
hormone levels in the blood affect the blood vessels and bone strength of people 
with kidney transplants. We would also like to see if blood and urine tests are 
effective in detecting a change in bone strength and blood vessel calcification 
after a kidney transplant. 
This research will help us identify people who might be at higher risk of heart 
attack, stroke and fragile bones because of their kidney disease. This will 
hopefully help us to prevent heart attack, strokes and fractures in these people. 
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III. POSSIBLE ALTERNATIVES: 
You may choose not to take part in this study. This will not affect your 
future medical care. If you decide to join the study, you are free to 
withdraw from the study at any time, and again this will not affect your 
medical care. 
 
Section C            
 
AGREEMENT TO CONSENT 
 
 The research project and the treatment procedures associated with it have 
been fully explained to me.  All experimental procedures have been identified and no 
guarantee has been given about the possible results.  I have had the opportunity to 
ask questions concerning any and all aspects of the project and any procedures 
involved.  I am aware that participation is voluntary and that I may withdraw my 
consent at any time.  I am aware that my decision not to participate or to withdraw 
will not restrict my access to health care services normally available to me.  
Confidentiality of records concerning my involvement in this project will be 
maintained in an appropriate manner.  When required by law, the records of this 
research may be reviewed by government agencies and sponsors of the research. 
 I understand that the sponsors and investigators have such insurance as is 
required by law in the event of injury resulting from this research. 
 I, the undersigned, hereby consent to participate as a subject in the above 
described project conducted at the Cork Teaching Hospitals.  I have received a copy 
of this consent form for my records.  I understand that if I have any questions 
concerning this research, I can contact the doctor(s) listed above.  If I have further 
queries concerning my rights in connection with the research, I can contact the 
Clinical Research Ethics Committee of the Cork Teaching Hospitals, Lancaster Hall, 6 
Little Hanover Street, Cork. 
After reading the entire consent form, if you have no further questions about giving 
consent, please sign where indicated. 
 
Doctor:                                                ______   
                         Signature of Subject or Guardian 
         
Witness:                                                                  Date:                  Time:     
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Appendix 2: ABC-HEART Study Data Collection Form, Version 1                           
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Appendix 3: Parathyroid Assessment of Symptoms Questionnaire, Version 1 
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Appendix 4:  DXA scan request form and questionnaire 
 
